

# Index

- A $\beta$  *see* amyloid- $\beta$   
 ABILHAND questionnaire **591**  
 abundance, in motor system  
     602–5  
 acarbose **424**  
 accelerometers, triaxial **66–7**  
 accidental injuries, wheelchair  
     users **162**  
 ACE (angiotensin-converting  
     enzyme) genotype **538**  
 acetyl L-carnitine **641**  
 acetylcholine (ACh) **415, 417**  
     activity-dependent learning  
         132  
     inhibitors *see* anticholinergic  
         drugs  
 acetylcholine receptors (AChRs)  
     2, **317, 415**  
 acetylcholinesterase (AChE)  
     inhibitors **479–80**  
     cognitive rehabilitation with  
         522  
     traumatic brain injury  
         **480, 541**  
 acetylsalicylic acid (ASA, aspirin)  
     **601–2**  
 acquired brain injury (ABI),  
     virtual reality  
     applications **203–4, 207**  
 ACTH therapy, multiple sclerosis  
     **638–9**  
 ActiGait® **257**  
 actin  
      $\beta$ -actin, axon tip synthesis  
         **424**  
     filamentous (F-actin) **301–2,**  
         **307–8**  
     microfilaments **423–4**  
 action coding system **512–13**  
 action disorganization syndrome  
     **450**  
 action potentials (APs)  
     conduction *see* conduction  
     recording, implanted  
         microelectrodes  
         **541–2, 556**  
     spike broadening **40, 66**  
     spike narrowing **66**  
     synaptic transmission **36**  
     action research arm test (ARAT)  
         **591, 595**  
     active movements, neglect  
         rehabilitation **468**  
     active range of motion  
         deforming spastic paresis **313**  
         post-stroke, predicting  
         recovery **334**  
 ACTIVE trial **517–18**  
 activities of daily living (ADLs)  
     apraxia **457**  
     assistive technology **154–7**  
     dementia **511**  
     disorders of consciousness  
         **397**  
     metabolic costs **369**  
     recovery after stroke **590–2**  
         predicting **593–4**  
     virtual reality applications  
         **207–8**  
     visual field rehabilitation and  
         **504–5**  
 activities-specific balance  
     confidence (ABC) test  
         **112**  
 activity-dependent plasticity **241**  
     axon sprouting **109**  
     CNS extracellular matrix **161**  
     sensorimotor function after  
         spinal cord injury and  
         **536–7**  
     spinal cord **83–92**  
     synaptogenesis **323–4**  
     *see also* experience-dependent  
         plasticity, Hebbian  
         plasticity, long-term  
         depression, long-term  
         potentiation  
 activity participation  
     interventions, dementia  
         **527–8**  
 acute inflammatory  
     demyelinating  
     polyradiculoneuropathy  
     (AIDP)  
     *see* Guillain-Barré  
     syndrome  
 acute stage of neurological  
     disease, rehabilitation  
     *see* early  
     neurorehabilitation  
 adaptations (functional) **7–8**  
     *see also* compensation  
 adeno-associated virus (AAV)  
     vectors **247, 515, 517**  
 adenosine triphosphate (ATP)  
     activation of microglia  
         **393–4**  
     autonomic function **417**  
     Schwann cell signaling **485**  
 adenovirus vectors **515, 517**  
 adherent cultures, neural  
     precursor cells **290–1**  
 ADL *see* activities of daily  
     living  
 adrenaline *see* epinephrine  
 adrenocorticotropic hormone  
     (ACTH), multiple  
     sclerosis **638–9**  
 adrenoreceptors (AR) **415**  
 advancing caregiver training  
     (ACT) **527**  
 aerobic capacity, maximal  
     *see* VO<sub>2</sub> max  
 aerobic training **372**  
     benefits **373–5**  
     multiple sclerosis **646–7**  
     recommendations **378**  
     *see also* exercise training  
 after-hyperpolarization (AHP)  
     amplitude, spinal  
     transection **177**  
 aggrecan **157, 381**  
     activity-related changes in  
         expression **161**  
     secretion after stroke **202**  
 aggression, dementia patients  
     **524**  
 aging  
     exercise capacity and **368–9**  
     hippocampal neurogenesis and  
         **289**  
     neuromuscular junction  
         morphology and  
         **480–1**  
     spinal stretch reflexes and  
         **87–8**  
     tactile perception and **141**  
     tinnitus and **134**  
     *see also* elderly  
 agitation  
     management in dementia  
         **525–7**  
     traumatic brain injury **543–4**  
 akinesia, Parkinson's disease  
     **571**  
 akinetic mutism **387**  
 AKT-mTOR pathway  
     *see* mTOR/mTOR  
     pathway  
 alcohol injections, deforming  
     spastic paresis **319**  
 Allen cognitive level screen-5  
     **513**  
 Allen diagnostic module-2 **513**  
 $\alpha$ -2 adrenergic agonists,  
     locomotor effects **181,**  
     **183**  
 $\alpha$ -2 adrenergic antagonists,  
     locomotor effects **181**  
 $\alpha$ -adrenoreceptors ( $\alpha$ -AR) **415**  
     injured spinal cord **178**  
 $\alpha$  coefficient, Cronbach's **36**  
 Alzheimer's disease (AD)  
     ApoE4 allele and **27, 394**  
     apraxia **448–9, 455–7**  
     brain reserve capacity and  
         **509–10**  
     cognitive/behavioral  
         assessment **512**  
     deep brain stimulation **528**  
     eye-blink conditioning  
         task **26**  
     functional neuroimaging  
         studies **510**  
     gene therapy **517–19**  
     inflammatory response **393–4**  
     learning studies **510, 518–22**  
     memory retraining **481–2,**  
         **518–20**  
     neuronal cell death **258–9, 261,**  
         **263, 268–9**  
     noninvasive brain stimulation  
         **226, 231, 234**  
     pharmacological therapies  
         **479–80**  
     risk factors **512**

- virtual reality applications **205**  
*see also* dementia
- amantadine  
 disorders of consciousness  
   **393, 539–40**  
 multiple sclerosis **641**  
 multiple system atrophy **425**  
 traumatic brain injury  
   **539–41**  
 unilateral neglect **469**
- American Heart Association  
 (AHA), stroke care  
 guidelines **177**
- American Spinal Injury  
 Association (ASIA)  
 impairment scale **350, 531–2, 617–18**
- $\alpha$ -amino-3-hydroxy-5-methyl-  
 isoxazole-4-propionic  
 acid receptors *see* AMPA  
 receptors
- 4-aminopyridine (4-AP) **458**  
 multiple sclerosis **459, 640–1**  
 spinal cord injury **249**
- AMPA receptors ( $\alpha$ -amino-3-  
 hydroxy-5-methyl-  
 isoxazole-4-propionic  
 acid receptors, AMPA-R)  
   **52**  
 binding proteins **55**  
 facilitation **38**  
 long-term depression **56–7**  
 long-term potentiation **54–5**  
 phosphorylation **55**  
 stroke recovery and **198–9**  
 synaptogenesis **319–20, 323**
- AMPAkines, stroke recovery and  
   **198–9**
- amphetamines (including  
 dexamphetamine)  
 genetic influences on response  
   **28**  
 impact on motor training  
   **319–20**  
 stroke rehabilitation **12, 242–3**  
 traumatic brain injury **539–40**
- amphibians  
 spinal cord regeneration  
   **332–3**  
 visual system regeneration  
   **333–4**  
*see also* frogs
- amphisomes **267**
- amputations  
 amphibian regenerative  
   responses **333**  
 brain plasticity after targeted  
   reinnervation **555**  
 cortical reorganization **291–3**  
 mechatronic upper limb  
   prostheses **184–6**  
 somatosensory reorganization  
   **77, 245, 291–2**  
*see also* phantom limb pain/  
 sensation
- amygdala  
 chondroitinase ABC injection  
   **160**  
 declarative memory **27, 31**
- amyloid **264**
- amyloid- $\beta$  (A $\beta$ ) **258–9, 383, 393–4**
- amyloid precursor protein (APP)  
   **259**
- amyotrophic lateral sclerosis  
 (ALS) **656–8**  
 cell death mechanisms **261, 264, 266, 268**  
 diaphragmatic pacing **126**  
 gene therapy **518, 520**  
 inflammation **395–6**  
 quality of life **655–8**  
 rehabilitation **657–8**  
 trophic factors and cell death  
   **259–60**
- Android-based communication  
 apps **221**
- anesthesia (loss of somatic  
 sensation) **298**
- anesthesia (regional)  
 motor cortical plasticity **245**  
 somatosensory reorganization  
   **245**  
 stroke motor recovery and  
   **244, 246**
- angiogenesis, stroke recovery and  
   **15**
- angiopietins, after stroke **204**
- angiotensin converting enzyme  
 (ACE) genotype **538**
- angiotensin II **417**
- angle of catch **313**
- anhidrosis **431**
- animal models **232–3**  
*see also* preclinical studies
- ankle-foot orthoses  
 energy costs of walking and  
   **377–8**  
 pressure relief (PRAFO) **397**
- ankle muscle responses,  
 vestibular inputs **357**
- ankle strategy, balance control  
   **108, 114**
- annexin A1 (ANXA1) **396–7**
- anomia, mechanisms of recovery  
   **442–3**
- anophthalmia **148**
- anosodiaphoria **469**
- anosognosia **469–71**  
 dementia rehabilitation and  
   **513–14**  
 for hemiplegia **470**  
 for neglect **470–1**
- antecedent-behavior-  
 consequences (ABC)  
 model **524**
- anterior cord syndrome **617**
- anterior ectosylvian sulcus (AES)  
   **127–8**
- anticholinergic drugs  
 dystonia **577**
- multiple sclerosis **641**
- anticipation, facilitating sensory  
 training **305**
- anticipatory postural  
 adjustments **108**  
 assessment **111**  
 treatments addressing **114**
- antidepressants  
 chronic pain in spinal cord  
 injury **623**  
 epilepsy **559**  
 post-stroke depression **608**  
 traumatic brain injury **540**
- antidiuretic hormone  
*see* arginine vasopressin
- antiepileptic drugs (AEDs)  
 adverse effects **552–3, 556–8**  
 prophylactic, traumatic brain  
 injury **392, 542**
- anxiety/anxiety disorders  
 after temporal lobectomy **561**  
 critically ill patients **265**  
 epilepsy **551, 556**  
 postictal **555**  
 spinal cord injury **629**  
 traumatic brain injury **544**  
 apallic syndrome *see* vegetative  
 state
- apathy, dementia patients **524**
- ApCAM (*Aplysia* neuronal  
 cell adhesion molecule)  
   **67**
- ApCPEB (*Aplysia* cytoplasmic  
 polyadenylation element-  
 binding protein) **67–8**
- aphasia **437–44**  
 after temporal lobectomy **561**  
 classification **608–9**  
 epidemiology **437**  
 mechanisms of recovery **441–3**  
 pharmacological interventions  
   **242–4**  
 prognosis **437**  
 rehabilitation **437–44, 608–9**  
 assistive technology **152–3**  
 behavioral modification **440**  
 communication devices **222, 226**  
 communication-oriented  
   **440**  
 early **271**  
 efficacy **443–4**  
 holistic vs. localizationist  
   **437–8**  
 learning theories **439**  
 loss vs. dysfunction of  
   language **438–9**  
 multisystemic view **440–1**  
 neoassociationist **440**  
 neurobiological basis **441–3**  
 neurolinguistic-cognitive  
   **440**  
 noninvasive brain  
 stimulation **227–9, 247–8, 146–7**
- pragmatic approaches  
   **440**  
 restitution vs. compensation  
   **438**  
 stimulation and facilitation  
   **439–40**  
 techniques **439–41**  
 theoretical basis **437–9**  
 training and practice effects  
   **241**
- Aplysia californica* **63–71**  
 associative learning **68–71**  
 behaviors and neural circuitry  
   **63–4**  
 nonassociative learning **23, 64–8**  
 principles of learning **71**
- apolipoprotein E (ApoE)  
 genotypes **27–8**
- apolipoprotein E4 (ApoE4)  
 genotype **27**
- Alzheimer's disease risk and  
   **27, 394**  
 traumatic brain injury  
 outcome and **27, 537–8**
- apoptosis **256, 258**  
 developing neurons **256**  
 Huntington's disease **268**  
 molecular program **257**  
 newly generated neurons in  
 adult brain **290**  
*see also* neuronal death,  
 programmed cell death
- apoptosome **257**
- Apple **221**
- apraxia **447–58**  
 clinical relevance **457**  
 clinical testing **455–7**  
 cognitive-motor deficits  
   **448–50**  
 frontal **447–8, 450**  
 historical note **447**  
 ideational **447–8, 450**  
 ideomotor (limb or  
 buccofacial) **448–50**  
 limbkinetic **448**  
 neuroanatomy **453–5**  
 syndromes **447–8**  
 theoretical models **450–3**  
 therapy **457–8**
- apraxia screen of TULIA (AST)  
   **456**
- ApTBL-1 (*Aplysia* tolloid/bone  
 morphogenetic-like  
 protein-1) **67**
- ApUch (*Aplysia* ubiquitin  
 C-terminal hydrolase)  
   **66–7**
- aquatic therapy, multiple  
 sclerosis **647**
- arginase I **357**
- arginine vasopressin (AVP,  
 antidiuretic hormone,  
 ADH) **417, 420, 624**

## Index

- arm movements  
 compensatory, brain damage 601–2  
 compensatory trunk movements assisting 601  
 stretch reflex thresholds 605
- artemin 404, 418, 521
- Ashworth scale, modified 542
- ASIA scale *see* American Spinal Injury Association (ASIA) impairment scale
- Aspen criteria, minimally conscious state 389
- asphyxia, perinatal 212
- aspiration (of gastric contents) 264, 396, 609–10
- aspirin (acetylsalicylic acid, ASA) 601–2
- assessment of life habits (Life-H) 42
- assistive brain–computer interfaces 570–1, 579–81
- assistive devices (assistive technology, AT) 150–9  
 activities of daily living 154–7  
 assessment for 150–1  
 cognitive impairments 152–4  
 credentialing program 172  
 falls prevention 114, 151–2  
 future 159  
 instrumental activities of daily living 157–8  
 mechatronic 177  
 neuromotor impairments 151–2  
 sensory perceptual impairments 154  
 standards 172–3  
 team approach 172
- assistive technology professional (ATP) 172
- assistive technology professional/seating and mobility specialist (ATP/SMS) 172
- associative learning 24–6, 63–71  
*Aplysia* 68–71  
 emerging principles 71  
 forms 63  
 hippocampal neurogenesis and 289
- associativity, long-term potentiation 51
- astrocytes 367–9  
 activation after stroke 201  
 Alzheimer's disease 393–4  
 axon regeneration role 371–2  
 development 368–9  
 functional diversity 367–9  
 after spinal cord injury 370–2  
 functions 367–8, 392  
 GABA uptake after stroke 198  
 glial scar formation 371, 376  
 immature, therapeutic potential 380
- implant–tissue interface 557–8
- injured spinal cord 448
- neurogenic potential 286
- neuronal-type Na<sup>+</sup> channels 463–4
- olfactory ensheathing cell interactions 503
- reactive 158–9, 371, 376  
 immature vs. mature 380  
 molecules secreted 381, 383  
*see also* astrogliosis, reactive regulation of synaptogenesis 322
- replacement therapy, spinal cord injury 442–3
- astrogliosis, reactive 158, 286, 376  
 cerebral palsy 213  
 glial scar formation 360, 371  
 growth-promoting molecules 383
- olfactory ensheathing cell transplants and 503  
 protective role 376
- ataxia, multiple sclerosis 640
- ATF3 422
- ATF6 266
- athletes, spinal cord plasticity 86–7
- atomoxetine 540
- ATP *see* adenosine triphosphate, Assistive Technology Professional
- Atrotech phrenic nerve stimulator 126
- attention  
 balance control and 110, 359  
 genetic factors 27–8  
 selective 495  
 sensory retraining and 305  
 training, neglect 465–9
- attention deficit hyperactivity disorder (ADHD)  
 in children with epilepsy 553, 556, 558  
 epilepsy risk in 554  
 genetic factors 27–8  
 virtual classroom 203
- attention deficits  
 noninvasive brain stimulation 227–8  
 traumatic brain injury 540–1  
 virtual reality applications 203–4
- attentional focus  
 gait training instructions 102  
 internal vs. external 96–7
- auditory assessment, disorders of consciousness 395
- auditory brainstem implants (ABIs) 544
- auditory cortex, plasticity 125–35  
 cochlear implants 133  
 congenital deafness 132
- during life span 132–3  
 object recognition 129–32  
 spatial functions 125–9  
 tinnitus 133–5
- auditory evoked potentials 390–1
- auditory feedback, virtual reality systems 200
- auditory midbrain implants (AMIs) 544
- auditory motion perception, middle temporal (MT) complex 142, 146–7
- auditory neglect 465
- auditory neuroprostheses 544–5  
*see also* cochlear implants
- auditory object recognition 129–32
- auditory perception, blindness 141–2, 145–7
- auditory rehabilitation, disorders of consciousness 395–6
- auditory spatial functions (sound localization) 125–9  
 blind people 141–2  
 neuroimaging 127–30  
 visual cortical involvement 146–7
- epigenetic adaptation 125–6
- visually deprived animals 126–7  
 neural basis 127–9
- auditory system  
 plasticity 125–35  
 transneuronal degeneration 4
- augmentation (of synaptic transmission) 36
- Ca<sup>2+</sup>-dependent mechanisms 42–3
- quantal mechanisms 38
- synapse specificity 44–5
- augmentative and alternative communication (AAC) 219–28  
*see also* communication devices
- augmentative and alternative communication (AAC) specialists 223
- Austrian Neurorehabilitation Society 261
- autism (autistic spectrum disorders, ASD)  
 communication support 226–7  
 pathogenic mechanisms 58, 259
- autonomic dysfunction 415–31  
 cardiovascular system 419–27  
 classification 415–17  
 clinical examination 419  
 clinical features 416–19  
 disorders of consciousness 392–3  
 gastrointestinal tract 428–9  
 localized 416, 418  
 reproductive system 429–30
- spinal cord injury 621
- thermoregulation 430–1
- traumatic brain injury 543
- urinary tract 427–9  
*see also* orthostatic hypotension
- autonomic dysreflexia/hyperreflexia 427, 621–2
- autonomic function assessment, experimental spinal cord injury 536
- autonomic nervous system (ANS) 415–17
- autophagosomes 267
- autophagy (autophagic cell death, ACD) 257, 267–9  
 chaperone-mediated (CMA) 267–8  
 molecular regulation 257  
 neurodegenerative diseases 267–9  
 subtypes and steps 267
- AVERT trial 269, 603
- Avery phrenic nerve stimulator 126
- avoidance learning 27–8
- axolotl (*Ambystoma mexicanum*) 284
- axon(s)  
 collaterals *see* collaterals, neuronal
- dystrophic *see* dystrophic growth cones
- myelinated *see* myelinated axons
- spared, conundrum of 9
- synaptogenesis 318–19
- tip, local protein synthesis 424
- unmyelinated 457
- axon arbors 10  
 formation of new, after axotomy 10, 12–14  
 principle of conservation of 12
- tortuous, suggesting abortive growth 7, 10, 12
- axon degeneration 274–9  
 demyelinating diseases 466  
 distal (dying back) 276–7  
 proteins blocking 275–6  
 Wallerian *see* Wallerian degeneration
- Wallerian-like 278–9
- axon growth  
 after axotomy 11–12  
*see also* axon regeneration
- branching mode 10, 12  
*see also* axon arbors
- collateral formation, after axotomy 12
- during development 114, 242–3
- molecular programs, post-stroke changes 200–1
- neuron-intrinsic regulators  
*see* neuron-intrinsic

- determinants of regeneration terminology 11–12 tract mode 10 *see also* axon sprouting; growth cones
- axon growth inhibitors 308–9, 349–60, 418–19 after stroke/brain injury 201–4 blocking strategies 354–7 categories 201 developmentally related 201, 203 glial scar-associated *see* chondroitin sulfate proteoglycans myelin-associated *see* myelin-associated axonal growth inhibitors vs. neuron-intrinsic regulators 345
- axon guidance 301–10 activity-dependent 109 cues (and receptors) 303–7 modulating growth cone responses 308 morphogens 306 neurotrophins 306 permissive and instructive 302 regulation of growth cone cytoskeleton 307–8 role in regeneration 309–10, 357–60 short- and long-range 302 during development 242–3, 302–8, 357–60 during regeneration 308–10 Sperry chemoaffinity hypothesis 115–18, 306
- axon injury effects of distance from cell body 415 molecular signaling 416 neuronal responses 1–7, 413 *see also* axotomy; denervation; peripheral nerve injury
- axon regeneration 8–11 abortive 7, 9–10 canonical (normal target-specific) 8 CNS 339–40 developmental loss 414, 425 extracellular influences 243 glial scar inhibiting 360, 376–86 mechanisms limiting 243–4 molecules inhibiting *see* axon growth inhibitors obstacles 114 overcoming myelin-induced block 354–7 strategies for enhancing 10–11, 243–5
- conditioning lesion effect *see* conditioning lesion effect
- disorderly 8 ectopic connection formation 10 effectors 422–5 electrodiagnostic testing 81 forms of growth 10 glial cell role 371–3 guidance 308–10 developmental cues 309–10, 357–60 inhibitory pathways 309–10 identification criteria 9 inhibitors *see* axon growth inhibitors
- invertebrates 329–30 lower vertebrates 329–34 neuron-intrinsic determinants 243, 413–26 neurotrophins and 402–8, 418 non-mammalian models 329–35 orderly 8 peripheral nervous system *see* peripheral nerve regeneration
- pitfalls for studies of 8–9 priming effects 16 region-specific 8 retinal ganglion cells *see* under retinal ganglion cells
- spinal cord injury 339 axon–glial cell contacts 10 bridges across lesion sites 243–4 mechanisms limiting 243–4 olfactory ensheathing cell transplants 504–6 PTEN deletion and 11 Schwann cell transplants 500–1 strategies for enhancing 243–5 terminology 11–12 vs. axon sprouting 11–12, 343–4 *see also* axon growth, axon sprouting
- axon sprouting 10, 12–15 activity-dependent guidance 109 corticospinal tract (CST) 5–14, 159 factors determining extent 15–17 interspecies differences 17 myelin-associated axonal growth inhibitors and 343–4 post-stroke 197, 199–201 contralateral cortex 199–200 ipsilateral cortex 200–2
- molecular growth programs 200–1 remote intracortical, motor cortex lesions 107 Schwann cell role 475–6, 481 Schwann cell transplants into spinal cord 499–500 spinal cord injury 536 terminology 11–13 triggers 15 vs. axon regeneration 11–12, 343–4 vs. axonal ingrowth 15 vs. generation of new collaterals 12
- axonal polyneuropathies common causes 79 electrodiagnostic testing 79 length-dependent 276 axonal transport 422 defects demyelination 278–9 length-dependent axonal neuropathies 277 retrograde neurotrophins 401 signals of axon injury 416
- axonotmesis, electrodiagnostic testing 81 axotomy 7, 17 axon regeneration after 8–11 distal axon degeneration *see* Wallerian degeneration fate of neurons after 4 Na<sup>+</sup> channel expression 462–3 oligodendrocyte death and demyelination 6–8 other types of axon growth after 11–12 retrograde atrophy and degeneration 4–7 site, neuronal response and 415 spared axon conundrum 9 synapse stripping 6 *see also* axon injury, peripheral nerve injury
- back pain, chronic, neuroplasticity 289–91 backrests, wheelchair 171 baclofen 428, 542, 577, 640 Bak 263 balance 355–64 compensatory strategies after stroke 15, 602 importance 105 terminology 105–6 balance control 105–10 attentional contributions 110, 359 cognitive influences 110, 112 extrinsic factors affecting 112
- resources required 106–10 role of eye movements 359–60 sensory contributions 107–8, 356–9 systems model 106 vestibular system role 108, 357–9 *see also* postural control
- balance disorders assessment 110–12 assistive technology 151–2 attentional resources needed 359 rehabilitation 112–15 *see also* vestibular dysfunction
- balance evaluation systems test (BESTest) 110 balance scale 38, 40–1 balance training 105–15 attentional focus studies 96–7 explicit vs. implicit learning 98 Parkinson's disease 572–3 vestibular dysfunction 363 virtual reality-based 113, 209
- ballet dancers, spinal cord plasticity 86–7 bands of Büngner 472, 496 baroreceptors 419–20 baroreflex system, bionic 422 Barthel Index (BI) 67 post-stroke pattern of recovery 590–4 predictive value 593–4 responsiveness 40–1
- basal ganglia learning and memory 24 praxis 455 basal metabolic rate (BMR) 369, 377 base of support (BoS) 105–6 basic fibroblast growth factor (bFGF, FGF-2) astrocyte responses 369 glial scar formation 378–9 neural precursor cell responses 287, 289 oligodendrocyte precursor cell responses 370 regeneration in amphibians 334 stroke therapy 248
- bathing assistive technology 154–5 dementia patients 525 bathroom grab bars 151 Bax 263 BBB (Basso, Beattie and Bresnahan) locomotor rating scale 533–4 BCI2000 system 572 BCIs *see* brain-computer interfaces

## Index

- Bcl-2 proteins  
mitochondrial function 263–4  
neuronal death 257–8  
non-cell death roles 257
- BCL-xL 44
- BDNF *see* brain-derived neurotrophic factor
- bed nuclei of the stria terminalis (BST) 27
- bed rest 265–8  
exercise capacity and 270, 369  
*see also* deconditioning
- bedside assistive devices 151
- behavioral change, spinal cord  
plasticity and 88–90
- behavioral disorders  
children with epilepsy 553, 556  
traumatic brain injury 543–4
- behavioral interventions  
aphasia 440  
chronic pain 293–5  
dementia 516–17, 524–6  
Parkinson's disease 571–2  
somatosensory loss 80
- behavioral problems in dementia 522  
assessment 511–14  
conceptual frameworks 523–4  
interventions 516–17, 524–7  
models guiding treatment 514–15
- Bergman glia 368–9
- Berlin apraxia test (BAXT) 456–7
- Berlin LSVT®BIG study 570
- BESTest (Balance Evaluation Systems Test) 110
- β-adrenoceptors (β-AR) 415
- β-amyloid *see* amyloid-β
- bias  
in clinical trials 234  
in prognostic studies 587–9
- Bienenstock–Cooper–Munro (BCM) model 56–7
- bilateral arm training with  
rhythmic auditory cueing (BATRAC) 90
- bilingual humans 131
- Binswanger's disease 569
- biofeedback  
memory dysfunction 481  
sensory, balance rehabilitation 114  
*see also* feedback
- biomechanical constraints on  
balance 106  
assessment 110  
treatment 112
- biomechanical factors, energy  
expenditure 374–6
- biomimetic neural prostheses  
*see* neural prostheses
- BION® device 130
- 2,2'-bipyridine (BPY) 159
- birds, adult neurogenesis 285
- Blackrock microelectrode array 577
- bladder care, disorders of  
consciousness 392
- bladder control  
assessment, experimental  
spinal cord injury 536  
development 85
- bladder dysfunction 427–9  
functional electrical  
stimulation 129–30  
multiple sclerosis 641, 648  
neural prostheses 543  
spinal cord injury 427–8, 621
- blast injuries 385–6, 535
- blepharospasm 574–5, 577–8
- blinded clinical trials 234
- blindfolding, tactile  
discrimination after  
141, 144
- blindness 144–8  
age at development 140  
auditory object recognition 132  
auditory spatial function  
126–30, 141–2  
cortical 502  
modality-independence of  
perceptual-cognitive  
functions 147  
neuroanatomical studies 147–8  
nonvisual perception 140–2  
somatosensory cortical  
plasticity 142  
visual cortical involvement in  
nonvisual tasks 144–7  
visual neuroprostheses 545–6,  
554–5  
*see also* visual deprivation
- blindsight 502
- blood–brain barrier (BBB) 368  
breakdown, glial scar  
formation 378  
microelectrode implantation  
disrupting 555–7
- blood pressure  
changes in orthostatic  
hypotension 420–1  
control 419–20
- blunt brain injuries 385
- body weight support system  
(BWSS) 628
- body weight-supported treadmill  
training (BWSTT) 64–6,  
369  
multiple sclerosis 647  
spinal cord injury 65, 630  
stroke 65, 372, 374, 607
- bone marrow stromal cells 448  
*see also* mesenchymal stem  
cells
- bone morphogenetic proteins  
(BMP)  
axon guidance 306
- induced astrocytes, spinal cord  
transplants 370, 372,  
443–4  
neural precursor cell responses  
287
- botulinum toxin (BTX)  
injections  
bladder dysfunction 428, 641  
dystonia 577  
hemiplegic shoulder pain 607  
spasticity 319, 604–5, 640
- bound Ca<sup>2+</sup> model, facilitation  
41
- bowel care, disorders of  
consciousness 392
- bowel function  
assessment, experimental  
spinal cord injury 536  
multiple sclerosis 641  
sacral anterior root  
stimulation and 130  
spinal cord injury 429, 621
- BPY (2,2'-bipyridine) 159
- bradykinesia, Parkinson's disease  
571
- Braille readers  
somatosensory cortical  
plasticity 142  
tactile perception 140–1
- Braille reading  
modality-independent visual  
cortical functions 147  
visual cortical involvement  
144–5, 147
- brain  
plasticity *see* plasticity  
reserve capacity 509–10  
responses to neural prostheses  
*see under* neural  
prostheses
- brain–computer interfaces  
(BCIs) 549–50, 565–73  
applications 571–2  
definition 565–6  
dementia 528–9  
direct speech 579  
invasive *see* intracranial  
brain–computer  
interfaces  
moderately invasive *see*  
electrocorticography  
(ECoG)-based  
brain–computer  
interfaces  
motor 570–2, 579–81  
noninvasive *see* electroen-  
cephalography (EEG)-  
based brain–computer  
interfaces  
potential users 570–1  
present-day types 567–70  
principles of operation 566–7  
process control vs. goal  
selection 571–2  
research and development 572
- selectivity–invasiveness  
tradeoff 556  
signal processing 570  
signal recording methods 567,  
577  
therapeutic uses 571
- brain damage *see* brain injury
- brain-derived neurotrophic  
factor (BDNF) 400  
amyotrophic lateral sclerosis,  
gene therapy 520  
exercise training and 373–4  
Huntington's disease, gene  
therapy 520  
neural precursor cell responses  
287  
neuropathological role 258–9  
peripheral nerve injury  
axon regeneration and  
403–4  
cell survival and 402  
plasticity-related functions  
26–8  
receptor 400  
regulation of synaptogenesis  
322–3  
spinal cord injury  
axon regeneration and  
405–6, 418  
cell survival and 405  
effects on specific fiber  
tracts 408  
functional effects 180, 184,  
406–7  
gene therapy 521  
increased expression 405  
methods of administration  
406  
with Schwann cell grafts  
501–2  
stroke recovery and 13, 199,  
603  
val<sup>66</sup>met gene polymorphism  
26–8
- brain disorders *see* brain injury
- brain injury  
cellular mechanisms of  
plasticity 196–207  
axon growth inhibitors  
201–4  
axonal sprouting/new  
connections 199–201  
cellular regeneration 204–5  
excitatory signaling 197–9  
functional imaging 196–7  
cognitive rehabilitation *see*  
cognitive rehabilitation  
etiologies 385–7  
motor compensation after  
600–2  
motor cortex reorganization  
52–3, 55  
perinatal *see* perinatal brain  
injury  
secondary 543

- stem cell therapies 586–93  
traumatic *see* traumatic brain injury  
*see also specific conditions*
- brain–machine interfaces (BMIs)  
*see* brain–computer interfaces
- brain size, reserve capacity and 509
- brain stimulation 141–7  
genetic influences on response 29  
*see also* deep brain stimulation, non-invasive brain stimulation
- brain tumors, hippocampal neurogenesis and 294
- BrainGate device 549, 578
- brainstem auditory evoked responses (BAERs) 390–1
- breathing assistance, high tetraplegia 126
- brevican 157, 381
- bromocriptine 540–1
- bromodeoxyuridine (BrdU)  
labeling, neural precursor cells 291–2
- Brown–Séguard syndrome 169, 617
- buffer saturation model, facilitation 42
- bulbosplinal projections, locomotor control 169
- Bundesarbeitsgemeinschaft für Rehabilitation* (BAR), *Phasenmodell der* 261
- bupirone 182
- C-Mill treadmill 100–3
- C3 transferase 421
- cadherins 323, 484
- Caenorhabditis elegans*  
axon guidance 304–5  
axon regeneration 329–30  
calcium signaling 416  
specificity of synaptic connections 323
- caffeine 424
- CAG triplet repeat diseases  
*see* polyglutamine (polyQ) repeat diseases
- Cajal, Ramón y *see* Ramón y Cajal
- calbindin 42
- calcineurin, long-term depression 56
- calcium ( $\text{Ca}^{2+}$ )  
cell death in degenerative diseases 262  
current facilitation 40–1  
extrusion, presynaptic terminals 40  
growth cone motility and 422  
mitochondrial handling 37, 40, 42–4  
postsynaptic signaling  
long-term depression 56  
long-term potentiation 53–4  
long-term sensitization 67  
presynaptic signaling 36–43  
delayed asynchronous release 40  
phasic release 39  
residual [ $\text{Ca}^{2+}$ ] 39–40  
short-term synaptic enhancement and 40–3  
signaling in axon injury 416  
uncaging 39  
Wallerian degeneration and 275
- calcium ( $\text{Ca}^{2+}$ )/calmodulin-activated kinase II (CaMK II)  
long-term depression 56  
long-term potentiation 53–5  
post-tetanic potentiation 43
- calyx of Held 39
- Canadian neurological scale (CNS) 593
- canes, walking 114, 156
- cannabinoids 640
- CAP-23 424
- captopril 427
- carbamazepine (CBZ) 552–3
- cardiovascular disease  
exercise capacity and 369–71  
spinal cord injury 421, 623  
stroke patients 263, 268
- cardiovascular system  
acute responses to exercise 367–8, 370  
assessment in spinal cord injury 621  
autonomic disorders 419–27  
effects of inactivity 268, 369  
training-induced adaptations 372
- Care of Persons with Dementia in their Environments (COPE) 527
- care pathways *see* clinical pathways
- caregivers  
amyotrophic lateral sclerosis 658  
dementia rehabilitation role 522–8  
formal and informal 523
- CAREN™ multisensory system 200–1, 206–7
- carotid sinus hypersensitivity (CSH) 425
- carotid sinus massage 421
- carpal tunnel syndrome, wheelchair users 161
- case manager 285
- caspases  
neurodegenerative disorders 259  
neuronal death 257–8  
non-cell death roles 257
- casting 316
- catechol-O-methyl transferase (COMT) gene 28–30, 538
- catechol-O-methyl transferase (COMT) inhibitors 568
- Catherine Bergego scale 470–1
- cationic liposomes 515
- Catwalk device 533–5
- cauda equina syndrome 617
- CAVE virtual reality system 200
- Cdc42 307–8, 359
- ceiling effects, outcome measures 41
- cell adhesion molecules  
axon regeneration role 425, 484  
neuronal regenerative ability and 415
- cell death 256–7  
necrotic 256  
*see also* apoptosis, autophagy, neuronal death, programmed cell death
- cell phones (mobile phones)  
reminder systems 483–4  
*see also* smartphones
- cell replacement therapies, spinal cord injury 435–50  
alternative sources of cells 448  
cell delivery methods 449  
clinical trials 442, 449–50  
development and properties of cells 437–9  
fetal tissue transplants 436–7  
mobilizing endogenous precursors 448–9  
neural stem and precursor cell transplants 380, 439–48  
practical issues 449–50  
properties of candidate cells 439–40  
rationale 436  
relay formation 446–8  
time of engraftment 449  
*see also* cellular therapies, stem cell therapies
- cell survival, neuronal  
*see* neuronal survival
- cellular therapies  
based on endogenous precursors 294–5, 448–9  
demyelinating diseases 465  
for-profit centers 449–50  
gene therapy approaches 514  
spinal cord injury 496–508, 588–90, 592, 631  
olfactory ensheathing cell transplants 496, 502–8
- Schwann cell transplants 496–502, 508
- trophic factor-secreting cells 521  
*see also* cell replacement therapies; stem cell therapies
- center of body mass (CoM) 105–6
- Centers for Medicare and Medicaid Services (CMS) 127, 163, 286
- central cord syndrome 617
- central nervous system (CNS)  
injury  
axon regeneration *see* axon regeneration  
glial scar *see* glial scar  
inflammatory response 392–7  
neural consequences 317  
neuronal effects 1–2  
neurotrophins and repair 405–8  
oligodendrocyte death and demyelination 6–8  
reactive growth responses of neurons 1–7  
reorganization of neuronal connections 8–17  
sensory loss 298–9  
*see also* brain injury, spinal cord injury
- central nervous system (CNS)  
stimulants 393, 528, 540
- central pattern generator (CPG)  
locomotor 83–4, 61–2  
cats 166–9  
changes after spinal cord injury 177  
coordinating interneurons 173  
human 343–4, 348  
mice 176–7  
rats 171–2  
swallowing 406–7
- CERE-110 (AAV-NGF) 519
- cereal-eating test 535–6
- cerebellar Purkinje cells 26, 56  
channelopathy in demyelinating disease 462, 464
- cerebellins 321–2
- cerebellum  
contralateral hypoactivity 317  
learning and memory 25–6  
lesions, spinal fixation 84  
long-term depression 26, 56–7  
M1 connectivity 143  
cerebral blood flow during exercise 368  
regional (rCBF) 84  
stroke 12

## Index

- cerebral cortex  
 contralateral, axon sprouting  
 after stroke 199–200  
 experience-dependent  
 plasticity  
 ipsilateral, axon sprouting  
 after stroke 200  
*see also* neocortex  
 cerebral edema, post-stroke 602  
 cerebral motor functions 99–110  
 organization 99–103  
 plasticity 103–9  
*see also* motor cortex  
 cerebral palsy (CP) 211–16  
 abnormal corticospinal  
 connections 85–6  
 exercise capacity 370  
 exercise training 375  
 gait disorder 347  
 infantile spinal stretch reflexes  
 85–6  
 neural plasticity 215–16  
 pathophysiology 212–15  
 underlying perinatal brain  
 injuries 211–12  
 virtual reality applications 210,  
 212  
 cervical dystonia (spasmodic  
 torticollis) 575–6  
 medical and surgical treatment  
 577–8  
 rehabilitation 578  
 cervical spinal cord,  
 propriospinal pathways  
 175  
 cervical spinal cord injury  
 autonomic dysfunction 421  
 clinical trial endpoints 237–9  
 forelimb motor recovery  
 measures 532–5  
 locomotor recovery in rats 171  
 nonhuman primates 537  
 recovery and functional  
 outcomes 625–7  
 upper extremity  
 neuroprostheses 546–7  
*see also* tetraplegia  
 chair, rising from a 42  
 channelopathy, demyelinating  
 disease 462, 464  
 chaperone-mediated autophagy  
 (CMA) 267–8  
 chaperones, neurodegenerative  
 diseases 264–7  
 Charcot–Marie–Tooth disease  
 demyelinating forms, axonal  
 loss 278  
 type 2A 277  
 type 2B 277  
 charge storage capacity (CSC)  
 542  
 chemoaffinity (or  
 chemospecificity)  
 hypothesis, Sperry's  
 115–18, 306, 334
- children  
 cochlear implants 544  
 with complex communication  
 needs 224–5  
 with epilepsy  
 cognitive impairments 552  
 management 557–8  
 psychiatric/behavioral  
 problems 553–4, 556  
 psychosocial impact 551  
 otitis media 132  
 virtual reality applications  
 203–4, 210  
 wheelchair design 169  
*see also* cerebral palsy;  
 perinatal brain injury  
 cholesterol, synapse formation  
 and 322  
 cholinergic polymorphisms 29  
 cholinesterase inhibitors  
*see* acetylcholinesterase  
 (AChE) inhibitors  
 chondroitin sulfate  
 proteoglycans (CSPGs)  
 155–7, 381–2  
 axon growth inhibition 158,  
 309, 344–5, 360, 381  
 axon regeneration inhibition  
 243, 378, 381–2, 419  
 ocular dominance plasticity  
 and 345  
 receptors 344–5, 381–2  
 secretion after CNS injury  
 201–3, 381  
 signaling, as therapeutic target  
 385  
 as therapeutic target 159–60,  
 244, 384–5  
 chondroitinase (Ch<sup>a</sup>se, chABC)  
 157  
 inhibition of scar formation 159  
 promoting axon regeneration  
 381, 384–5  
 spinal cord injury 6, 80,  
 159–60, 244  
 chronic phase 161  
 with rehabilitation 161  
 with Schwann cell grafts 501  
 chorioamnionitis 212  
*CHRNA4* gene 28  
 chronic inflammatory  
 demyelinating  
 polyneuropathy (CIDP)  
 662–3  
 concurrent diseases 80  
 electrodiagnostic testing 79–80  
 chronic pain 289–95  
 behavioral interventions  
 293–5  
 musculoskeletal  
*see* musculoskeletal pain,  
 chronic  
 pharmacological interventions  
 295  
 plasticity and 289–93
- spinal cord injury 623  
*see also* neuropathic pain  
 ciliary neurotrophic factor  
 (CNTF)  
 astrocytes induced by 370, 372  
 derived astrocytes, spinal cord  
 transplants 443–4  
 gene therapy  
 amyotrophic lateral sclerosis  
 520  
 Huntington's disease 520  
 inducing axon regeneration  
 385, 417  
 cingulate motor area (CMA) 53,  
 55, 103  
 post-stroke changes 85–6  
 citalopram 29, 320  
 citicholine 539  
 classical (Pavlovian)  
 conditioning 24–7, 63  
 cellular analog 51  
 neural mechanisms in *Aplysia*  
 68–70  
 pain-related responses 291  
 classical test theory 35–8  
 clavicle, osteolysis of distal 161  
 climbing fibers, cerebellar 26, 56  
 clinical pathways 70–6, 281  
 benefits and risks 72  
 continuous team education 72  
 definition and characteristics  
 71  
 design and implementation  
 74–5  
 evidence for efficacy 72–4  
 clinical practice guidelines 70  
 clinical test for sensory  
 integration in balance  
 (CTSIB) 110–11  
 clinical trials 1–6, 231–40  
 biological interventions 2  
 confounding factors 5–6,  
 238–40  
 CONSORT checklist 2–3  
 inclusion/exclusion criteria  
 232–4  
 interventions 4  
 methodological quality 11  
 outcome measures 4–5, 235–8  
 phases and stages 1–2, 236–7  
 preclinical criteria prior to  
 231–2  
 principles for conduct of valid  
 239–40  
 randomization 2–4, 234–5  
 study designs 2–5, 234–5  
*see also* randomized controlled  
 trials  
 clonazepam 640  
 clonidine  
 challenge, autonomic  
 dysfunction 422  
 locomotor effects 181, 183  
 clothing fasteners 155  
 cluster headache 293
- CNS *see* central nervous system  
 cochlear implants (CI) 133,  
 544–5, 554  
 plastic responses 555  
 cognitive activities, dementia  
 prevention 511, 518  
 cognitive behavioral therapy  
 (CBT)  
 epilepsy 559  
 post-stroke depression 608  
 cognitive function  
 assessment in dementia  
 511–14  
 balance control 110, 112  
 language interactions 440–1  
 cognitive impairments  
 after temporal lobectomy  
 560–1  
 assistive technology 152–4  
 communication support 225–6  
 epilepsy 551–2, 557–8  
 learning by individuals with  
 515–17  
 multiple sclerosis 641  
 transient, epilepsy 552  
 traumatic brain injury 543  
 virtual reality applications  
 203–8  
*see also* dementia, mild  
 cognitive impairment,  
*specific deficits*  
 cognitive neuroscientific models,  
 dementia 514  
 cognitive orthotics 153  
 cognitive rehabilitation 218–35  
 challenges 218–19  
 definition 218  
 dementia 515  
 memory dysfunction 481  
 noninvasive brain stimulation  
 146–7, 219–35  
 choice of technique 221  
 clinical evidence 227–31  
 diagnostic applications  
 223–4  
 with other therapeutic  
 interventions 224–5  
 technical and other  
 challenges 225–7  
 theoretical framework  
 221–3  
 online training programs 219  
 virtual reality systems 203–7  
 cognitive reserve 509  
 cognitive stimulation, in  
 dementia 514–15, 526  
 cognitive tasks, secondary  
 during balance tasks 112, 359  
 improving motor learning  
 97–8  
*see also* dual-task paradigms  
 cognitive training  
 dementia 514–15  
 healthy older people 517–18  
 memory dysfunction 481

- multiple sclerosis **648–9**  
 cohort, prospective inception **589**  
 collagen, after spinal cord injury **158–9**  
 collagenous scar **158–9**  
 collaterals, neuronal  
   growth of new, after injury **10, 12–14**  
   principle of sustaining **5**  
 coma **262, 387**  
 coma near coma scale **389**  
 coma recovery scale–revised (CRS-R) **389**  
 commissureless (Comm) **308**  
 commodes, bedside **156**  
 communication devices **152–3, 219–28**  
   control inputs **220–1**  
   direct speech brain–computer interfaces **579**  
   disorders of consciousness **397**  
   funding **223–4, 226**  
   mobile devices and apps **221–3, 225**  
   outputs **220–1**  
   selection of dedicated **223**  
   specific clinical populations **224–7**  
   types available **219–20**  
   visual scene approach **220, 222, 225–6**  
   web resources **230**  
 communication-oriented  
   approaches, aphasia rehabilitation **440**  
 communication systems, disorders of  
   consciousness **395–7**  
 compensation **7, 599–605**  
   adaptive **7–8**  
   after brain damage **600–2**  
   aphasia **438**  
   balance rehabilitation **112–13**  
   definitions **7–8, 599–600**  
   measurement **605**  
   mechanisms **602–5**  
   motor map plasticity and **109**  
   neural **509**  
   noninvasive brain stimulation promoting **222**  
   redundancy and **603–5**  
   stroke recovery and **15–16**  
   substitutive *see* substitution vs. neural repair **8–9**  
   *see also* motor compensation  
 compensatory plasticity **91**  
 competence–environmental press model (CEPM) **523**  
 complex regional pain syndrome (CRPS) **293**  
 compound motor action potential (CMAP) **80–2**  
 compressive neuropathies, electrodiagnostic testing **78, 81**  
 computed tomography (CT), head injury **536**  
 computer adapted testing (CAT) **38–9**  
 computer-assisted scale administration **38**  
 computer training  
   memory deficits **480**  
   unilateral neglect **469**  
 computers  
   for word processing **158**  
   *see also* mobile electronic devices, tablet computers  
 COMT (catechol-O-methyl transferase) gene **28–30, 538**  
 conditioning  
   classical (Pavlovian) *see* classical conditioning  
   contextual **30**  
   fear *see* fear conditioning  
   operant *see* operant conditioning  
   trace **29–30**  
   *see also* learning  
 conditioning lesion effect **379, 416, 245**  
   cAMP dependence **356, 379**  
 conduction (action potential) **459–60**  
   continuous, demyelinated axons **460–1**  
   demyelinated/dysmyelinated axons **459–60**  
   discontinuous, recovering demyelinated axons **462**  
   myelinated axons **457, 459**  
   remyelinated axons **464–5**  
   slowed **459**  
   spinal cord axons  
     remyelinated by Schwann cells **498–9**  
   temporal dispersion **459**  
   unmyelinated axons **457**  
   *see also* nerve conduction studies  
 conduction block **459–60**  
   electrodiagnostic testing **78**  
   frequency-related **460**  
   impedance mismatch/matching and **464–5**  
   role of blocking factors **460**  
   total **460**  
 cone electrode **577**  
 confounders, clinical trials **5–6, 238–40**  
 connections, neuronal  
   *see* neuronal connections  
 consciousness, disorders of **385–400**  
   acute rehabilitation **391–400**  
   facilitating plasticity **394**  
   goals **394–5**  
   medical and nursing care **392–3**  
   prognostic evaluation **398–9**  
   programs and protocols **394–8**  
   clinical assessment **391**  
   clinical presentations **262–3, 387–8**  
   diagnostic procedures **388–91**  
   duration, predictive value **399**  
   etiologies **385–7**  
   evoked potentials **390–1**  
   neurobehavioral evaluation **388–90**  
   neuroimaging **390**  
 CONSORT (consolidated standards of reporting trials) checklist **2–3**  
 Consortium for Spinal Cord Medicine **532, 162**  
 constipation **429**  
 constrained action hypothesis, external focus of attention **96**  
 constrained-induced aphasia therapy (CIAT), memantine with **244**  
 constraint-induced movement therapy (CIMT) **10, 337, 606–7**  
   early intensive **16, 335–6**  
   increased sensory input **136**  
   outcome measures **338**  
   timing **241**  
 construct validity **37**  
 contact heat evoked potentials (CHEP) **618–19**  
 content validity **36–7**  
 context specificity of training  
   *see* specificity of training  
 contextual conditioning **30**  
 contextual-interference effect **98–9**  
 contiguity, in associative learning **24**  
 contingency, in associative learning **24**  
 continuous performance tasks (CPT), virtual classroom **203**  
 continuous team education **72**  
 contracts, self-rehabilitation **321**  
 contractures  
   casting and serial casting **316**  
   chronic stretch **314–15**  
   disorders of consciousness **397**  
   spastic paresis **312**  
 contrecoup brain injury **385**  
 control groups **4, 234–5**  
 conus medullaris syndrome **617**  
 cooling therapy, multiple sclerosis **647–8**  
 cooperativity, long-term potentiation **51**  
 coordinative structures, motor control **603**  
 Copenhagen stroke study **593**  
 Cornichon proteins **55**  
 corpus callosum, surgical transection **560**  
 cortical map plasticity after stroke **13–14**  
   *see also under* motor cortex  
 cortical motoneurons (CM cells) **101–2**  
   changes after stroke **85–6**  
   degeneration after spinal cord injury **5–6**  
   *see also* corticospinal tract axons, upper motor neurons  
 cortical visual prostheses **545–6**  
 corticobasal degeneration (CBD) **569–70**  
   apraxia **448–9, 454, 457**  
   inflammatory response **394**  
 corticospinal tract (CST)  
   activity-dependent plasticity **88**  
   during development **85–6**  
   lesions  
     locomotor recovery **169, 173**  
     neurotrophin-3 gene therapy **521**  
     Nogo-A antibody therapy **179**  
   olfactory ensheathing cell transplants **504–5**  
   recovery and compensation for **57**  
   retrograde neuronal degeneration **5–6**  
   Schwann cell accumulation **498**  
   stroke **56, 87**  
   origins and pathways **55–6**  
   regeneration from endogenous progenitor cells **445**  
   stroke recovery and **14, 333, 596**  
   voluntary motor control **55–6**  
 corticospinal tract axons **55–6**  
   regeneration **11**  
   cerebral palsy **215**  
   gene knockout studies **342–3**  
   neurotrophins and **408**  
   sprouting **5–14, 159**  
   *see also* upper motor neurons  
 corticostriatal fibers, effects of cortical injury **107**  
 COSMIN checklist **39**  
 cost–benefit analysis, rehabilitation robotics **181**  
 cough, aspiration risk and **264**



## Index

- coup brain injury 385
- cranial nerve palsies, after  
temporal lobectomy 563
- CREB *see* cyclic AMP response  
element-binding protein
- credentialing, assistive  
technology 172
- criterion-related validity 37
- critical illness 264–5
- critical illness myopathy (CIM)  
264–5, 663, 666
- critical illness polyneuropathy  
(CIP) 264–5, 663
- critical pathways *see* clinical  
pathways
- critical periods (sensitive periods)  
acquisition of musical abilities  
131
- auditory system development  
132–3
- functional recovery after CNS  
injury 371
- language acquisition 131
- locomotor recovery in  
spinalized rats 171
- metaplasticity after stroke 206
- for plasticity, termination by  
perineuronal nets 156–7
- stroke recovery 17, 202, 595–6
- visual system development 140
- Cronbach's  $\alpha$  coefficient 36
- cross-modal plasticity, visual  
system 140–8
- cross-talk, pathological 460
- crossover studies 235
- crustaceans, axon regeneration  
329–30
- CSPG *see* chondroitin sulfate  
proteoglycans
- cueing techniques  
gait training 66
- Parkinson's disease 571–2
- unilateral neglect 467–8
- cuneate nucleus, changes after  
sensory loss 78–9
- CX3CL1 (fractalkine) 396
- CX3CL1R (fractalkine receptor)  
396
- cybernetics 184
- cybersickness 199
- cyclic AMP (cAMP)  
axon guidance 308
- conditioning lesion effect  
356, 379
- downstream effects, as  
therapeutic targets 356–7
- infusion, spinal cord injury  
159
- modulation of axon  
regeneration 355–6,  
419–21
- Schwann cell grafts into spinal  
cord and 502
- cyclic AMP/protein kinase  
A (cAMP/PKA) pathway
- axon regeneration and 356
- mediating sensitization 65–7
- cyclic AMP response element-  
binding protein-1  
(CREB1) 66–7
- cyclic AMP response element-  
binding protein-2  
(CREB2) 67, 416
- cyclic GMP (cGMP), axon  
guidance 308, 420
- cyclic nucleotides, modulation of  
axon regeneration 420–1
- cytokines  
axon regeneration and 416–18
- cerebral palsy 215
- inflammatory response 393
- responses to implanted devices  
557
- cytoskeletal proteins  
axon regeneration role 422–4
- axonal transport 422
- Schwann cells 485
- synthesis in axon tip 424
- cytoskeleton  
granular disintegration,  
degenerating axons 275
- growth cone 301–2, 422–3
- regulation 307–8
- cytoskeleton-associated protein  
of 23 kDa (CAP-23) 424
- dantrolene 542
- Data Safety Monitoring Board  
(DSMB) 235
- DCC (deleted in colorectal  
cancer) receptor  
axon guidance 304, 308
- netrin binding 358
- deafness *see* hearing impairment
- deconditioning 367
- effects of exercise training  
372–4
- neurological disorders 369–72
- see also* bed rest
- deep brain stimulation (DBS)  
543–4
- dementia 528
- dystonia 577–8
- Parkinson's disease 345,  
543–4, 568–9
- tinnitus 135
- vs. intracortical  
brain–computer  
interfaces 577
- deep venous thrombosis (DVT),  
spinal cord injury 620–2
- default mode, transcending the  
492
- Defense Advanced Research  
Projects Agency  
(DARPA) 184–6
- deficit-compensating strategy  
600
- degeneration  
axon *see* axon degeneration
- cascading 6
- delayed  
neuronal, after ischemia 6
- oligodendrocytes, after  
axonal injury 6–8
- retrograde, after axotomy 4–7
- transneuronal, after  
denervation 4
- Wallerian *see* Wallerian  
degeneration
- degenerative diseases  
*see* neurodegenerative  
diseases
- DEKA Gen 2 arm system 185
- delayed non-matching to sample  
task 30–1
- delirium 265
- dementia 529
- behavioral problems  
*see* behavioral problems  
in dementia
- cognitive/behavioral  
assessment 511–14
- cognitive neuroscientific  
models 514
- neurogenesis theory 294
- new medications and devices  
528–9
- Parkinson's disease 569
- prevention 511
- rehabilitation 529
- caregiver involvement  
522–8
- cholinesterase inhibitor  
therapy with 522
- efficacy of learning 517–22
- learning theory and 515–17
- models 514–15
- neural substrate supporting  
509–10
- relevance 510–11
- risk factors 512
- semantic, apraxia 449–50
- vascular *see* vascular dementia
- dementia of Alzheimer's type  
(DAT) *see* Alzheimer's  
disease
- dementia with Lewy bodies  
(DLB) 569
- demyelinated axons 457–67
- conduction abnormalities  
459–60
- continuous conduction 460–1
- discontinuous conduction 462
- impedance mismatch/  
matching 464–5
- molecular remodeling 462
- Na<sup>+</sup> channel transfer from glia  
462–4
- demyelinating diseases  
axonal degeneration 278
- cell transplantation 465
- neuroprotection of axons 466
- potassium channel blockers  
459
- sodium channelopathy 462,  
464
- demyelinating polyneuropathies  
axonal degeneration 278
- electrodiagnostic studies 79–80
- demyelination 457
- axonal degeneration 278–9
- trauma-induced 6–8
- dendrites 3–4, 318–19
- dendritic cells 393
- dendritic spines 318, 324
- denervation 2–4
- diffuse vs. concentrated 15–16
- fate of CNS neurons after 2
- neuronal structural  
modifications 3–4
- neurotransmitter receptor  
changes 2–3
- reinnervation after  
*see* reinnervation
- transneuronal atrophy 3–4
- transneuronal degeneration 4
- see also* axon injury, axotomy
- denervation supersensitivity 2–3
- denial 469
- dental hygiene 155
- dentate gyrus (DG), adult  
neurogenesis 285, 288–90
- depression (clinical)  
after temporal lobectomy 561
- critically ill patients 265
- deep brain stimulation 544
- in epilepsy 551, 553–6, 558–9
- epilepsy risk in 554
- genetic factors 28
- hippocampal neurogenesis 294
- multiple sclerosis 641
- post-stroke 607–8
- postictal 555
- spinal cord injury 620, 628–9
- traumatic brain injury 544
- depression (neural)  
long term *see* long-term  
depression
- mechanisms in *Aplysia* 64–5
- short term *see* short-term  
depression
- dermatomyositis 80, 665–6
- descending pathways  
changes in injured spinal cord  
179–80
- control of locomotion 167,  
172–6
- control of spinal reflexes 85
- specific effects of  
neurotrophins 407–8
- spinal cord plasticity after  
lesions to 84
- stroke-related injury 86, 90–1
- voluntary motor control 55–7
- descriptive studies 2
- desmopressin 424, 428
- development  
astrocyte function 368
- axon growth 114, 242–3

- axon guidance 242–3, 302–8, 357–60  
 neural cell 368  
 neuromuscular synapse remodeling 482  
 neuronal cell death 255–8  
 molecular regulation 257–8  
 morphological features 256–7  
 neurotrophic hypothesis 255, 257, 400  
 retinotectal pathway 114–18  
 somatosensory system plasticity 79–80  
 spinal cord plasticity 84–6  
 trophic factors in neural 255
- developmental age  
 axonal growth after transection and 12  
 reinnervation of denervated neurons and 16–17
- developmentally related axon growth inhibitors 201, 203
- dexamethasone (DEX) 560
- dexamphetamine  
*see* amphetamines
- dexanabinol 539
- dexterity, manual *see* hand function
- diabetes insipidus 541
- diabetes mellitus  
 gastrointestinal dysfunction 429  
 type II, spinal cord injury 624
- diabetic neuropathy 79, 81, 663–4
- diaphragmatic pacing 126
- diaschisis after stroke, recovery from 12, 602
- diazepam 640
- dietitian 283
- differential learning 99–100
- diffuse axonal injury (DAI) 385, 399, 537
- diffusion tensor imaging (DTI)  
 disorders of consciousness 399  
 predicting stroke recovery 43–4, 90, 596  
 with transcranial magnetic stimulation 224  
 traumatic brain injury 537
- digital voice recorders 153
- dihydroergotamine 423–4  
 L-threo-3-4-  
 dihydroxyphenylserine (L-DOPS) 424
- disability assessment scale 313
- disinhibition (unmasking) 240  
 somatosensory system injury 76, 78
- disorders of consciousness scale (DOCS) 389–91, 399
- distal axonal degeneration (DAD) 276–7
- distributed network effects, noninvasive brain stimulation 222–3
- dizziness, post-traumatic 544  
 DKL-1 416
- donepezil 244, 479–80, 541, 641
- dopamine  
 control of locomotion 183, 344  
 denervation supersensitivity 2  
 reward learning 27
- dopamine agonists  
 impact on motor training 320  
 locomotor recovery in spinal animals 182  
 Parkinson's disease 567–8  
 stroke rehabilitation 243–4  
 traumatic brain injury 539–41  
 unilateral neglect 469
- dopamine  $\beta$ -hydroxylase (D $\beta$ H) deficiency 424
- dopamine transporter gene 28
- L-DOPS (L-threo-3-4-dihydroxyphenylserine) 424
- dorsal column lesions  
 chondroitinase ABC therapy 159–60  
 locomotor recovery in cats 169  
 somatosensory system plasticity 78–9
- dorsal funiculus, locomotor control in rats 172–3
- dorsal premotor cortex (PMD and prePMD) 53, 99–100, 103  
 reorganization after stroke 85–6, 89  
 voluntary motor control 55
- dorsal root ganglion (DRG) neurons  
 cAMP dependence of conditioning lesion effect 356  
 CSPGs and regeneration 382  
 cytoskeletal proteins in regenerating 423  
 neurotrophins and regeneration 403–4, 418  
*see also* sensory neurons
- dorsal root injury, somatosensory system plasticity 77
- dorsolateral funiculus (DLF) lesions, locomotor recovery in cats 169  
 locomotor control in cats 167
- Dosset boxes 484
- double blind clinical trials 234
- Down's syndrome (DS) 259, 210, 370, 375
- Dragon (RGMb) 306–7
- dressing  
 assessment in dementia 513  
 assistive technology 155  
 dressing sticks 155
- drinking, assistive technology 156
- driving  
 spinal cord injury 625–7  
 virtual reality applications 207–8
- drop foot *see* foot drop
- Drosophila melanogaster*  
 axon guidance 303–4, 308  
 specificity of synaptic connections 323  
 Wallerian degeneration 276
- drug-induced myopathies 80
- dSarm 276
- Dscam 304, 323
- dual-task paradigms  
 Alzheimer's disease 519  
 balance control 112, 359  
 virtual reality 205–7  
*see also* cognitive tasks, secondary
- Duncan, Carl 27–8
- dying back, axonal 276–7
- dynactins 422
- dynamic gait index 42, 112
- dynamic postural stability during gait 109–10  
 assessment 112  
 treatments to enhance 114
- dynamic post-urography 110–13
- dynamic splints 315
- dynamic turnover, principle of 16–17
- dynamic visual acuity (DVA) testing 360–1
- dynammin-related protein 1 (DRP-1) 262–3
- dynein 422
- dysexecutive syndrome 489–91  
*see also* executive dysfunction
- dysmyelinated axons 457–67  
 conduction abnormalities 459–60  
 Na<sup>+</sup> channels 461  
*see also* demyelinated axons
- dysmyelination 457
- dysphagia 405–12  
 causes 407  
 disorders of consciousness 396–7  
 evaluation *see* swallowing, evaluation  
 learned non-use 411–12  
 multiple sclerosis 648  
 Parkinson's disease 574  
 pharyngeal stimulation 138, 245, 410–11  
 recovery 409–10  
 treatment 407–11  
 acute phase 264  
 alternative explanations of effects 412  
 effects on plasticity 409–11
- multiple sclerosis 648  
 negative effects 412  
 outcome measures 409  
 Parkinson's disease 574  
 rehabilitative 408–9  
 stroke 609–10
- dystonia 567, 574–9  
 classification 574–5  
 clinical features and diagnosis 576–7  
 focal hand *see* hand dystonia, focal  
 genetics 575–6  
 medical and surgical treatment 577–8  
 neurobiology 555, 576  
 Oppenheim (DYT1) 575–6  
 rehabilitation 578–9
- dystrophic growth cones (dystrophic axons) 7, 9–10, 376–8  
 cellular interactions 380  
 stabilization by NG2+ cells 384
- DYT1 gene polymorphism 30
- e-books 158
- early neurorehabilitation 261–72  
 bed rest and its consequences 265–8  
 clinical syndromes 262–3  
 comorbidity and complications 263–4  
 critical illness 264–5  
 interventions 268–71  
 organization 271–2, 279–80  
 upper extremity 270–1, 335–6
- eating, assistive technology 156
- ecological validity 25
- economics  
 clinical pathways 73  
 neurorehabilitation 285–6  
 traumatic brain injury 535
- ectopic impulse generation 460
- Edinburgh virtual errands test (EVET) 206
- education  
 continuous team 72  
 epilepsy 559  
 falls prevention 114
- educational level  
 dementia development and 509–10  
 impact of epilepsy 551, 556–7  
 spinal muscular atrophy 658–9
- EEG *see* electroencephalography
- effect size 38
- ejaculation, retrograde 429
- elderly  
 auditory function 132–3  
 carotid sinus hypersensitivity 425  
 cognitive remediation studies 517–18  
 dementia prevention 511

## Index

- elderly (cont.)  
 efficacy of aphasia rehabilitation 444  
 falls 105  
 motor learning strategies 97  
 stroke recovery 9  
*see also* aging
- electric powered wheelchairs (EPW) 165–8
- electrical feedback approaches 528
- electrical stimulation  
 biomimetic neural prostheses 542  
 injured spinal cord in animal models 183–4  
 neuromodulation approaches 543–4  
 paired associative, spastic paresis 321  
*see also* brain stimulation, functional electrical stimulation, peripheral nerve stimulation
- electroconvulsive shock (ECS), memory dysfunction 27–8
- electrocorticography (ECoG)-based brain–computer interfaces 549, 567  
 clinical use 577  
 methods 568–9  
 vs. intracortical BCIs 578
- electrodes  
 functional electrical stimulation systems 121–2, 254–5  
 implantable 121–2, 255  
 intracranial brain–computer interfaces 577–9  
 surface 121, 254–5  
*see also* microelectrodes, implanted
- electrodiagnostic tests 77–82  
 spinal cord injury 617–19  
*see also* electromyography, nerve conduction studies
- electroejaculation 130, 430, 631
- electroencephalography (EEG) 565  
 after stroke 87  
 predicting recovery from brain injury 399
- electroencephalography (EEG)-based brain–computer interfaces (BCIs) 549, 567  
 methods 567–8  
 vs. intracortical BCIs 578
- electromyography (EMG) 77–82  
 assessment of weakness 77–80  
 basic principles 77  
 gait analysis 62, 81, 343  
 interpretation of report 81  
 in movement 80–1  
 outcome assessment 81–2
- powered orthoses using 184  
 spinal cord injury 619  
 surface (SEMG) 80–1
- electronic aids for daily living (EADLs) 152
- electronic memory aids 483–4
- eMagin head-mounted display (HMD) 200–1
- embodied cognition theory 441
- embryonic stem (ES) cells  
 derived motor neurons, spinal cord transplants 444–5  
 directed differentiation 437  
 isolation and properties 439  
 neural induction 439  
 spinal cord transplants 442, 449, 589
- emotional disorders  
*see* psychiatric disorders
- employment  
 after temporal lobectomy 562
- epilepsy and 551, 556–8  
 polio patients 660
- encephalopathy of prematurity 211
- endocrine dysfunction  
 spinal cord injury 624  
 traumatic brain injury 541
- endoneurial tubes, peripheral axon regeneration along 473–4
- endoplasmic reticulum (ER) stress 262, 264–7
- endurance  
 immobility and 270  
 local muscular 331  
 walking tests measuring 42
- endurance training, multiple sclerosis 646–7
- energy conservation course, multiple sclerosis 648
- energy expenditure 374–8  
 biomechanical and metabolic factors 374–6  
 effects of rehabilitation 377–8  
 factors affecting 376–7
- enriched environments  
 adult neurogenesis and 289  
 stroke recovery and 603
- enrichment strategies, rehabilitation trials 5
- enteral nutrition *see* tube feeding
- enteric nervous system 415
- entrainment enhancement, noninvasive brain stimulation 223
- entrapment neuropathies 78
- environment 279  
 enriched *see* enriched environments  
 influences on balance control 112
- environmental control devices/units (ECUs) 150, 152, 625
- environmental cueing, memory dysfunction 515
- environmental dependency syndrome 490
- environmental modification  
 falls prevention 114–15  
 memory dysfunction 485
- environmental skill-building program (ESP) 527
- ependymal cells 392  
 injured spinal cord 448
- Eph receptors  
 axon guidance 306  
 regulation of synaptogenesis 321, 323
- retinotectal pathway  
 development 116  
 regeneration 118–19
- ephedrine 423
- ephexin 359
- ephrins 203  
 axon guidance 306  
 axon regeneration 309, 344, 359–60, 383  
 changes after stroke 203  
 regulation of synaptogenesis 321, 323
- retinotectal pathway  
 development 116  
 regeneration 118–19
- epidermal growth factor (EGF) astrocyte development 369  
 neural precursor cell responses 287, 289
- epidural spinal cord stimulation 183–4, 548
- epigenetic adaptation, sound localization cues 125–6
- epilepsy 550–63  
 cognitive impairments 551–2, 557–8  
 gene therapy 522  
 impact on patients' lives 550–1  
 obstacles to personal and social development 551–7  
 pediatric *see* children, with epilepsy  
 post-traumatic 392, 542  
 psychiatric disorders 550–1, 553–6, 558–60  
 psychosocial problems 556–7, 559  
 rehabilitation 550–63  
 epilepsy surgery and 559–63  
 need for 550  
 strategies 557–9  
 surgery 559–63  
*see also* seizures
- epileptic aphasia of childhood, acquired 550
- epimysial electrodes 121, 255
- epinephrine (E)  
 autonomic function 417
- facilitation of memory 28  
 plasma, orthostatic hypotension 421–2
- epithelial V-like antigen (EVA-1) 305
- erectile dysfunction 429–30, 641
- ergometry, functional electrical stimulation 125, 630
- ERGYS clinical rehabilitation system 125
- ERK (extracellular-regulated kinase) pathway  
 axon injury 416  
 axon regeneration and 356  
 long-term potentiation 54  
 neuronal survival 257
- errorless learning 97–8  
 aphasia 439  
 dementia 515–17, 521–2  
 executive dysfunction 482
- erythropoietin 424, 539
- escaped fibers, during muscle reinnervation 474–5, 478–9
- essential tremor (ET) 567, 569
- ethical issues, implanted neural prostheses 550
- EVA-1 (epithelial V-like antigen) 305
- evoked potentials  
 disorders of consciousness 390–1  
*see also* motor evoked potentials; somatosensory evoked potentials
- excitability, brain  
 after stroke 197–9  
 noninvasive brain stimulation inducing 246
- excitatory postsynaptic potentials (EPSP) 36
- EXCITE trial 335, 337, 606–7
- excitotoxicity  
 cerebral palsy 214  
 neurodegenerative diseases 261–2
- executive dysfunction 489–96  
 clinical features 489–91  
 noninvasive brain stimulation 227  
 rehabilitation 492–6
- executive function 489  
 cognitive theories 491–2  
 virtual reality applications 205–7
- exercise  
 amyotrophic lateral sclerosis 657  
 brain reserve capacity and 509  
 functional electrical stimulation 125, 630  
 induced hypotension 422  
 inflammatory myopathies 665–6  
 physiology of acute 367–8, 370

- exercise capacity 367–74  
 factors affecting 368–9  
 measurement 368–9  
 neurological disorders 369–72  
*see also*  $VO_2$  max
- exercise training  
 critical illness myopathy 666  
 energy costs of walking after 378  
 genetic influences on response 28  
 long-term adaptations 372  
 in neurological disorders 372–5  
 modes 372–3  
 multiple sclerosis 373, 375, 646–7  
 Parkinson's disease 375, 570  
 post-polio syndrome 659  
 postural tachycardia syndrome 426  
 recommendations 378  
 stroke 9–10, 373, 375  
 early phase 268–71  
 timing of onset 373  
*see also* treadmill training
- expanded disability status scale (EDSS), Kurtzke 643
- experience-dependent plasticity  
 cerebral cortex 103–6  
 disorders of consciousness 394  
 genetic factors 29  
 memory consolidation 31  
 ocular dominance 160  
 post-injury 108–9  
 stroke recovery 12–15  
*see also* activity-dependent plasticity, learning
- experimental allergic encephalomyelitis (EAE)  
 axonal degeneration 278  
 $Na^+$  channel expression 461–2  
 neuroprotection of axons 466  
 stem cell therapies 587–8
- experimental spinal cord injury  
 232–3, 529, 531  
 bilateral staggered hemisection 175–6, 182  
 clinical translation issues 247–9  
 complete section *see* spinal cord transection  
 incomplete 169–76, 180  
 locomotor recovery 161, 166–84, 349  
 cat models 166–71, 348  
 interventions stimulating 180–4, 536–7  
 kinematic analysis *see* under kinematic analysis  
 mouse models 176–7  
 olfactory ensheathing cell transplants 505  
 outcome measures 530, 532–4  
 rat models 171–6  
 spinal plasticity underlying 177–80  
 locomotor training 61, 170–1, 180–1, 184  
 lower vertebrates 330–4  
 models and outcomes 530, 532  
 nonhuman primates 537, 248  
 sensorimotor outcome assessment 529–37  
 unilateral hemisection 532  
 changes in 5-HT neurons 179  
 changes in descending pathways 179  
 locomotor recovery 169–71, 173, 177  
 experimental study designs 2  
 experimental treatments  
 clinical trials *see* clinical trials  
 criteria for initiating human studies 231–2  
 expiratory muscle strength training (EMST), Parkinson's disease 574
- explicit motor learning strategies 97–8
- extinction 160  
 chronic musculoskeletal pain 291, 294–5
- extracellular matrix (ECM)  
 effects of rehabilitation on 161  
 injured nervous system 157–9, 243  
 normal/uninjured nervous system 155–7  
 as therapeutic target, in spinal cord injury 159–60, 244
- extracellular matrix (ECM) molecules  
 axon guidance cues 303–4  
 inhibiting axon regeneration 243, 376–86  
 secreted after stroke 201–3  
*see also* chondroitin sulfate proteoglycans
- extubation 267
- eye movements, role in balance 359–60
- eye patches, neglect 468
- eyeblink conditioning 25–6, 29–30
- EyeToy, Sony PlayStation 200, 202, 209
- F-actin (filamentous actin) 301–2, 307–8
- FAAST (flexible action and articulated skeleton toolkit) 202
- facial nerve injury, electrodiagnostic testing 81–2
- facilitated communication (FC) 227
- facilitation (neural) 36  
 $Ca^{2+}$ -dependent mechanisms 41–2  
 intermediate-term, in *Aplysia* 68  
 long-term (LTF), in *Aplysia* 66–8  
 quantal mechanisms 38  
 synapse specificity 44–5  
 vs. long-term potentiation 51  
*see also* sensitization
- facilitation site models 41–2
- factorial study designs 235
- falls 105  
 carotid sinus hypersensitivity 425  
 fear of 110, 112  
 prevention 112–15, 151–2  
 Parkinson's disease 572–3  
 traumatic brain injury 535  
 vestibular dysfunction 363–4
- familiar auditory sensory training task (FAST) 394
- family caregivers, dementia 523, 525–8  
 epilepsy patients 559, 562  
 nursing assistant interactions, dementia 524  
 support, disorders of consciousness 393, 398
- fampridine *see* 4-aminopyridine
- Fas-Fas ligand, neuronal death 257
- fatigue  
 multiple sclerosis 641  
 traumatic brain injury 544
- fear  
 of falling 110, 112  
 ictal 554–5  
 fear conditioning 26–7, 30  
 chondroitinase ABC therapy 160
- feedback  
 electrical 528  
 facilitating sensory training 305  
 gait training 66  
 neglect rehabilitation 468, 471  
*see also* biofeedback, visual feedback
- feeding behavior, *Aplysia* 69–70
- female reproductive dysfunction 430
- fetal neural precursor cells, human, spinal cord transplants 441
- fetal spinal cord (FSC) transplants, spinal cord injury 436–7
- fetal tissue transplants, spinal cord injury 436–7
- fibrinogen 344, 378
- fibroblast growth factor-2 (FGF-2) *see* basic fibroblast growth factor
- fibroblast growth factors (FGFs), synaptogenesis 322
- fibroblasts  
 generation of neurons from 448  
 olfactory ensheathing cell populations 504
- fibromyalgia 290, 295
- fibronectin 158–9, 383
- fibrous scar 158–9
- Fick equation 367–8
- filopodia  
 dendritic 318  
 growth cone 301–2, 422–3
- Finetech–Brindley (Vocare) bladder control system 129–30, 428–9, 543
- finger extension, post-stroke 334, 596
- finger-tapping task 85
- ingolimid 640
- fish  
 adult neurogenesis 284–5  
 axonal regeneration 118–19, 330–2  
 retinotectal map development 114–15
- fitness, physical 269–70  
*see also* exercise capacity
- flecainide, axonal neuroprotection 466
- flexion-withdrawal reflexes 83, 535  
 development 85–6
- Flk1 *see* vascular endothelial growth factor receptor 2
- floor effects, outcome measures 41
- Florida apraxia battery (FAB) 456
- fludrocortisone 422–3
- fluoxetine 29, 320
- fMRI *see* functional magnetic resonance imaging
- focal hand dystonia *see* hand dystonia, focal
- Food and Drug Administration (FDA) 449
- food preparation, assistive devices 158
- food reaching and grasping tasks 534–6
- foot drop  
 functional electrical stimulation 125, 606  
 motor neuroprostheses 256–8  
 neural prostheses 547–8
- footprint analysis 533–5
- foreign body response, implanted neuroprostheses 557–8

## Index

- forelimb  
 amputations, somatosensory reorganization 77  
 injuries, motor cortex plasticity 106  
 motor recovery measures 534–5  
 musculature, cortical representations 99–100  
*see also* upper extremity  
 4.1N protein 55  
 fractalkine (CX3CL1) 396  
 fractalkine receptor (CX3CL1R) 396  
 fragile-X syndrome 58  
 free radicals 261–2  
 Freehand System® 127–9, 258–9, 546, 630  
 Frenchay arm test (FAT) 313  
 frequency of rapid alternating movements, of maximal amplitude 313  
 frequenin (NCS-1) 42  
 Fresnel prisms 501  
 frogs  
 regeneration of retinal ganglion cell axons 118–19, 306, 334  
 retinal regeneration 333–4  
 retinotectal map development 114–15  
 spinal cord regeneration 333  
 frontal lobe  
 executive function 489  
 lesions  
 apraxia 450  
 dysexecutive syndrome 489–91  
 memory functions 31–2  
 motor functions 53, 102–3  
 frontal lobe epilepsy 560  
 frontotemporal dementia 260–1  
 frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) 394  
 Fugl-Meyer assessment of motor performance (FMA)  
 arm subscale (FM-A) 41, 338  
 leg subscale (FM-L) 40–1  
 functional activities, virtual reality applications 207–8  
 functional assessment, sensorimotor  
*see* sensorimotor function assessment  
 functional connectivity analysis, aphasia 443  
 functional electrical stimulation (FES) 120–30, 555  
 applications 123–30, 546–8  
 critical illness myopathy 666  
 mechanisms of action 120–1  
 motor neuroprostheses 253–6  
 spinal cord injury 125–30, 630–1  
 functional recovery research 125–6  
 functional uses 126–30  
 therapeutic exercise 125  
 spinal muscular atrophy 658  
 stimulation parameters 122–3  
 stroke rehabilitation 124–5, 547–8, 605–6  
 system components 121–2, 128  
*see also* neural prostheses  
 functional independence  
 measure (FIM) 67  
 pattern of recovery after stroke 591–3  
 predictive value in stroke 594  
 functional magnetic resonance imaging (fMRI) 84  
 aphasia rehabilitation 442–3  
 blindness 129–30  
 stroke 13–14, 87–9  
 predicting recovery 44–5, 90–1  
 tactile perception 142–4  
 transcranial magnetic stimulation (TMS) with 224  
 traumatic brain injury 537  
 functional neuroimaging  
 Alzheimer's disease 510  
 aphasia rehabilitation 442–3  
 blindness  
 auditory spatial function 127–30  
 visual cortical function 144  
 disorders of consciousness 390  
 praxis control 454  
 stroke/focal brain injury 84–92  
 cerebral reorganization 13–14, 85–9, 196–7  
 choice of motor task 84–5  
 predicting recovery 43–5, 90–1  
 therapeutic interventions 90  
 techniques 84  
 transcranial magnetic stimulation (TMS) with 224  
 visual cortical function and tactile perception 142  
*see also specific modalities*  
 functional neuromuscular stimulation (FNS)  
*see* functional electrical stimulation  
 functional reach test 110  
 functional residual capacity (FRC) 266  
 GABA ( $\gamma$ -aminobutyric acid)  
 effects of spinal cord injury 177–8  
 retinotectal pathway development 117–18  
 signaling after stroke 197–9  
 somatosensory system injury 76  
 GABA<sub>A</sub> receptor  $\alpha$ -5 inverse agonists, stroke recovery and 198  
 GABA<sub>A</sub> receptors, spinal cord injury 178  
 GABAergic neurons, replacement after spinal cord injury 446  
 gabapentin 428, 552–3, 623  
 gait  
 compensatory strategies after stroke 15–16, 602  
 dynamic stability during  
*see* dynamic postural stability during gait  
 speed *see* walking speed  
*see also* locomotion; walking  
 gait analysis 62–3  
 clinical relevance 42–3, 350  
 electromyography (EMG) 62, 81, 343  
 gait disorders 63–4, 343–51  
 assistive technology 151–2  
 hemiparesis 63–4, 346–8, 604  
 paraparesis 64  
 Parkinson's disease 344–5  
 spastic 345–8  
 gait trainer device 65, 190  
 gait training 64–6  
 applying learning theories 100–3  
 approaches 64  
 attentional focus and 102  
 cues and feedback 66  
 electromechanical and robotic-assisted 190–5  
 advantages 190–2  
 devices available 190  
 disadvantages 192  
 multiple sclerosis 647  
 subgroup analysis 193–4  
 systematic review of evidence 192–5  
 home based 66  
 implicit 102  
 neural repair strategies and 67  
 Parkinson's disease 66, 571–2  
 pulse therapies 66  
 rationale 61–2, 349  
 spinal cord injury 184, 348–50  
 rationale 61–2  
 stroke 190–5, 271, 348  
 task-oriented 64–6  
 variability of practice 102–3  
 virtual reality applications 210  
*see also* treadmill training  
 games, computer  
 exercise training 372  
 rehabilitation robotics with 181–2  
 gaming platforms, virtual reality systems using 202  
 $\gamma$ -aminobutyric acid *see* GABA  
 $\gamma$ -retrovirus gene vectors 515, 517  
 gangliosides, myelin-associated glycoprotein interactions 352  
 GAP-43 (growth-associated protein-43) 10, 332, 424  
 gastroesophageal reflux 264  
 gastrointestinal dysfunction 428–9  
 spinal cord injury 429, 621  
*see also* bowel function  
 gastroparesis 429  
 GAT-3/4 198  
 gaze stability  
 functional measurements 360  
 role in balance control 359–60  
 vestibular exercises 361  
 gene therapy 514–22  
 ex vivo 514–15  
 in vivo 514–15  
 spinal cord injury 247, 518, 521  
 trophic factor delivery 514–22  
 limitations 522  
 methodologies 514–17  
 specific neurological diseases 517–22  
 vector selection 516–17  
 vectors 515–17  
 genetic factors 25–30  
 attention to task 27–8  
 axon regeneration in adulthood 243  
 depression 28  
 learning 27  
 less studied 29–30  
 neuroplasticity 25–7  
 therapeutic responses 28–9  
 traumatic brain injury outcome 537–8  
 genitourinary evaluation, spinal cord injury 621  
 germinal matrix hemorrhage, perinatal 211  
 Geron Corporation 442, 449  
 ghrelin 429  
*Ginkgo biloba* 480  
 Glasgow coma scale (GCS) 389  
 glatiramer acetate 640  
 glial cells 367–73  
 axon regeneration role 371–3  
 lower vertebrates 333–4  
 CNS inflammation 392–3  
 diversity, development and functions 367–71  
 Na<sup>+</sup> channel transfer to axons 462–4  
 regulation of synaptogenesis 322  
 types 367, 392  
*see also* astrocytes; microglia; oligodendrocyte(s); Schwann cells

- glial-derived neurotrophic factor (GDNF)  
 amyotrophic lateral sclerosis gene therapy 520  
 Huntington's disease gene therapy 520  
 Parkinson's disease gene therapy 519  
 peripheral axon regeneration and 403–4  
 peripheral neuron survival and 402  
 spinal cord injury  
 gene therapy 521  
 with Schwann cell grafts 501  
 stroke gene therapy 522  
 therapeutic potential 259  
 glial fibrillary acidic protein (GFAP), traumatic brain injury 536  
 glial-restricted precursors (GRP) differentiation from  
 neuroepithelial cells 437  
 isolation and properties 438–9  
 spinal cord transplants 380, 441–7, 449  
 glial scar 158–9, 376–86  
 around implanted devices 557–8  
 methods of studying 560–1  
 strategies for minimizing 559–60  
 cellular environment 379–81  
 dystrophic axons 376–8  
 formation 157–8, 360, 371, 378–9  
 growth-inhibiting molecules 381–3  
 growth-promoting molecules 383–4  
 inhibition of axon  
 regeneration 360, 376–86  
 molecular environment 381–4  
 penumbra vs. core 384  
 potential interventions 384–5  
 protective role 376  
 spinal cord injury 157–9  
 gliosis, reactive *see* astrogliosis, reactive  
 Gln-Tyr-Asn-Ala-Asp (QYNAD) peptide 460  
 globus pallidus internus (GPi) stimulation  
 dystonia 577–8  
 Parkinson's disease 543–4, 568–9  
 glutamate  
 cerebral palsy 212–14  
 control of locomotion 182  
 denervation supersensitivity 3  
 enhanced uptake, long-term sensitization 66  
 long-term potentiation 52–5  
 neurodegenerative diseases 262  
 stroke recovery and 198–9  
 glutamate receptors (GluR) cerebral palsy 214  
 long-term depression 55–7  
 long-term potentiation 52–5  
 metaplasticity 57  
 neurodegenerative diseases 262  
 role in locomotion 182  
 subtypes 52–3  
 synaptogenesis 319–20  
*see also specific subtypes*  
 glycine, spinal cord injury 177–8  
 glycogen synthase kinase (GSK) 420  
 glycoprotein 130 (gp130) 416–17  
 glycosaminoglycans (GAGs) 156  
 goal-attainment scaling 313  
 goal-directed behavior 495–6  
 goal selection and goal neglect theory 492  
 goldfish, neural regeneration 284–5, 331–2  
 grab bars 151  
 Gram-positive organisms, cerebral palsy pathogenesis 214  
 granular degeneration of cytoskeleton, Wallerian degeneration 275  
 granule cells, hippocampal, newly generated 289–90  
 granulocyte colony-stimulating factor (G-CSF), stroke therapy 248  
 grasping  
 motor compensations after stroke 600–2  
 strategy, balance control 109  
 systems restoring, in tetraplegia 127–9  
 tasks, animal models 534–6  
 virtual reality applications 208, 210  
 grating orientation tactile discrimination task 141–2  
 grid-walking test 533, 536  
 GRIP1 protein 57  
 grooming, assistive technology 155  
 grooming test 534–5  
 group B streptococcus (GBS), cerebral palsy pathogenesis 214  
 growth, axon *see* axon growth  
 growth-associated proteins 424  
*see also* GAP-43  
 growth cones 301–2  
 calcium and motility 422  
 cytoskeleton 301–2, 422–3  
 regulation 307–8  
 dystrophic *see* dystrophic growth cones  
 guidance *see* axon guidance  
 local protein synthesis 424  
 modulating response to guidance cues 308  
 regenerating axons 423, 425  
 growth factors  
 distal axonal degeneration 277  
 neural induction of pluripotent stem cells 439  
 neural precursor cell responses 287–8  
 neural stem cell differentiation 437–8  
 therapeutic studies 248, 245  
*see also* neurotrophic factors; *specific factors*  
 growth hormone deficiency 393, 541  
 guanfacine 469  
 guidelines, clinical practice 70  
 Guillain-Barré syndrome (GBS) 660–2  
 electrodiagnostic testing 79, 81  
 exercise capacity 370  
 exercise training 375  
 pathophysiology 459–60  
 rehabilitation and outcome 660–2  
 therapy in acute phase 660–1  
 gunshot wounds, head 385–6  
 gustatory sweating 431  
 H-reflexes  
 adaptive changes in normal life 86–8  
 operant conditioning studies 88–91  
 therapeutic applications of conditioning 92  
 H200 system *see* Ness H200 system  
 habituation 23, 63  
 neural mechanisms in *Aplysia* 64–5  
 sensory, balance rehabilitation 112–13  
 hand dystonia, focal 555, 576  
 rehabilitation 578  
*see also* writer's cramp  
 hand function  
 neuroprostheses, spinal cord injury 127–9, 546–7  
 stroke  
 changing somatosensory input 246  
 compensatory strategies 16, 600–2  
 functional electrical stimulation 124  
 predicting recovery 595–7  
 virtual reality systems 208–10  
 hand function survey 300  
 hand grip tasks, functional neuroimaging 85  
 handrails 151–2  
 haptic discrimination  
 blindness 141  
 neural basis of visual involvement 143–4  
 visual cortical involvement 142  
*see also* tactile perception  
 haptic feedback, virtual reality systems 200–1  
 harnesses, for gait training 65  
 Harrison, Ross Granville 301  
 head and neck supports, wheelchair 171–2  
 head injury *see* traumatic brain injury  
 head mounted displays (HMD), virtual reality systems 199–201  
 head movements  
 measuring gaze stability during 360  
 vestibular control 108, 357–9  
 head-related transfer function (HRTF) 126  
 headache  
 chronic tension 289  
 post-traumatic 544  
*see also* migraine  
 hearing assessment, disorders of consciousness 395  
 hearing impairment 132–5  
 auditory prostheses 544–5  
 cochlear implants 133, 544–5  
 cortical reorganization in congenital 132  
 during life span 132–3  
 tinnitus and 134–5  
 heart disease  
 exercise capacity and 369–71  
 stroke patients 263, 268  
 heart rate (HR)  
 during exercise 368  
 training-induced changes 372  
 VO<sub>2</sub> max estimation 368  
 heat shock factors (HSFs) 264–6  
 heat shock proteins (HSPs) 264–7  
 heat stress response (HSR) 264–6  
 Hebbian plasticity 50  
 cortical motor systems 104  
 development of visual connections 116–18  
 long-term potentiation 51–2  
 NMDA receptor activation 53  
 somatosensory system 76–7  
*see also* activity-dependent plasticity  
 hedgehog proteins 306  
 hemi-cord syndrome (Brown-Séquard syndrome) 169, 617  
 hemineglect *see* neglect, unilateral  
 hemiplegia/hemiparesis after temporal lobectomy 562–3  
 anosognosia for 470

## Index

- hemiplegia/hemiparesis (cont.)  
 assistive technology 152  
 compensatory movements 15–16, 600–1  
 corticospinal tract lesions 56  
 functional electrical stimulation 124–5  
 gait disorder 63–4, 346–8  
 peripheral nerve stimulation 137–8  
 shoulder pain *see* shoulder pain, hemiplegic  
 threshold joint angles 605  
 upper extremity rehabilitation 330–9  
*see also* stroke
- herbal remedies, memory dysfunction 480
- hereditary spastic paraparesis (HSP) 277–8
- herpes simplex virus (HSV) vectors 515, 517
- heterotopic ossification (HO) 543, 622–3
- hierarchical substitution, principle of 16
- high-load brief stretch (HLBS) 315
- high resolution perimetry (HRP) 503–4
- hip strategy, balance control 108–9, 114  
 vestibular loss 357
- hippocampal formation 50
- hippocampus  
 adult neurogenesis 288–90  
 induced 292–3  
 medical implications 294  
 architecture 50–1  
 learning and memory 25, 28–31  
 long-term depression 55–6  
 long-term potentiation 51–5  
 neural precursor cells 285  
 slice preparation 50–1
- hippothalamy, multiple sclerosis 647–8
- HIV *see* human immunodeficiency virus
- Holmes–Adie pupil 419, 431
- home automation systems 152
- home-based interventions, dementia 527–8
- home environment  
 control devices 150, 152  
 falls prevention 114–15
- homeostatic plasticity 2–3, 11–12
- horizontal fibers, motor cortex 104
- horizontal ladder test 533–4
- Horner’s syndrome 419
- hospital stay, duration, effects of clinical pathways 72–3
- 5-HT *see* serotonin
- 5-HTTLPR (serotonin-transporter-linked polymorphic region) 28
- human immunodeficiency virus (HIV)-associated peripheral neuropathy 277
- human immunodeficiency virus (HIV)-related myopathy 80
- huntingtin (Htt) 260, 264, 268
- Huntington’s disease (HD)  
 apraxia 448, 457  
 cell death mechanisms 259–61, 268  
 gene therapy 518–20  
 mitochondrial dysfunction 264  
 rehabilitation 579
- hyaluronic acid 243
- hyaluronidase 157
- hydrocephalus 393, 541–2
- 5-hydroxytryptamine *see* serotonin
- 25-hydroxyvitamin D (25-OHD) deficiency, Parkinson’s disease 573
- hyperacuity task, tactile *see* tactile hyperacuity task
- hypercalcemia, immobilization 624
- hyperhidrosis 431
- hypertension  
 autonomic disorders 426–7  
 supine 427
- hypertensive subcortical arteriosclerotic encephalopathy 569
- hyperthermia 431
- hypopituitarism, post-traumatic 393, 541
- hypotension  
 orthostatic (postural) *see* orthostatic hypotension  
 postprandial 422, 424
- hypothalamus, thermoregulation 430
- hypothermia  
 autonomic dysfunction 431  
 therapeutic, traumatic brain injury 538–9
- hypoxic-ischemic encephalopathy 212, 214
- IBB forelimb dexterity test 534, 536
- iceberg effect 76
- ICF *see* International Classification of Functioning, Disability and Health
- ideomotor apraxia test (IAT) 456
- imagery techniques  
 Parkinson’s disease 571  
 phantom limb pain 294  
 unilateral neglect 469
- imaging *see* neuroimaging
- immersion, virtual reality systems 198–9
- immune response, activation 393
- impedance mismatch/matching, demyelinated axons 464–5
- implantable electrodes 121–2, 255  
*see also* microelectrodes, implanted
- implantable neuroprostheses *see* neural prostheses
- implanted pulse generator (IPG) 122
- implicit motor learning strategies 97–8, 102
- importins 416
- impulse reflection 460
- IN-1 monoclonal antibody 340, 350, 355  
*see also* Nogo-A antibodies
- inclusion body myositis (IBM) 665–6
- Independence 3000 IBOT Transporter 166–7
- Independent Data Monitoring Committee (IDMC) 235
- induced pluripotent stem (iPS) cells  
 directed differentiation 437  
 neural induction 439  
 production and properties 439  
 spinal cord transplants 445
- infants, language and speech development 131
- infections, maternal intrauterine 212, 214–15
- inferential study designs 2
- inferior parietal lobule (IPL), blind humans 129–30
- inflammatory myopathies 80, 665–6
- inflammatory response 392–7  
 $\alpha$ -synucleinopathies 394  
 Alzheimer’s disease 393–4  
 amyotrophic lateral sclerosis 395–6  
 axon regeneration and 416–18  
 cerebral palsy 214–15  
 glial cells 392–3  
 glial scar formation 378–9  
 implanted neuroprostheses 542–3, 557–8  
 microelectrode insertion procedure 557  
 microglial signaling in resolution 396–7  
 Parkinson’s disease 394  
 signaling mechanisms 393–4  
 tauopathies 394
- inhibition (neural)  
 after stroke 198  
 impaired, in dystonia 576  
 injured spinal cord 177–8  
 non-invasive brain stimulation inducing 246–7  
*see also* disinhibition
- inhibitory postsynaptic potentials (IPSP) 36
- inpatient rehabilitation facility (IRF) 286
- instrumental activities of daily living (IADL), assistive devices 157–8
- instrumental learning *see* operant conditioning
- insular cortex, changes after stroke 85
- insulin-like growth factor-1 (IGF-1)  
 after stroke 201, 204  
 gene therapy, amyotrophic lateral sclerosis 520  
 neural precursor cell responses 287, 290
- integrated care pathways *see* clinical pathways
- integrins 304, 358
- intellectual disability 58
- intensity of therapy  
 aphasia 443–4  
 disorders of consciousness 394  
 stroke 9, 282–4, 335–6, 604
- intensive care unit (ICU) 262, 264–8
- intensive language action therapies 440
- interdisciplinary model 281
- interferon- $\beta$ -1a 640
- interferon- $\beta$ -1b 640
- interferon- $\gamma$  (IFN- $\gamma$ ) 378–9
- interhemispheric balance effect, noninvasive brain stimulation 223
- interhemispheric inhibition (IHI) 142–3
- interhemispheric rivalry concept 144–5
- interim analysis 235
- interleukin-1 (IL-1) 215, 378, 538
- interleukin-1 receptor antagonist (IL-1ra) 538
- interleukin-6 (IL-6) 416, 538
- interleukin gene polymorphisms 28, 538
- intermediate-term sensitization and facilitation, in *Aplysia* 68
- intermittent catheterization (IC), spinal cord injury 621, 623
- internal capsule  
 corticospinal tract axons 55  
 lesions, post-stroke hand function and 596–7
- International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP) 449

- International Classification of Functioning, Disability and Health (ICF) 278–9  
multiple sclerosis 643  
outcome measures and 35, 236–7  
recovery and compensation 599–600  
stroke recovery and 7, 585–6
- international conference on harmonization (ICH) 234
- International Society for Stem Cell Research (ISSCR) 449
- international standards for the neurological classification of spinal cord injury (ISNCSCI) 237–8, 617
- interneurons (INs)  
*Aplysia* reflexes 64  
spinal, locomotor control 167, 169, 173
- interpositus nucleus (IP), cerebellar 25–6
- interpretability, outcome measures 38
- InterQual guidelines 286
- interrater reliability 36
- InterStim system, Medtronic 543
- intracortical brain–computer interfaces (BCIs) 549, 567, 569–70  
advantages 577–9  
direct speech 579  
future engineering efforts 581–2  
motor 579–81  
problems of long-term use 556, 581–2  
tetraplegia 578–9  
*see also* microelectrodes, implanted
- intracortical microstimulation (ICMS) 101, 104–5
- intracranial brain–computer interfaces (BCIs) 577–82  
future engineering efforts 581–2  
signal sources and electrode types 577–9  
*see also* electrocorticography (ECoG)-based brain–computer interfaces, intracortical brain–computer interfaces
- intramuscular electrodes 121–2, 255
- intraneural electrodes 255
- Intrater reliability 36
- intrauterine infections, maternal 212, 214–15
- intravenous immunoglobulin (IVIg) 660, 662–4
- intraventricular hemorrhage, perinatal 211
- invertebrates  
learning 23  
nervous system regeneration 329–30  
*see also* *Aplysia californica*; *Caenorhabditis elegans*; *Drosophila melanogaster*
- ion channels, myelinated axons 457–9
- iPads, communication apps 221–3, 225
- IRE1 266
- IREX (Interactive Rehabilitation Exercise) system 200, 209
- ischemia, delayed neuronal death 6
- ischemic nerve block, motor cortical plasticity 245
- IST-12 upper extremity neuroprosthesis 547
- item response theory (IRT) 38–9
- Jackson, Hughlings 439
- JAK-STAT pathway, axon regeneration 417, 421
- Jebsen–Taylor test (JTT) of hand function 245, 300
- jewelry 155
- JNK pathway 257, 401–2
- The Jogger 153
- Jun 422
- kainate receptors (KAR) 52
- Kalman filter 580
- Kdr *see* vascular endothelial growth factor receptor 2
- Kinect gaming system, Microsoft 200, 202
- kinematic analysis  
deforming spastic paresis 314  
experimental spinal cord injury 533  
cats 166, 168–70  
mice 176–7  
rats 171–4  
motor compensation 605  
movements in virtual vs. real environments 210
- kinematic impairment index (KIM) 338–9
- kinesin 422
- knowledge, explicit vs. implicit 97–8
- Kruppel-like factors (KLFs) 414
- L-DOPA *see* levodopa
- L-DOPS (L-threo-3-4-dihydroxyphenylserine) 424
- L1 protein (L1CAM)  
axon guidance 305–6  
axon regeneration 332, 415, 425
- L300 system, Ness 256
- Lambert–Eaton myasthenic syndrome (LEMS) 80, 664–5
- lamellipodia, growth cone 301–2, 422–3
- laminins  
after spinal cord injury 158–9  
axon guidance 303–4, 308  
CSPG interactions 381–2  
glial scar 383  
receptors 304  
structure 303
- lamotrigine 466, 552–3
- lamprey  
heterogeneity in neuronal regenerative ability 331, 415  
neurofilaments in regenerating axons 331, 423  
spinal cord regeneration 330–1
- Landau–Kleffner syndrome 550
- language  
acquisition 129–31  
automatic-voluntary dissociation 439  
disorders, acquired 437  
function after temporal lobectomy 561  
loss vs. dysfunction 438–9  
post-stroke recovery  
noninvasive brain stimulation 146–7, 227–9, 247–8  
pharmacotherapy 242–4  
training and practice effects 241
- processing  
holistic vs. localizationist approaches 437–8  
multisystemic interactions 440–1  
visual cortex in blindness 147  
*see also* aphasia
- LAR (leukocyte antigen-related) proteins 309, 322, 381–2
- Lashley, Karl 28, 107
- lateral funiculus, locomotor control in rats 172–3
- lateral occipital complex (LOC)  
haptic shape perception 143–4  
normal tactile perception 142–3  
tactile perception in blindness 145
- laterality index (LI), predicting stroke recovery 44–5
- Laufband* therapy *see* body weight-supported treadmill training
- learned non-use  
aphasia 439  
dysphagia 411–12  
traumatic brain injury 544
- learning  
in Alzheimer's disease 510, 518–22  
associative *see* associative learning  
cellular and molecular mechanisms 22–32, 58, 63–71  
*Aplysia* 63–71  
extracellular matrix 157  
in cognitive impairment 515–17  
in dementia 517–22  
differential 99–100  
elementary forms 63  
enhanced, memory deficits 481–2  
errorless *see* errorless learning  
explicit vs. implicit 97–8, 102  
genetic influences 27  
instrumental *see* operant conditioning  
modulating chronic pain 290–1  
motor *see* motor learning  
nonassociative  
*see* nonassociative learning  
probabilistic 24  
rehabilitation and 71  
sensorimotor or cognitive skills 23–4  
sensory retraining and 303, 305–6  
stimulus–response (S–R) 24  
stroke recovery and 197–9  
transfer, facilitating 306  
*see also* conditioning, memory
- learning theories  
aphasia rehabilitation 439  
applied to gait training 100–3  
dementia rehabilitation 515–17
- Lee Silverman voice therapy (LSVT), Parkinson's disease 573–4
- leeches, axon regeneration 329–30
- leisure activities  
assistive devices 158  
virtual reality applications 208
- Lennox–Gastaut syndrome 560
- lentivirus gene vectors 515, 517
- leucine-rich repeat kinase 2 (LRRK2) 260, 395
- leucine-rich repeat transmembrane proteins (LRRtMs) 321–2
- leukemia inhibitory factor (LIF) 417
- levodopa (L-DOPA)  
effects on locomotor activity 168, 183  
impact on motor training 320  
multiple system atrophy 424



## Index

- levodopa (L-DOPA) (cont.)  
 Parkinson's disease 567–8  
 stroke rehabilitation 243–4
- Lewy bodies 260, 395  
 dementia with (DLB) 569
- Liepmann, H. 447
- Life-H test 42
- light stimulation  
 retinotectal pathway  
 development and 117–18  
 retinotectal pathway  
 regeneration and 119
- LILRB2 (leukocyte  
 immunoglobulin-like  
 receptor B2) 353
- limbic system, role in tinnitus  
 134–5
- limits of (postural) stability 105–7  
 assessment 110  
 treatment for reduced 112
- lineage-restricted progenitors  
 (or precursors) 437  
 isolation and properties 438–9  
 terminology 284, 435  
*see also* glial-restricted  
 precursors, neuronal-  
 restricted precursors
- linear discriminant analysis  
 (LDA) 581
- linear summation model,  
 facilitation 41
- Lingo1 204, 309, 342, 353
- link protein 157
- lipopolysaccharide (LPS) 214
- liposomes 515–16
- lizards  
 adult neurogenesis 284  
 axon regeneration 119, 334
- local field potentials (LFPs),  
 brain–computer  
 interfaces 567, 570
- locked-in syndrome 262, 387–8
- locomotion  
 central pattern generator  
*see* central pattern  
 generator (CPG),  
 locomotor  
 control in humans 343–4, 346,  
 348  
 energy expenditure during  
 374–8  
 spinal cord injury *see*  
*under* experimental  
 spinal cord injury; spinal  
 cord injury  
*see also* gait; treadmill  
 locomotion; walking
- locomotor disorders *see* gait  
 disorders
- locomotor experience applied  
 post-stroke (LEAPS)  
 trial 65
- locomotor training  
 experimental spinal cord injury  
 61, 170–1, 180–1, 184, 348
- humans *see* gait training
- locus ceruleus cell transplants,  
 spinal cord injury 437
- Lokomat system 65, 190, 210
- long-term depression (LTD)  
 55–8  
 cerebellar 26, 56–7  
 extracellular matrix  
 components and 157  
 hippocampal 55–6  
 learning and memory and 58  
 limitations of studies  
 investigating 57–8  
 as mechanism of human  
 neuroplasticity 241  
 metaplasticity and 57  
 neuropathological insights 58
- long-term facilitation (LTF),  
 in *Aplysia* 66
- long-term memory *see* memory,  
 long-term
- long-term potentiation (LTP)  
 50–5, 57–8  
 classical conditioning in  
*Aplysia* and 68–9  
 expression, mechanisms 53–5  
 extracellular matrix  
 components and 157  
 functional electrical  
 stimulation and 120–1  
 glutamate and glutamate  
 receptors 52–5  
 Hebbian properties 51–2  
 heterosynaptic 51  
 homosynaptic 51  
 induction, mechanisms 53–4  
 learning and memory links 58  
 limitations of molecular  
 studies 57–8  
 as mechanism of human  
 neuroplasticity 241–2  
 metaplasticity and 57  
 neuropathological insights 58  
 newly generated hippocampal  
 granule neurons 289  
 pathway, neuron and synapse  
 specificity 51  
 relationship with long-term  
 depression 56  
 stroke recovery and 197
- long-term sensitization, *Aplysia*  
 66–8
- Lou Gehrig's disease  
*see* amyotrophic lateral  
 sclerosis
- lower extremity, botulinum toxin  
 injections 319
- lower extremity function  
 assessment 313–14, 349–50  
 paraplegia 627–8  
 stroke 604  
 predictive value 595  
*see also* standing; walking
- lower extremity rehabilitation  
 deforming spastic paresis 318
- early onset 271
- functional electrical  
 stimulation 126–7, 630
- motor neuroprostheses 256–9
- neural prosthetic systems  
 547–8
- robotics, orthotics, and  
 prosthetics 190–5
- stroke 604–7
- virtual reality applications 210  
*see also* gait training
- lower motor neuron lesions,  
 electrodiagnostic testing  
 78–80
- LRRK2 (leucine-rich repeat  
 kinase 2) 260, 395
- LRRTM (leucine-rich repeat  
 transmembrane) proteins  
 321–2
- LTD *see* long-term depression
- LTP *see* long-term potentiation
- lumbar spinal cord  
 locomotion in cats 168–9  
 locomotion in rats 171–2, 175
- lumbar support, wheelchairs  
 171
- lysosomes 267
- M1 *see* primary motor cortex
- macroautophagy 267  
*see also* autophagy
- macrophages  
 glial scar formation 378, 381  
 regulation of activity 393  
 responses to implanted devices  
 557–8  
 zymosan-induced activation  
 385  
*see also* microglia
- MAG *see* myelin-associated  
 glycoprotein
- magnetic resonance imaging  
 (MRI)  
 functional *see* functional  
 magnetic resonance  
 imaging  
 parkinsonism 568  
 spinal cord injury 619–20  
 traumatic brain injury 536–7  
*see also* diffusion tensor  
 imaging
- magnetic resonance spectroscopy  
 (MRS), traumatic brain  
 injury 537
- magnetoencephalography  
 (MEG) 84
- MAGUK (membrane-associated  
 guanylate kinase) family  
 proteins 55
- male sexual dysfunction 429–30
- Maloney murine leukemia virus  
 (MLV) 515
- mammalian target of rapamycin  
*see* mTOR
- manual dexterity task 105–6
- MAPK (mitogen-activated  
 protein kinase), long-  
 term sensitization 67
- maternal intrauterine infections  
 212, 214–15
- matrix metalloproteinases  
 (MMPs) 157–8, 383–4
- maximal frequency of rapid  
 alternating movements  
 313
- maximal oxygen consumption  
*see*  $\text{VO}_2 \text{ max}$
- mechanical in-exsufflator  
 (MI-E) 622
- mechanical ventilation 265–7  
 amyotrophic lateral sclerosis  
 657  
 Guillain–Barré syndrome 661  
 weaning from 267–8
- mechanosensitivity, increased  
 460
- medial geniculate nucleus, role in  
 tinnitus 134
- medial temporal lobe, learning  
 and memory 24, 28–9
- median nerve section,  
 somatosensory system  
 changes 78
- median nerve stimulation  
 cortical effects 137  
 paretic hand in stroke 137–8
- medical alert tags 153
- medical model 280
- Medicare  
 funding of communication  
 devices 223  
*see also* Centers for Medicare  
 and Medicaid Services
- medication reminders 153,  
 157–8, 484
- medications, impact on motor  
 recovery 319–20
- Medtronic InterStim system 543
- medulla, parapyramidal region  
 (PPR), control of  
 locomotion 172, 182
- melodic intonation therapy  
 (MIT) 440, 442
- memantine 244, 480
- memory 478–9  
 associative 24–6  
 cellular mechanisms 22–32, 58  
 consolidation 27–8  
 declarative (explicit) 28–32,  
 479  
 animal studies 29–31  
 human observations 28–9  
 extracellular matrix function  
 157  
 hippocampal neurogenesis  
 and 290  
 intermediate-term, in *Aplysia*  
 68  
 long-term 478–9  
 categories 22–3

- mechanisms in *Aplysia* 66–8
- nonassociative 23
- nondeclarative (implicit) 23–8
- priming 24
- procedural 23–4
- processing in Alzheimer's disease 510
- prospective 479, 484, 491
- reconsolidation 31
- semantic, neocortical storage 31–2
- somatosensory pain 290–1
- stroke recovery mechanisms and 197–9
- working (short-term) *see* working memory
- see also* learning
- memory aids, external 153–4, 483–5
- memory awareness rating scale–adjusted (MARSA) 513–14
- memory books, personalized 524
- memory dysfunction 478–85
- after temporal lobectomy 560–1
- compensatory strategies 481–5
- epilepsy 558
- frontal lobe lesions 490–1
- rehabilitation strategies 478
- restitution-oriented therapies 479–81
- traumatic brain injury 540–1
- virtual reality applications 204–5
- memory glasses 484
- memory training 480–1
- dementia 518–20, 526
- healthy elderly 518
- mental health problems *see* psychiatric disorders
- mesencephalic locomotor region (MLR) 169, 175
- mesenchymal stem cells (MSC) 448, 587, 591
- spinal cord transplants 589
- transplants in multiple sclerosis 587–8
- transplants in stroke 590–1
- mesial temporal sclerosis (MTS) 559–60
- metabolic equivalents (METs) 369–70
- training effects 372, 375
- metabolic syndrome 369
- metabotropic glutamate receptors (mGluRs) 52–3
- long-term depression 56–7
- metaplasticity 57
- metaplasticity 57
- critical period of, after stroke 206
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism 260
- methylphenidate dementia 528
- disorders of consciousness 393, 539
- genetic influences on response 28
- post-stroke depression 608
- traumatic brain injury 539–40
- methylprednisolone 502, 629–30, 639–40
- microautophagy 267
- microelectrodes, implanted 556–8
- brain tissue responses 542–3, 557–9
- dexamethasone-releasing 560
- insertion-mediated damage 555–7
- intracranial brain–computer interfaces 577–9
- materials 556
- recording by 541–2, 556
- reducing stiffness 559–60
- see also* electrodes
- microglia 367
- Alzheimer's disease 393–4
- cerebral palsy 212–15
- implanted device responses 542, 557–9
- inflammatory response 392–4
- Parkinson's disease 394–5
- regulation of activity 393
- role in axonal regeneration 372–3
- signaling in neuroprotection 396–7
- microtubules (MT)
- axonal transport 422
- growth cone 301–2, 423
- regenerating axons 423–4
- microwave ovens 158
- micturition control *see* bladder control
- micturition syncope 425
- middle occipital gyrus (MOG), blindness 129–30
- middle temporal (MT) complex
- cross-modal motion perception in blindness 146–7
- normal cross-modal motion perception 142
- midodrine 423
- migraine 293
- mild cognitive impairment (MCI)
- deep brain stimulation 528
- virtual reality applications 205
- see also* dementia
- military traumatic brain injury 535
- Milliman Care guidelines 286
- mind mapping technique 482
- minimal clinically important difference (MCID) 38, 41, 236
- minimal detectable change (MCD) 41
- minimally conscious state (MCS) 263, 387–8
- diagnosis of emergence 389
- emergence and prognosis 398
- experience of pain 393
- incidence and prevalence 388
- minimization principle 603
- minocycline, microelectrode insertion and 560
- mirror therapy 148, 294
- mitochondria
- axonal degeneration and 277
- dysfunction in neurodegenerative diseases 262–4
- fission and fusion 262–3
- neuronal cell death and 257–8, 263
- presynaptic
- Ca<sup>2+</sup> extrusion 37, 40, 42–3
- Ca<sup>2+</sup> uptake 37, 40, 44
- regulation of energy supply 44
- mitofusin-1 (Mfn1) 263
- mitofusin-2 (Mfn2) 263
- mutations 277
- mitogen-activated protein kinase (MAPK), long-term sensitization 67
- mitophagy 268
- mitoxantrone 640
- mixed reality stroke rehabilitation system 338–9
- mnemonics 483
- mobile electronic devices
- assistive technology 157, 159
- communication apps 221–3, 225
- memory aids 153, 483–4
- virtual reality-based rehabilitation 212
- see also* cell phones, smartphones
- mobility devices 64, 156–7
- electric powered 165–8
- see also* wheelchairs
- mobility impairment
- multiple sclerosis 640–1
- recovery after stroke 593
- see also* locomotion, motor impairments, walking
- mobility scooters 157, 166
- mobilization
- critical illness myopathy 666
- early post-stroke 268–9
- modafinil 540, 641
- Molaison, Henry 28–9
- Molyneux, William 140
- monoamine oxidase B inhibitors 568
- mossy fibers 26
- motion sensitivity quotient (MSQ) 362
- motor abundance 602–5
- motor activity log (MAL) 338
- motor adaptation 8
- motor brain–computer interfaces 579–81
- continuous decoders 579–80
- discrete decoders 580–1
- motor compensation
- after brain damage 600–2
- definition 8
- maladaptive 603–4
- measurement 605
- mechanisms 602–5
- stroke recovery and 15–16, 595
- motor control
- disrupted, Parkinson's disease 571
- voluntary *see* voluntary motor control
- motor cortex 99–110
- adult neurogenesis 292–3
- functional organization 99–103
- nomenclature 99–100
- non-primary areas (NPMAs) 53–5
- functional organization 101–3, 53–5
- reorganization after brain injury 55, 85–9
- plasticity after deafferentation 245
- plasticity of motor maps 103–9, 13
- behavioral experience
- modulating post-injury 108–9
- experience-dependent 103–6
- post-injury 106–8
- post-stroke 106, 108, 196, 13–14, 85–9
- role in rehabilitation 109–10
- primary *see* primary motor cortex
- somatotopic organization 101
- stroke
- axon sprouting 197, 199–200
- functional changes 106, 108, 196
- transcranial direct current stimulation 247–8
- see also* specific areas
- motor equivalence 602–3
- motor evoked potentials (MEPs) 141–3
- spinal cord injury 618–19
- stroke 43
- motor function
- cerebral *see* cerebral motor functions
- early rehabilitation 268–71

## Index

- motor impairments  
 assistive technology 151–2  
 brain–computer interfaces 570–2, 579–81  
 communication devices 224  
 Parkinson's disease 570–1  
 virtual reality applications 208–10
- motor learning 95–103  
 Alzheimer's disease 520  
 attentional focus effects 96–7  
 definition 104  
 Fitts and Posner's (standard) model 95–6  
 implicit vs. explicit knowledge 97–8  
 motor cortex plasticity 104  
 noninvasive brain stimulation and 145  
 principles, rehabilitation study designs 5–6  
 Schmidt's schema theory 99  
 theories applied to treadmill training 100–3  
 variability of practice 98–100  
 context-conditioned variability 98–9  
 differential learning 99–100  
*see also* motor skill acquisition
- motor neglect 465
- motor neuron disease  
*see* amyotrophic lateral sclerosis
- motor neurons/motoneurons (MNs)  
 activity-dependent plasticity 88–90  
*Aplysia* reflexes 64  
 changes after spinal cord injury 177  
 cortical *see* cortical motoneurons  
 diseases of 655–60  
 fetal spinal cord transplants 437  
 genetically engineered progenitors 448  
 neurotrophins and regeneration after injury 402–3  
 reinnervation of muscle *see* muscle, reinnervation  
 replacement, spinal cord injury 444–5, 448  
 trophic factors in development 255
- motor neuroprostheses (MNP) 253–9  
 functional electrical stimulation 253–6  
 orthotic uses 253  
 principles of action 253  
 systems for restoring limb function 256–9  
 therapeutic uses 253  
*see also* neural prostheses
- motor recovery  
 brain injury, motor cortex reorganization 52–3, 55  
 compensation and 599–605  
 ICF definitions 599–600  
 importance of spared territory 57  
 medications influencing 319–20  
 spinal cord injury 625  
 nonhuman primates 537  
 preclinical measures 532–5
- stroke  
 AMPA receptor signaling 198–9  
 Brunnstrom stages 603–4  
 compensatory strategies 15–16  
 cortical map plasticity 13–14  
 neuroimaging for predicting 43–5  
 noninvasive brain stimulation therapy 247–8  
 pharmacological interventions 242–3  
 somatosensory input and 244–5  
 spontaneous 592  
 training and practice effects 241  
 transient regional anesthesia 246  
 upper extremity 333–4  
*see also* stroke recovery
- traumatic brain injury 544
- motor restoration, neural prostheses 546–50
- motor skill acquisition  
 definition 104  
 motor cortex plasticity 105–6  
 Schmidt's schema theory 99  
 spinal cord plasticity 91  
 in normal life 86–8  
 operant conditioning studies 88–90  
*see also* motor learning
- motor system  
 redundancy and abundance in 602–5  
 voluntary motor control 51–7
- motor tasks, functional neuroimaging 84–5
- motor training  
 deforming spastic paresis 316–18  
 impact of systemic medications 319–20  
 neural consequences 317–18  
 pharmacological interventions with 242–3  
 role in functional recovery 241  
 timing 318
- motor unit recruitment  
 electrically induced 120, 254  
 strength and 330  
 motor unit transformation, spastic gait 347  
 motor vehicle collisions 535, 615  
 Move, Sony PlayStation 202  
 movement disorders 567–79  
 electric powered mobility devices 167–8  
*see also* dystonia, Parkinson's disease
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced parkinsonism 260
- mTOR (mammalian target of rapamycin)/mTOR pathway  
 axon regeneration 11, 345, 357, 379, 419–20  
 Huntington's disease 268  
 Muller glia 368
- multidisciplinary model 280–1
- multiple brain trauma/lesions, noninvasive brain stimulation 225–6
- multiple object test 456
- multiple sclerosis (MS) 637–49  
 clinical features 637  
 diagnosis 637–9  
 exercise capacity 369–70  
 pathogenesis 637  
 axonal degeneration 278, 466  
 conduction abnormalities 459  
 Na<sup>+</sup> channel blocking factors 460  
 Na<sup>+</sup> channel expression 461–2, 464
- rehabilitation 641–9  
 evaluating outcome 642–3  
 exercise training 373, 375, 646–7  
 multidisciplinary 643–6  
 noninvasive brain stimulation 227  
 specific modalities 646–9  
 treatment 638–41  
 axonal neuroprotection 466  
 disease-modifying 640  
 potassium channel blockers 459, 640–1  
 relapses 638–40  
 stem cell therapies 586–8, 592  
 symptomatic 640–1
- multiple sclerosis functional composite (MSFC) 643
- multiple system atrophy (MSA) 419, 569  
 diagnosis 422  
 gastrointestinal dysfunction 429  
 orthostatic hypotension 424–5
- Parkinson variant (MSA-p) 569  
 supine hypertension 427  
 urinary dysfunction 428
- multipotent progenitor cells (multipotent stem cells)  
 glial scar 380  
 isolation and properties 437–8  
 terminology 283–4, 435  
 transplants, spinal cord injury 440–1  
*see also* neural stem cells
- MUNC-13 43
- MUNC-18 321, 323
- muscarinic receptors 415
- muscle  
 denervation supersensitivity 2  
 effects of bed rest 265–8  
 effects of stretch 314  
 excessive extrasegmental co-contraction 312  
 functional electrical stimulation 120  
 length–force relationship 330–1  
 power 331  
 reinnervation 474–84  
 causes of failure 484  
 damaged/regenerated muscle fibers 479–81  
 endoneurial tubes guiding 473–4  
 escaped fibers 474–5, 478–9  
 guidance of nerve sprouts 481  
 guidance of Schwann cell growth 481  
 molecular mechanisms 484–6  
 reoccupation of synaptic sites 481–2  
 from severed nerve 475–6  
 sprouting of nerve terminal 475–6  
 study methods 474  
 vital imaging 476–9  
 spastic overactivity 312  
 local treatments 318–19  
 transcranial magnetic stimulation and 320  
*see also* spasticity  
 strength *see* strength  
 weakness *see* weakness  
*see also* neuromuscular junctions
- muscle contractures  
*see* contractures
- muscle diseases 80, 665–6
- muscle fibers  
 damaged, reinnervation 479–81  
 newly generated, innervation 481
- muscle-specific tyrosine kinase (MuSK) 317

- muscle tone  
assessment 542  
Parkinson's disease 345  
spasticity 346–7
- muscular efficiency, walking 376
- musculoskeletal assessment,  
spinal cord injury 620
- musculoskeletal pain, chronic  
amyotrophic lateral sclerosis  
657
- behavioral interventions  
294–5
- cortical reorganization 289–91
- post-polio syndrome 660
- music interventions, dementia  
526–7
- musical abilities, acquisition  
131–2
- musician's cramp 577–8
- myasthenia gravis (MG) 80, 664
- myelin 369
- inhibition of axon  
regeneration 339–40
- peripheral pattern 497
- myelin-associated axonal growth  
inhibitors 243, 309,  
339–46, 349–54
- changes after stroke 203–4
- genetic studies 342–3
- molecular identification 340–2
- other 344–5
- prototypic *see* myelin-  
associated glycoprotein,  
Nogo, oligodendrocyte  
myelin glycoprotein
- receptors 341–2, 352–3
- signaling pathway 309–10,  
341–2, 354, 359
- sprouting vs. regeneration 343–4
- synaptic plasticity and 345
- as therapeutic target 354–5,  
244–5
- myelin-associated glycoprotein  
(MAG) 203, 341–2,  
351–60
- axon growth inhibition 309,  
351, 418–19
- axonal degeneration and  
demyelination 278–9
- gene knockout studies 343
- receptors 341–2, 352–3
- signaling pathway 204,  
309–10, 341–2, 354
- stroke 204
- myelin basic protein (MBP),  
traumatic brain injury 536
- myelinated axons 457
- action potential conduction  
457, 459
- molecular organization 457–9
- neuroprotection in  
demyelinating diseases 466
- myelination  
by grafted olfactory  
ensheathing cells 506–8
- see also* demyelination,  
remyelination
- myoelectric control, implanted  
upper extremity  
neuroprostheses 546–7
- Myomo e100 robotic system 178,  
183–4
- myopathies 80, 665–6
- myosin light chain kinase  
(MLCK) 43
- N-cadherin (NCAD) 425, 484
- N-methyl-D-aspartate  
*see* NMDA
- Na<sup>+</sup> *see* sodium
- nail care 155
- nanoparticles, DNA delivery 516
- Narp 323
- narrow beam-walking test 533–4
- nasogastric (NG) tube, stroke  
609–10
- natalizumab 640
- National Institutes of Health  
Stroke Scale (NIHSS)  
591, 593–4
- national joint committee for the  
communication needs of  
persons with disabilities  
225–6
- NCAM *see* neural cell adhesion  
molecule
- necroptosis 257
- necrotic cell death 256
- need-driven dementia-  
compromised behavior  
(NDB) model 524
- neglect, unilateral 463–9
- anosognosia for 470–1
- assessment 463–5
- neuroanatomy 463–4
- noninvasive brain stimulation  
147, 231–2
- specific modalities 465
- treatment 465–9, 610–11
- virtual reality applications  
204
- negotiated equilibrium concept,  
spinal cord 90, 92
- nematodes *see* *Caenorhabditis  
elegans*
- neoassociationist approach,  
aphasia rehabilitation 440
- neocortex  
adult neurogenesis 286, 290,  
292–3
- learning and memory 31–2  
*see also* cerebral cortex
- neogenin 307, 415
- neonatal brain injury  
*see* perinatal brain injury
- nerve conduction studies (NCs)  
interpretation of report 81
- lower motor neuron lesions  
78–80
- outcome assessment 81–2
- spinal cord injury 619
- wheelchair users 161  
*see also* conduction
- nerve cuff electrodes 122, 255
- nerve electrodes 255
- nerve growth factor (NGF) 400
- Alzheimer's disease gene  
therapy 517–19
- cellular actions 400–1
- Parkinson's disease gene  
therapy 519
- peripheral axon regeneration  
and 403–4
- peripheral neuropathy therapy  
521
- receptor 400
- signal transduction 401
- spinal axon regeneration and  
408, 418
- spinal cord injury, gene  
therapy 502, 521
- therapeutic studies 385
- nerve regeneration *see* peripheral  
nerve regeneration
- nerve terminal sprouting,  
Schwann cells mediating  
475–6
- Ness H200 system 124, 129,  
256
- Ness L300 system 256
- nestin 292
- NET (norepinephrine  
transporter) gene 30
- netrins 203
- axon regeneration 310, 344,  
358
- changes after stroke 203
- developmental axon guidance  
304
- receptors 304
- synaptogenesis 322–3
- network effects, distributed,  
noninvasive brain  
stimulation 222–3
- networked neuroprosthesis  
(NNP) 549–50, 130
- NeuN 288–9
- neural cell adhesion molecule  
(NCAM) 306, 383, 425
- neural precursor cells (NPC)  
adult CNS 283–95
- endogenous, for cell  
replacement 294–5,  
448–9
- generation from pluripotent  
stem cells 439
- glial scar 380
- heterogeneity 284
- hippocampal neurogenesis  
288–90
- isolation and culture in vitro  
290–1
- lineage-restricted *see* lineage-  
restricted progenitors
- medical relevance 294–5
- methodological issues of in  
vivo study 291–2
- motor neuron generation from  
448
- olfactory bulb neurogenesis  
286–7
- populations in adult CNS  
285–6
- terminology 283–4, 435
- transplantation 285–6, 439–49  
*see also* neural stem cells;  
neurogenesis, adult;  
progenitor cells
- neural prostheses (biomimetic,  
implantable) 120, 541–50
- brain responses 554–61
- foreign body/inflammatory  
542–3, 557–8
- insertion-mediated damage  
555–7
- methods of studying 560–1
- neurodegenerative 556–8
- plastic 555
- strategies for addressing  
559–60
- current clinical applications  
554–5
- interface features 541–3
- recording 541–2, 556
- stimulation 542
- motor restoration 546–50
- integrated control 548–50
- lower extremity function  
547–8
- natural volitional control  
549–50
- upper extremity function  
546–7
- neuromodulation through  
stimulation 543–4
- selectivity–invasiveness  
tradeoff 556
- sensory restoration 544–6
- social and ethical issues 550
- spinal cord injury 546–7, 630
- bladder control 543
- integrated motor control  
systems 549
- standing and walking  
547–8
- upper extremity function  
546–7
- see also* functional electrical  
stimulation, motor  
neuroprostheses
- neural repair  
stroke  
parallelogram concept  
205–7
- principles of 196–207
- vs. compensation 8–9
- neural stem cells (NSCs)  
adult CNS 283–4, 586–7
- development and properties  
437–9, 591

## Index

- neural stem cells (NSCs) (cont.)  
 generation from pluripotent stem cells 439  
 multipotent *see* multipotent progenitor cells  
 planarians 329  
 subgranular zone (type-1 cells) 288  
 terminology 283–4, 435  
 transplants  
 memory dysfunction 479  
 multiple sclerosis 586–7  
 spinal cord injury 588–9  
 stroke 590  
*see also* stem cell therapies  
*see also* neural precursor cells, pluripotent stem cells
- NeuralStem Inc. 441, 450
- neuregulin 485
- neurexins 67, 321–3
- neuro-eye therapy (NeET) 502–5
- neurobehavioral sequelae, traumatic brain injury 543–4
- neurocan 157, 381  
 secretion after stroke 202
- NeuroControl Corporation (NCC) 128–30, 546  
*see also* Freehand System®
- neurodegeneration, at  
 electrode–brain interface 556–9  
 strategies for minimizing 559–60
- neurodegenerative diseases  
 neurogenesis theory 294
- neuronal dysfunction and death 258–69
- noninvasive brain stimulation 226–7, 231, 234
- neuroelectric blocking factors 460
- neuroepithelial (NEP) cells  
 isolation and properties 437–8  
 transplantation studies 441
- neurofibrillary tangles (NFTs) 394
- neurofilaments (NFs)  
 axonal transport 422  
 demyelination and 278  
 distal axonal degeneration 277  
 regenerating axons 331, 423  
 Wallerian degeneration 274
- neurogenesis, adult 1, 283–95  
 brain lesions/stroke 204–5  
 consequences of disturbed 293–4  
 defined 284  
 discovery in mammals 285  
 hippocampus 288–90  
 induced in non-neurogenic regions 292–3  
 lack of constitutive cortical 290  
 medical relevance 294–5  
 methodological aspects of *in vivo* studies 291–2
- non-mammalian vertebrates 284–5
- normally non-neurogenic regions 286
- olfactory bulb 286–7
- regions in brain 285–6
- spinal cord injury 448–9
- stroke 12–13, 204–5  
*see also* neural precursor cells, neural stem cells
- neuroglycan 2 (NG2) 157, 381
- neuroimaging  
 disorders of consciousness 390  
 functional *see* functional neuroimaging  
 parkinsonism 568  
 spinal cord injury 619–20  
 traumatic brain injury 536–7
- neuroligins 67, 321
- neurolinguistic-cognitive approach, aphasia rehabilitation 440
- neurological assessment, spinal cord injury 617
- neuromuscular disorders  
 electrodiagnostic testing 80  
 rehabilitation 655–66
- neuromuscular electrical stimulation (NMES)  
*see* functional electrical stimulation
- neuromuscular junctions (NMJ)  
 aging animals 480–1  
 developmental remodeling 482  
 diseases of 655, 664–5  
 remodeling after muscle fiber damage 480  
 Schwann cell role in remodeling 482  
 Schwann cell territories 482–4  
 Schwann cells and axonal reoccupation 481–2  
 synapse formation 317
- neuron(s)  
 collaterals *see* collaterals, neuronal  
 contralateral, axon sprouting after stroke 199–201  
 denervated *see* denervation  
 growth inhibitors *see* axon growth inhibitors  
 molecular signaling of axon injury 416  
 responses to injury 1–7, 413  
 trophic factors in development 255
- neuron-intrinsic determinants of regeneration 413–26  
 developmental loss 414, 425  
 extrinsic modulation 416–19  
 gene expression state 243  
 heterogeneity 414–15  
 intrinsic modulation 419–22  
 site of injury and 415  
 therapeutic modulation 245
- vs. extrinsic inhibitors 345
- neuronal atrophy  
 rescue 415  
 retrograde, after axotomy 4–6  
 transneuronal, after denervation 3–4
- neuronal Ca<sup>2+</sup> sensor-1 (NCS-1) 42
- neuronal connections  
 ectopic, regenerating axons 10  
 effects of injury 1–2  
 reorganization after injury 8–17, 199–201
- neuronal death 255–69  
 after axotomy 4–6  
 after denervation 4  
 around implanted devices 557, 559  
 strategies for minimizing 559–60
- autophagic (type 2)  
*see* autophagy
- cascading 6
- cytoplasmic (type 3) 256–7
- delayed, after ischemia 6
- developmental 255–8  
 molecular regulation 257–8  
 morphological features 256–7
- mechanisms in neurodegenerative diseases 261–9
- neuropathological role 258–61
- newly generated cells in adult brain 287, 290
- nuclear (type 1) 256
- p75N<sup>T</sup>F-mediated regulation 257, 401–2
- types 256–8  
*see also* neuronal survival
- neuronal replacement therapies  
 based on endogenous precursors 295, 445  
 spinal cord injury 443–8  
 alternative sources of cells 448  
 relay formation 446–8
- neuronal-restricted precursors (NRP)  
 differentiation from neuroepithelial cells 437  
 isolation and properties 438  
 spinal cord transplants 443–4, 446–7, 449
- neuronal survival  
 molecular regulation 257–8  
 neurotrophins and 402–3, 405  
 regeneration programs and 415  
 site of axotomy and 415  
*see also* neuronal death
- NeuroPage 153, 483–4
- neuropathic pain  
 cortical reorganization 291–3  
 GABAergic neuron replacement 446
- pharmacological therapy 295
- spinal cord injury 623
- neurophysiological tests  
 spinal cord injury 617–19  
*see also* electrodiagnostic tests
- neuropilin 1 (Nrp1)  
 after brain injury and stroke 203  
 axon guidance 306  
 regulation of axon regeneration 358
- neuropilin-2, synaptic pruning 324
- neuropilins 305, 358
- neuropraxia, electrodiagnostic testing 78, 81
- neuroprostheses *see* neural prostheses
- neuroprotection  
 axonal, in demyelinating diseases 466  
 by enhanced somatosensory input 136  
 spinal cord injury 249
- neuropsychologist 283
- neurorehabilitation  
*see* rehabilitation
- neurospheres 290–1, 370, 441
- NeuroText 484
- neurotmesis, electrodiagnostic testing 81
- neurotransmitter receptors  
 denervated neurons 2–3  
 injured spinal cord 178
- neurotransmitters  
 autonomic nervous system 415, 417  
 facilitating synaptogenesis 318–19  
 synaptic transmission 36  
 asynchronous release 40  
 phasic release 39  
 quantal mechanisms 38
- neurotrophic factors (NTFs, trophic factors)  
 delivery by gene therapy 514–22  
 molecular signaling 257–8  
 neuronal development 255, 258  
 peripheral axon regeneration 485  
 role in neuropathology 258–61  
 Schwann cell grafts into spinal cord and 501–2  
 therapeutic potential 259, 245  
*see also* growth factors, neurotrophin(s)
- neurotrophic hypothesis of neural development 255, 257, 400
- neurotrophic tyrosine kinase receptor (NTKR) genes 30

- neurotrophin(s) (NTs) 400–8  
 axon guidance 306  
 axon regeneration 402–8, 418  
 cellular actions 400–1  
 family members 400  
 hearing impairment 545  
 peripheral nerve injury 402–5  
 receptors 400  
 signal transduction 400–1  
 spinal cord injury 404–8, 418  
 acute vs. chronic lesions 406  
 cell survival effects 405  
 changes in expression 405–6  
 effects on specific fiber tracts 407–8  
 functional effects 182, 406–7  
 methods of administration 406
- neurotrophin-3 (NT-3) 400  
 gene polymorphism 30  
 peripheral nerve injury  
 axon regeneration and 403–4  
 cell survival effects 402–3  
 peripheral neuropathy therapy 521  
 receptor 400  
 spinal cord injury  
 axon regeneration and 385, 406  
 fiber tract specificity 408  
 functional effects 406–7  
 gene therapy 406, 521  
 with Schwann cell grafts 501
- neurotrophin-4 (NT-4, NT-4/5) 400  
 axon regeneration after spinal cord injury 408  
 cell survival after spinal cord injury and 405  
 receptor 400
- neurovascular niche, post-stroke neurogenesis 205
- NeuroVR 201
- neurturin (NTN) 519–20
- NeuRx Diaphragm Pacing System® 126
- newts, adult neurogenesis 284
- NFIL3 (nuclear factor regulated by IL-3) 421–2
- NG2 (neuroglycan 2) 157, 381
- NG2+ cells 286  
 glial scar 380  
 role in axonal regeneration 372–3  
 stabilization of dystrophic growth cone 384  
*see also* oligodendrocyte precursor cells
- nicotinamide mononucleotide acetyltransferases  
*see* Nmnat1, Nmnat2, Nmnat3
- Nintendo Wii 201–2, 209–10
- nitric oxide (NO)  
 autonomic function 417  
 neurodegenerative diseases 261–2
- NMDA (N-methyl-D-aspartate), initiation of locomotion 171, 181
- NMDA antagonists, traumatic brain injury 539
- NMDA receptors (NMDA-R) 52  
 associative learning in *Aplysia* 68–9  
 cerebral palsy 214  
 fragments, traumatic brain injury 536  
 locomotion control 181–2  
 long-term depression 55–6  
 long-term potentiation 53  
 metaplasticity 57  
 neurodegenerative diseases 262  
 retinal ganglion cell axon development 117  
 retinal ganglion cell axon regeneration 119  
 synaptogenesis 319–21, 323–4
- Nmnat1 275–6  
 Nmnat2 276  
 Nmnat3 276
- NOD-like receptors (NLRs), Alzheimer's disease 394
- nodes of Ranvier 369, 457  
 action potential conduction 459  
 remyelinated axons 464  
 sodium channels 458
- Nogo 203, 340–1, 350–1  
 changes after stroke 204  
 gene cloning 340–1  
 gene knockout studies 342–3, 351  
 inhibition of axon regeneration 309, 418–19  
 inhibition of axon sprouting 343  
 isoforms 340–1, 350  
 neutralizing agents 342, 244–5  
 receptors 341–2, 352–3  
 signaling pathway 204, 309–10, 341–2, 354  
 synaptic plasticity and 345
- Nogo-A antibodies  
 development 340, 342, 350  
 preclinical studies 80, 179, 340
- Nogo receptor 1 (NgR1) 204, 341–2, 352  
 antagonists 342, 355  
 co-receptors 309–10, 342, 352–3  
 inhibition of axon regeneration and 418  
 signaling pathway 354  
 synaptic plasticity and 345
- Nogo receptor 2 (NgR2) 204, 341–2, 352
- Nogo receptors (NgR) 309, 342
- inhibition of axon regeneration 309–10
- noise exposure, loud 134
- nonassociative learning 23, 63–71  
*Aplysia* 23, 64–8  
 emerging principles 71  
 forms 63
- non-convulsive status epilepticus (NCSE) 265
- noninvasive brain stimulation (NBS, NIBS) 141–7  
 cognitive rehabilitation 146–7, 219–35  
 choice of technique 221  
 clinical evidence 227–31  
 diagnostic applications 223–4  
 focal lesions 225  
 with other therapeutic interventions 224–5  
 technical and other challenges 225–7  
 theoretical framework 221–3
- deforming spastic paresis 320–1
- dementia 528
- neurorehabilitation strategies 246–8  
 combined approaches 248  
 facilitation of lesioned hemisphere 247–8  
 inhibition of healthy hemisphere 247
- safety 142  
 stroke 143–7  
 techniques 219, 246  
*see also* transcranial direct current stimulation, transcranial magnetic stimulation
- non-traumatic spinal cord injury (NTSCI) 615
- noradrenergic pathways, control of locomotion 182–3
- norepinephrine (noradrenaline) 415, 417  
 inducing locomotor activity 171, 183  
 plasma, orthostatic hypotension 421–2
- norepinephrine transporter (NET) gene 30
- Notch 205, 448
- Nottingham sensory assessment (NSA) 300
- NT *see* neurotrophin(s)
- NT-3 gene polymorphism 30
- NTKR (neurotrophic tyrosine kinase receptor) genes 30
- nuclear factor regulated by IL-3 (NFIL3) 421–2
- nucleus accumbens 27, 135
- nursing assistants 524
- nursing homes 285
- nutritional support  
 disorders of consciousness 392  
*see also* tube feeding
- O2A precursor cells  
*see* oligodendrocyte type-2 astrocyte (O2A) precursor cells
- object recognition, auditory 129–32
- occipital cortex  
 auditory activation in blindness 129–30, 132  
 auditory object recognition in blindness 132  
 blood flow in blindness 127  
 metabolic activity in blindness 144  
*see also* visual cortex
- occupational therapist (OT) 283
- occupational therapy (OT)  
 disorders of consciousness 397–8  
 multiple sclerosis 648  
 stroke 10
- octreotide 424
- ocular dominance columns, development 116–17
- ocular dominance plasticity 160
- odor discrimination 29
- odor perception, blindness 141
- olfactory axons, growth of new 502–3
- olfactory bulb, adult neurogenesis 286–7
- olfactory ensheathing cells (OEC), spinal cord transplants 496, 502–8  
 A- and S-cell populations 504  
 axon regeneration after 373, 405, 504–6  
 migration after 503  
 myelin formation 506–8  
 rationale 502–3  
 tunnel formation 504
- olfactory feedback, virtual reality systems 201
- olfactory stimulation, visual cortex in blindness 147
- oligodendrocyte(s) 367, 369–71  
 axon regeneration role 372–3  
 development 368–72  
 function and diversity 369  
 myelination role 7, 457  
 remyelination 464–5  
 replacement  
 demyelinating diseases 465  
 spinal cord injury 441–2  
 trauma-induced death 6–8
- oligodendrocyte lineage cells (OLs)  
 axon regeneration role 372–3  
 mechanisms of perinatal injury 212–15  
 stages of development 212–13

## Index

- oligodendrocyte lineage cells (OLs) (cont.)  
vulnerability to perinatal injury 212–13
- oligodendrocyte-myelin glycoprotein (OMgp) 203, 342, 351–2  
after stroke 204  
gene knockout studies 343  
inhibition of axon regeneration 309, 418–19  
receptors 341–2, 352–3  
signaling pathway 204, 309–10, 341–2, 354
- oligodendrocyte precursor cells (OPCs) 367, 369–71, 591  
axon regeneration role 372–3  
cell surface markers 369–70  
glial scar 380  
injured spinal cord 448  
Schwann cell generation 373  
transplants  
multiple sclerosis 588  
spinal cord 441–2, 503, 589  
stroke 591–3
- oligodendrocyte type-2 astrocyte (O2A) precursor cells 368, 370, 438  
transplant studies 441
- OMgp, OMG  
*see* oligodendrocyte-myelin glycoprotein
- online cognitive training programs 219
- open label clinical trials 234
- OpenViBE system 572
- operant conditioning (instrumental learning) 27–8  
dementia 515–17  
neural mechanisms in *Aplysia* 69–70  
pain-related responses 291  
spinal stretch reflexes/  
H-reflexes 88–91
- opioid analgesics 623
- Optacon 141
- optic atrophy protein 1 (Opa1) 263
- optic nerve 114  
damage, regeneration after  
lower vertebrates 118–19, 306, 332, 334  
signaling pathways 11  
*see also* retinal ganglion cells
- optic tectum  
development of retinal connections 114–18  
regeneration of retinal connections 118–20, 332, 334  
retinotopic map 114–15
- optimal linear estimator (OLE) 580
- optokinetic stimulation, balance rehabilitation 113
- oral feeding, disorders of consciousness 392, 396–7
- ORMOSIL (organically modified silica) 516
- orthostatic hypotension 420–4  
initial 426  
management 422–4  
neurogenic 421  
supine hypertension 427  
symptoms 420–1
- orthotics  
energy costs of walking and 377–8  
lower limb mechanical-assisted 190–5  
motor neuroprostheses 253  
paraplegia 627  
powered 183–4  
tetraplegia 625–7  
upper extremity mechatronic 177, 183–4
- orthotist 283
- oscillopsia 360
- osteoporosis, spinal cord injury 624
- otitis media 132
- outcome measures  
clinical trials 4–5, 235–8  
COSMIN checklist 39  
developing and testing 35–9  
dynamic approaches 38–9  
electrodiagnostic tests 81–2  
evaluative scale development 35–6  
applications 38  
generating items 35–6  
pre-testing 36  
reducing number of items 36  
testing 36–8
- experimental spinal cord injury *see under*  
sensorimotor function assessment
- floor and ceiling effects 41
- stroke rehabilitation 35–45  
laboratory gait analysis 42–3  
national guidelines 42  
neuroimaging-based 43–5  
principles of selection 40–2  
walking 66–7
- oxidative stress 214, 261–2, 265
- oxybutynin 428, 641
- oxygen consumption, maximal *see*  $\text{VO}_2 \text{max}$
- P* (synaptic release probability) 38  
mechanisms of increasing 40–1  
origins of short-term synaptic plasticity 38
- p53 genotype 538
- p75 neurotrophin receptor (p75NTR) 400
- expression after spinal cord injury 405–6
- inhibition of axon growth 309–10, 342, 352–3, 402
- neuronal death and survival 257, 401–2
- peripheral axonal regeneration and 403
- signaling 354
- P300-based brain–computer interface 567–8
- P300 component, evoked potentials 390–1
- PACE (promoting aphasics communicative effectiveness) 438, 440
- paclitaxel-induced painful peripheral neuropathy 277
- pager-based reminder systems 153, 483–4
- pain  
amyotrophic lateral sclerosis 657  
assessment 393, 620  
chronic *see* chronic pain  
experimental spinal cord injury 535  
multiple sclerosis 641  
neuropathic *see* neuropathic pain  
plasticity and 289–93  
post-polio syndrome 660  
post-stroke 263–4  
spinal cord injury 620, 623
- paired associative stimulation, spastic paresis 321
- paired-pulse facilitation *see* facilitation
- panic, ictal 554–5
- parallel fibers, cerebellar 56
- parallel group studies 235
- Paralyzed Veterans of America (PVA) 532, 162
- paramedical treatment (PMT), dystonia 578–9
- paraplegia/paraparesis  
gait disorder 64  
locomotor training 348–9  
lower extremity functional electrical stimulation 126–7  
recovery and functional outcomes 627–8  
*see also* spinal cord injury
- parapyramidal region (PPR) of medulla, control of locomotion 172, 182
- Parastep System® 127, 627, 630
- parasympathetic nervous system 415–16
- parietal cortex  
auditory spatial processing 128  
changes after stroke 85  
memory functions 32  
motor functions 102–3
- reorganization in congenital deafness 132  
visual cortical input 143
- PARK1* gene mutations 567
- parkin 260, 263–4, 268  
gene mutations 567
- parkinsonism 567  
differential diagnosis 569–70  
MPTP-induced 260  
neuroimaging 568  
vascular 569
- Parkinson's disease (PD) 567–74  
apraxia 448, 455, 457  
balance control studies 96–7  
clinical features and diagnosis 567–8, 570–1  
deep brain stimulation 345, 543–4, 568–9  
dementia (PDD) 569  
exercise capacity 370  
gait disorder 344–5  
gene therapy 518–19  
genetics 567  
medical treatment 345, 424–5, 568–9  
neurobiology 567  
autophagic cell death 268  
inflammatory response 394  
mitochondrial dysfunction 263–4, 277  
neuronal cell death 260–1  
probabilistic learning 24  
rehabilitation 570–4  
balance training 572–3  
behavior modification 571–2  
exercise training 375, 570  
gait retraining 66, 571–2  
motor fluctuations 570–1  
noninvasive brain stimulation 226–7, 231, 234  
psychosocial counseling 574  
speech and swallowing therapy 573–4  
urinary dysfunction 427
- paroxysmal autonomic instability with dystonia (PAID) 543
- paroxysmal kinesigenic dystonia/dyskinesia 577
- participatory action research (PAR), dementia 526
- passive movements, neglect rehabilitation 468
- passive range of motion disorders of consciousness 397  
exercises 315  
maximal, deforming spastic paresis 313
- pasta-eating test 535–6
- pathogen-associated molecular patterns (PAMPs) 214
- pathological cross-talk 460
- patient-reported outcomes  
measurement information system (PROMIS) 39

- Pavlov, Ivan 24
- Pavlovian conditioning  
*see* classical conditioning
- paw placement test 534
- PC12 cell line, neurotrophin signaling 401
- PDZ (PSD-95/Discs large/ZO-1) domain proteins 55, 57
- PEAT (planning and execution assistant and trainer) 153
- pediatric interactive therapy system (PITS) 210
- pediatric patients *see* children
- pegylated neutral/anionic liposomes 516
- pelvic support, wheelchairs 171
- penetrating brain injuries 385–6
- penumbral tissue 225, 384  
 reperfusion 602  
 reversibility of damage 15–16
- perceptual training, neglect 469
- percutaneous intramuscular electrodes 121
- Perdue pegboard test 605
- pericytes 367, 380
- perimetry, high resolution (HRP) 503–4
- perinatal brain injury  
 associated with cerebral palsy 211–12  
 etiological factors 212  
 neural plasticity after 215–16  
 pathophysiology of cerebral palsy 212–15
- perineuronal nets (PNN) 155–7  
 activity-related changes 161  
 around CNS lesions 158  
 chondroitinase ABC therapy targeting 80, 160
- peripheral ganglia, denervation supersensitivity 2
- peripheral nerve grafts 119, 475
- peripheral nerve injury  
 chondroitinase ABC therapy 160  
 electromyographic evaluation 81  
 neurotrophins and axon regeneration 402–5  
 repair procedures 474  
 sensory loss 298–9  
 somatosensory system changes 78, 245  
 spinal transections with 178–9  
*see also* axotomy
- peripheral nerve regeneration  
 339–40, 349  
 across lesion site 473–4  
 between cut ends of nerves 475  
 endoneurial tubes promoting 473–4  
 historical note 472–3  
 neurotrophins and 402–5  
 role of Schwann cells 373, 403, 405, 472–86
- peripheral nerve stimulation (PNS<sub>ss</sub>) 135–8, 244–5  
 cortical effects 135–7, 244–5  
 deforming spastic paresis 321  
 paretic upper limb in stroke 137–8, 245  
 pharynx in dysphagic stroke 138, 245  
 rationale 135–7
- peripheral nerves, functional electrical stimulation 120
- peripheral nervous system (PNS) injury, sensory loss 298–9
- peripheral neuropathies 655, 660–4  
 electrodiagnostic testing 78–80  
 gene therapy 518, 521–2  
 quality of life 656  
*see also* axonal polyneuropathies
- peripheral somatosensory input  
*see* somatosensory input
- periventricular hemorrhagic infarction, perinatal 211
- periventricular leukomalacia (PVL) 211–16
- PERK 266
- PerMMA (personal mobility and manipulation appliance) 167–8
- perseveration 490
- persistent inward currents (PICs), after spinal cord injury 177–8
- personal emergency response system (PERS) 154
- pesticides 260
- PET *see* positron emission tomography
- phagocytes, removal of dying cells 258
- phantom limb pain/sensation 555  
 behavioral interventions 293–4  
 cortical reorganization 291–3  
 pharmacological therapy 295  
 somatosensory pain memory concept 290–1
- phantom sensation, tinnitus as auditory 133–5
- pharmacological therapy  
 chronic pain 295  
 genetic influences on response 28–9  
 human neurorehabilitation 241–3  
 locomotor recovery after spinal cord injury 181–4  
 spinal cord injury 629–30  
 stroke rehabilitation 242–4
- Pharos Cognit 153
- pharyngeal stimulation  
 cortical effects 136, 410–11  
 dysphagic stroke 245, 138
- phenobarbital 552–3
- phenol injections, deforming spastic paresis 319
- phenytoin 466, 552–3
- φ-nodes 462
- phosphacan 157, 202, 381
- phosphatase and tensin homolog deleted on chromosome ten *see* PTEN
- phosphatase PP2B/calcineurin 56
- phosphatidylinositol 3-kinase/ AKT (PI3K/AKT) pathway 257, 401
- phosphodiesterase 4 (PDE4) 356  
 inhibitor 356
- phospholipase C (PL-C) 43
- phospholipase Cγ (PL-Cγ) pathway 257, 401
- phrenic nerve pacing 126, 631
- physical activity  
 chronic neurological conditions 371–2  
 exercise capacity and 369  
 hippocampal neurogenesis and 289–90  
*see also* exercise physical and rehabilitation medicine (PRM) 283
- physical therapist (PT) 283
- physical therapy (physiotherapy) disorders of consciousness 397  
 dystonia 578  
 multiple sclerosis 646  
 Parkinson's disease 570  
 post-polio syndrome 659  
 stroke, with pharmacotherapy 242–3
- physostigmine 541
- PICK1 protein 57
- Pick's disease 260–1
- picture exchange communication system (PECS) 227
- picture planner 153
- pilot studies 5
- PINK1 (PTEN-inducing putative kinase 1) 260, 263–4, 268, 277
- PirB (paired immunoglobulin-like receptor B) 341–2, 353
- place cells, hippocampal 29
- placebo control groups 4, 234–5  
 placebo effect 234, 412
- plan, rehabilitation 282–5
- planarians, CNS regeneration 329
- planning and execution assistant and trainer (PEAT) 153
- plasma exchange 660, 664
- plasticity 555  
 activity-dependent *see* activity-dependent plasticity  
 auditory functions 125–35  
 cellular and molecular mechanisms after injury 196–207
- cerebral motor functions 99–110
- cerebral palsy and neonatal brain injury 215–16
- compensatory 91
- cross-modal, visual system 140–8
- experience-dependent  
*see* experience-dependent plasticity
- functional electrical stimulation and 120–1
- genetic factors affecting 25–7
- homeostatic 2–3, 11–12
- mechanisms 241–2
- multisite and multilevel 88–91
- pain and 289–93
- primary 91
- reactive 91
- rehabilitation and 6, 109–10, 240–8, 284–5
- response to neural interfaces 555
- sensory retraining and 303, 305–6
- short-term *see* short-term plasticity
- somatosensory system 75–80
- spinal cord *see* spinal cord plasticity
- stroke recovery 12–15
- underlying recovery 25
- visual connections 114–20  
*see also* synaptic plasticity
- platelet-derived growth factor (PDGF) 287, 370–1
- PlayStation, Sony  
 EyeToy 200, 202, 209  
 Move 202
- plexins 358  
 axon guidance 305–6  
 synaptic pruning 324
- pluripotent stem cells 435  
 directed differentiation 437  
 induced *see* induced pluripotent stem (iPS) cells
- isolation and properties 439
- neural induction 439  
*see also* embryonic stem (ES) cells
- Pocket Endeavor software 153
- podiatrist 285
- poliomyelitis 659–60  
*see also* post-poliomyelitis syndrome
- polyamines 357
- polyglutamine (polyQ) repeat diseases 260, 268  
*see also* Huntington's disease
- polymyositis 80, 665–6
- polyneuropathies 660–4  
*see also* axonal polyneuropathies, peripheral neuropathies
- pontomedullary locomotor region (PLR) 175



## Index

- population vector algorithm (PVA) 580
- positron emission tomography (PET) 84
- aphasia rehabilitation 442
- blindness 127–30
- parkinsonism 568
- stroke 11–13, 44, 197
- swallowing control 409
- traumatic brain injury 537
- post-poliomyelitis syndrome 369–70, 375, 377, 659–60
- postprandial hypotension 422, 424
- postsynaptic density (PSD) 317–20
- postsynaptic potentials (PSP) 36–8
- postsynaptic terminal, differentiation 322–3
- post-tetanic potentiation (PTP, potentiation) 36
- Ca<sup>2+</sup>-dependent mechanisms 42–3
- quantal mechanisms 38
- synapse specificity 44–5
- vs. long-term potentiation 51
- see also* long-term potentiation
- post-traumatic epilepsy 392, 542
- post-traumatic stress disorder (PTSD) 265, 544, 629
- post-traumatic syringomyelia 623
- postural control
- seated, functional electrical stimulation 127
- virtual reality-based assessment 355
- see also* balance control
- postural hypotension *see* orthostatic hypotension
- postural orientation 105–10
- postural responses, automatic, to perturbations 108–9
- assessment 111–12
- treatments addressing 114
- postural stability (or equilibrium) 105–10
- assessment 355–6
- dynamic, during gait *see* dynamic postural stability during gait
- limits of *see* limits of stability
- see also* balance control
- postural support systems, wheelchair 170–2
- postural tachycardia syndrome (PoTS) 425–6
- postural verticality 107, 110
- posturing, daily 315
- posturography, dynamic 110–13
- potassium channel blockers
- multiple sclerosis 459, 640–1
- see also* 4-aminopyridine
- potassium (K<sup>+</sup>) channels, myelinated axons 458–9
- potassium chloride co-transporter-2 (KCC2) 178
- potentiation
- long-term *see* long-term potentiation
- post-tetanic *see* post-tetanic potentiation
- short-term (STP) 51
- power, muscle 331
- PQRST technique 482
- practice effects, in neurorehabilitation 240–1
- praxis
- neuroanatomy 453–5
- theoretical models 450–3
- see also* apraxia
- preclinical studies
- criteria for translation to humans 231–2
- neurorehabilitation 5
- precursor cells, neural *see* neural precursor cells
- preference-based stroke index (PBSI) 38
- prefrontal cortex (PFC)
- executive control 492, 495
- memory functions 32, 490–2
- motor functions 102
- reward circuit 135
- ventromedial (VMPFC), role in tinnitus 134–5
- visual cortical input 143
- pregabalin 623
- prehension synergy 603
- premature infants, perinatal brain injury 211
- premotor cortex (PM)
- axon sprouting after stroke 197, 200
- changes after M1 injury 107–8
- dorsal *see* dorsal premotor cortex
- post-stroke reorganization 85, 87, 89
- reorganization after brain injury 55, 317
- ventral *see* ventral premotor cortex
- premyelinating oligodendrocyte lineage cells (preOLs)
- injury in cerebral palsy 212
- mechanisms of perinatal injury 212–15
- presence, virtual 198–9
- presenilins 259, 294
- pressure relief ankle–foot orthosis (PRAFO) 397
- pressure relief measures
- disorders of consciousness 397
- spinal cord injury 621
- upper limb orthoses 183
- wheelchair users 168
- pressure ulcers 163, 622
- presupplementary motor area (pre-SMA) 53, 99–100, 103
- presynaptic apparatus, assembly 15, 319
- presynaptic inhibition, spasticity 346
- priapism 620
- primary motor cortex (M1, area F1) 51–3
- amputation-related plasticity 292
- brain–computer devices 581
- brain injury/stroke-related reorganization 52–3, 85–9, 91
- cerebellar connectivity 143
- experience-dependent plasticity 104–5
- focal lesions
- local reorganization after 52, 317
- recovery and compensation for 57
- remote changes after 55, 106–8
- neurons *see* upper motor neurons
- organization 51–2, 101
- somatosensory input and 135–6
- transcranial magnetic stimulation studies 142–3
- see also* motor cortex
- primary plasticity 91
- primary somatosensory cortex (S1)
- changes after M1 injury 107–8
- enhanced sensory input and 135
- experience-dependent plasticity 109
- plasticity in blindness 142
- reorganization in chronic pain 289
- see also* somatosensory cortex
- primary visual cortex (V1)
- ablation, blindsight after 502
- congenital blindness 148
- cortical visual prostheses 546
- primates, nonhuman
- cortical motor areas 53, 99–103
- declarative memory 30–1
- emotional communication 131
- somatosensory system
- plasticity 75–80
- spinal cord injury research 248, 537
- priming effects 16, 24
- prism adaptation, neglect 468
- prisms, optical
- neglect 468, 610
- visual field impairments 501
- pro-oligodendrocytes 369
- probabilistic learning 24
- progenitor cells
- lineage-restricted *see* lineage-restricted progenitors
- multipotent *see* multipotent progenitor cells
- subgranular zone (type-2 cells) 288
- terminology 283–4
- see also* neural precursor cells, neural stem cells
- progesterone 539
- prognostic studies, assessing quality 587–90
- programed cell death (PCD)
- developing neurons 255–6, 258
- molecular regulation 257–8
- morphological features 256–7
- see also* apoptosis, neuronal death
- progranulin 261
- progressive supranuclear palsy (PSP) 569
- apraxia 448, 457
- inflammatory response 394
- progressively lowered stress threshold (PLST) 523
- prolyl 4-hydroxylase (PH)
- inhibition 159
- PROMIS (patient-reported outcomes measurement information system) 39
- proprioceptive feedback, neglect rehabilitation 469
- proprioceptive reflexes 83
- development 85
- Parkinson's disease 345, 571
- propriospinal pathways
- locomotion control 167, 173–6
- locomotor recovery after spinal cord injury 172–3, 175–7, 179, 184
- prostheses
- implantable neural *see* neural prostheses
- lower limb mechanical-assisted 190–5
- upper extremity mechatronic 177, 184–6
- proteasome 266
- protein(s)
- aggregation, neurodegenerative diseases 264–7
- synthesis, axon tip 424
- protein kinase A (PKA)
- axon guidance 308
- axon regeneration and 356
- behavioral sensitization 65–7

- long-term potentiation 55  
regulation of neuronal survival 257
- protein kinase C (PKC)  
long-term depression 57  
long-term potentiation 54–5  
neuronal survival 257  
neurotrophin signaling 401  
post-tetanic potentiation 43  
sensitization in *Aplysia* 65–6
- protein kinase M (PKM), *Aplysia*  
homolog 68
- protein tyrosine phosphatase (PTP) $\sigma$  344–5, 381–2
- proteoglycans  
glial scar 360, 381  
*see also* chondroitin sulfate  
proteoglycans
- proximity principle,  
reinnervation 15
- pruning effect 12
- PSD-95 protein 55, 319, 323
- pseudoplasticity 76, 78
- psychiatric disorders  
after temporal lobectomy 561–3  
critically ill patients 265  
deep brain stimulation 544  
in epilepsy 550–1, 553–6, 558–60  
epilepsy risk in 553–4  
spinal cord injury 628–9  
traumatic brain injury 543–4
- psychogenic non-epileptic  
events, post-surgical 562
- psycholinguistic approach,  
aphasia 438–40
- psychological interventions,  
multiple sclerosis 649
- psychological/psychoeducational  
approaches, dementia 523–6
- psychosis  
after temporal lobectomy 561  
ictal 555  
postictal (PIP) 555
- psychosocial counseling,  
Parkinson's disease 574
- psychosocial problems  
epilepsy 556–7, 559  
epilepsy surgery and 562
- psychostimulants 393, 528, 540
- PTEN (phosphatase and tensin  
homolog deleted on  
chromosome ten)  
axon regeneration 11, 345,  
357, 379, 419–20  
myelin-associated glycoprotein  
and 354
- PTP (protein tyrosine  
phosphatase)- $\sigma$  344–5,  
381–2
- pull-test maneuver, Parkinson's  
disease 572
- pulmonary dysfunction, spinal  
cord injury 620, 622
- pulmonary embolism (PE),  
spinal cord injury 620–2
- punishment 63
- pure autonomic failure (PAF)  
gastrointestinal dysfunction 429  
orthostatic hypotension 422–4  
urinary dysfunction 428
- purinergic receptors 393–4  
amyotrophic lateral sclerosis 395  
Schwann cell signaling 485
- Purkinje cells, cerebellar  
*see* cerebellar Purkinje cells
- pushrim activated power assisted  
wheelchairs (PAPAW) 164–5
- putrescine 357
- pyramidal neurons, hippocampal 29
- quadriplegia *see* tetraplegia
- quality of life (QoL)  
epilepsy 550–1  
neuromuscular disorders 655–6  
polio 660  
spinal cord injury 628–9  
visual field rehabilitation  
and 504
- quality of life in epilepsy  
inventory (QOLIE) 550
- quantal content 38
- quantal hypothesis of  
neurotransmitter release 36–8
- quantitative  
electroencephalogram  
(QEEG) biofeedback 481
- quasi-experimental studies 2
- quipazine 182
- QYNAD (Gln-Tyr-Asn-Ala-  
Asp) peptide 460
- Rab proteins 277
- rabies virus, as neuronal marker 101
- Rac1 307–8
- radial nerve stimulation 137
- RAGE (advanced glycoxidation  
end-products),  
Alzheimer's disease 394
- Ramón y Cajal, Santiago  
axon guidance 301  
axon sprouting 12  
CNS axon regeneration 1, 339,  
496, 529  
peripheral nerve regeneration 472–3
- Ran binding protein (RANBP1) 416
- randomization 2–4, 234–5
- randomized controlled trials  
(RCTs)
- CONSORT checklist 2–3
- rehabilitation  
enrichment strategies 5  
interventions 4  
methodological quality 11  
multicenter 1–2  
study designs 234–5  
*see also* clinical trials
- range of motion *see* active range  
of motion, passive range  
of motion
- rapamycin 420
- raphe cell transplants, spinal  
cord injury 437
- Ras, long-term potentiation 54
- Ras-Raf-Mek-Erk pathway 401
- Rasch analysis 39, 591
- reaching  
compensatory strategies after  
stroke 600–2  
tasks, animal models 534–6  
virtual reality applications 208,  
210
- reaction times, motor cortex  
organization and 53
- reactive astrogliosis  
*see* astrogliosis, reactive
- reactive oxygen species (ROS) 261–2, 265
- reactive plasticity 91
- reading aids 158
- reality orientation therapy 524–5
- reciprocating gait orthosis  
(RGO) 127
- recovery  
definitions 8, 599–600  
genetic factors 25  
plasticity underlying 25  
stroke *see* stroke recovery  
vs. outcome 7  
*see also* motor recovery
- recreational therapist (RT, TRec) 283
- red nucleus 5, 56
- redundancy  
and compensation 603–5  
motor system 602–5  
referent body configuration  
(R) concept 603
- redundancy gain (RG) 503
- redundant target effect (RTE) 503
- referent body configuration (R) 603
- reflexes, spinal cord injury 178–9
- regeneration  
axon *see* axon regeneration  
invertebrate nervous system 329–30  
non-mammalian models 329–35
- regeneration-associated genes  
(RAGs) 243
- rehabilitation  
(neurorehabilitation) 278–86
- acute stage of disease *see* early  
neurorehabilitation
- brain-computer interface  
(BCI)-based 571
- clinical pathways *see* clinical  
pathways
- clinical trials 1–6
- cognitive *see* cognitive  
rehabilitation
- definitions 261, 278
- delivery 279, 281
- dose-response relationships 110
- early *see* early  
neurorehabilitation
- economics 285–6
- experimental spinal cord  
injury 160–1, 536–7
- genetic factors 25–30
- intensity *see* intensity of  
therapy
- learning and 71
- motor recovery and  
compensation 599–605
- multisensory approaches 148
- neuroplasticity and 6, 109–10,  
240–8, 284–5
- outcome measures  
*see* outcome measures
- peripheral somatosensory  
input and 244–6
- phases 261–2
- planning 282–5
- principles 279
- service provision 279–85
- Slinky model 279
- during therapeutic clinical  
trials 233–4, 239
- timing after injury 109–10
- training and practice effects 240–1
- World Health Organization  
model 278–9
- Rehabilitation Engineering and  
Assistive Technology  
Society of North America  
(RESNA) 172
- rehabilitation engineering  
technologist (RET) 172
- rehabilitation medicine 283
- rehabilitation nurse 283
- rehabilitation physician 283
- rehabilitation team 278–82  
members 282–3, 285  
specialized stroke unit 601
- reinforcement 63
- reinnervation  
denervated neurons 14–17  
early studies 1  
muscle *see* muscle,  
reinnervation  
new presynaptic  
specializations 15  
priming effects 16

## Index

- reintegration to normal living (RNL) index **38**
- relay formation, injured spinal cord **446–8**
- reliability, outcome measurement **36**
- reminiscence therapy **524, 526**
- remyelination  
 olfactory ensheathing cell grafts and **506–8**  
 restoration of conduction **464–5**  
 Schwann cell grafts and **464–5, 497–9**
- renin–angiotensin system **420**
- reperfusion therapies, stroke **11**
- repetitive strain injuries, wheelchair users **161–2**
- repetitive therapy, stroke rehabilitation **605**
- reproductive system dysfunction **429–30**
- reptiles, axon regeneration **334**
- repulsive guidance molecules (RGMa, RGMb, RGMc) **306–7, 344**
- RESCUE study **572**
- resiniferatoxin, intravesical **428**
- resistance training  
 multiple sclerosis **646**  
 upper extremity rehabilitation **336**
- resources for enhancing  
 Alzheimer's caregiver health (REACH) **527**
- respiratory complications  
 severe brain injury **393**  
 spinal cord injury **622**  
 spinal muscular atrophy **658**
- respiratory failure, acute neuromuscular **265**
- respiratory function  
 exercise capacity and **371**  
 polio patients **660**  
 spinal cord injury **620**
- respiratory system, effects of bed rest **266–8**
- respiratory training  
 multiple sclerosis **648**  
 spinal muscular atrophy **658**
- responsiveness, outcome measurement **37–8**
- restitution (functional)  
 aphasia **438**  
 definition **7–8**  
 noninvasive brain stimulation promoting **222**  
 vs. compensatory strategies **8–9**
- restless legs syndrome **567**
- reticular formation, voluntary motor control **56**
- reticulon family of proteins **340**
- reticulospinal–propriospinal system, integrated **173–5**
- reticulospinal tract  
 locomotor control **167, 172–3, 179**  
 neurotrophins and axon regeneration **408**  
 post-stroke changes **86**  
 voluntary motor control **56**
- retina  
 immature, waves of activity **118**  
 regeneration in amphibians **333–4**
- retinal ganglion cells (RGC)  
 114–20  
 axon development **114–18**  
 axon regeneration **118–20**  
 cAMP elevation and **356**  
 cell survival and **415**  
 developmental loss of ability **414**  
 inhibition by CSPGs **382**  
 lower vertebrates **118–19, 306, 332, 334**  
 molecules regulating **417, 420**  
 signaling pathways **11**
- retinal prostheses **545–6, 554–5**
- retinotopic map **114–15**  
 development **114–18**  
 regeneration **118–20**
- retraction balls **7, 9**
- retrograde atrophy **4–6**
- retrograde degeneration **4–7**
- retroviruses  
 gene therapy vectors **515, 517**  
 labeling neural precursor cells **292**
- reward learning/circuitry **27**
- Rho GTPases  
 inhibition of axon regeneration **309–10, 354, 419**  
 modulation of neuronal growth response **421**  
 regulation by protein kinase A **308**  
 regulation of growth cones **307–8, 359**  
 as therapeutic target **355, 385, 421**
- Rho kinase (ROCK) **421**
- Rho/ROCK signaling pathway **158, 354**
- rhythmic auditory stimulation (RAS), Parkinson's disease **572**
- Rig1 **308**
- riluzole **260, 657**
- rise-to-walk (RTW) test **42**  
 fluidity scale, evaluation **38, 43**
- rising to walk **42**
- rivastigmine **469, 479–80, 541**
- Rivermead assessment of somatosensory performance (RASP) **300**
- Rivermead mobility index (RMI), recovery after stroke **593**
- Robo (Roundabout) **304–5, 308, 359**
- robotic systems  
 assisting gait training **65, 647**  
 functional electrical stimulation with **124**  
 genetic influences on response **29**  
 lower limb rehabilitation **190–5**  
 mobility assistance **157**  
 upper extremity rehabilitation **177–83, 338**
- robotic wheelchairs **166–7**
- rolipram **356**
- Ross' syndrome **431**
- rostral migratory stream (RMS), migration of precursor cells **285, 287**
- rotary pursuit learning, Alzheimer's disease **520–1**
- Roundabout *see* Robo
- route finding training, virtual reality **208**
- RPTP- $\sigma$  (protein tyrosine phosphatase- $\sigma$ , PTP- $\sigma$ ) **344–5, 381–2**
- RT300/RT600 devices **125**
- rubrospinal tract  
 lesions **5, 169, 405, 408**  
 voluntary motor control **56–7**
- Rutgers ankle rehabilitation system (RARS) **210**
- Rutgers Master II force feedback glove **200–1**
- S1 *see* primary somatosensory cortex
- S100 $\beta$ , traumatic brain injury **536**
- saccadic exploration training **501–3**
- sacral nerve root stimulators **129–30, 543, 630–1**
- salamanders  
 spinal cord regeneration **332–3**  
 visual system regeneration **333–4**
- saliency of rehabilitation, disorders of consciousness **394**
- salt loading, chronic **161**
- SAP97 (synapse-associated protein 97kDa) **55**
- Sarm1 **276**
- scar  
 collagenous (fibrous) **158–9**  
 glial *see* glial scar
- scavenger receptors **393**
- schizophrenia **58, 207, 294**
- Schwann cells (SC)  
 axonal protection **277**  
 injured spinal cord **497–8**
- myelinating and nonmyelinating types **472**
- myelination role **457**
- neuromuscular synaptic remodeling and **482**
- olfactory ensheathing cell transplants and **507**
- oligodendrocyte precursor cell-derived **373**
- peripheral nerve regeneration **373, 405, 472–86**  
 across lesion site **473–4**  
 causes of failure **484**  
 between cut ends **475–6**  
 damaged/regenerated muscle fibers **479–81**  
 endoneurial tubes and **473–4**  
 escaped fibers **474–5, 478–9**  
 molecular mechanisms **403, 484–6**  
 nerve sprout formation **481**  
 reoccupation of synaptic sites **481–2**  
 sprouting of nerve terminal **475–6**  
 study methods **474**  
 vital imaging **476–9**
- remyelination of spinal cord axons **464–5, 497–9**
- spinal cord transplants  
 496–502, 508, 589–90  
 axon branching and terminal arborization **499–500**  
 axonal regeneration **500–1, 505**  
 gene transduction studies **502, 521**  
 migration properties **503**  
 with neurotrophic factors **501–2**  
 with olfactory ensheathing cells **502**  
 plus other interventions **501–2**  
 rationale **496–7**  
 remyelination and conduction **497–9**  
 territories, at neuromuscular junction **482–4**  
 transplants in multiple sclerosis **588**  
 trophic support for axons **472**  
 tropic influences on growth **481**
- schwannosis **497–8**
- SCI *see* spinal cord injury
- scoliosis supports, wheelchair **171**
- scooters, mobility **157, 166**
- seat cushions, wheelchair **170**
- seated postural control, functional electrical stimulation **127**

- seating protocols, disorders of consciousness **397**
- seating technology, wheelchair *see under* wheelchairs
- secondary brain injury **543**
- secretases **259**
- SeeMe virtual reality system **202**
- seizures
- cognitive deterioration and **551–2**
  - hippocampal neurogenesis induced by **289**
  - post-traumatic **392, 542**
  - psychiatric symptoms **554–5**
  - transcranial magnetic stimulation-induced **142**
  - see also* epilepsy
- selective serotonin reuptake inhibitors (SSRIs) **29, 608**
- selegiline **424–5**
- self-awareness, lack of *see* anosognosia
- self-rehabilitation contracts **321**
- self-stretch **315**
- semantic dementia, apraxia **449–50**
- semantic feature analysis (SFA) **439, 443–4**
- semantic memory, neocortical storage **31–2**
- semaphorins **157, 203**
- axon guidance **305–6**
  - brain lesions **203**
  - inhibition of axon regeneration **309–10, 344, 358–9, 382–3**
  - spinal cord injury **158**
- SENSe training program **304**
- sensitive periods *see* critical periods
- sensitization **23, 63**
- chronic musculoskeletal pain **289**
  - intermediate-term **68**
  - long-term **66–8**
  - neural mechanisms **65–8**
  - short-term **65–6**
  - vs. classical conditioning **68**
  - see also* facilitation
- sensorimotor function
- assessment
  - experimental spinal cord injury **83, 529–37**
  - bowel, bladder, and autonomic function **536**
  - different paradigms **530–1**
  - forelimb motor recovery **534–5**
  - histopathology and **536**
  - integrative measures **535–6**
  - locomotor recovery **530, 532–4**
  - outcomes to measure **529–30**
  - rehabilitation and **536–7**
- sensory testing and pain **535**
- white matter sparing **530**
- human spinal cord injury **531–2, 617**
- sensorimotor rhythms
- ECoG-based brain–computer interfaces **568–9**
  - EEG-based brain–computer interfaces **568**
- sensorin **67**
- sensory channel reweighting, balance control **108**
- sensory cortex *see* somatosensory cortex
- sensory cueing, Parkinson's disease **571–2**
- sensory loss (somatic) **298–307**
- assessment *see* sensory testing
  - assistive technology **154**
  - functional implications **299**
  - nature of impairment **298–9**
  - potential for recovery **300–1**
  - rehabilitation *see* sensory rehabilitation
  - somatosensory system plasticity after **76–80, 301–2**
- sensory neurons (SNs)
- Aplysia* reflexes **64**
  - neurotrophins and regeneration **403–4**
  - transplantation into adult CNS **384**
  - see also* dorsal root ganglion (DRG) neurons
- sensory orientation (in balance) **107–8**
- assessment **110–11**
  - treatments addressing **112–14**
- sensory rehabilitation **301–7**
- efficacy **300–4**
  - future directions **306–7**
  - neural prostheses **544–6**
  - principles of plasticity and learning **303, 305–6**
- sensory stimulation
- disorders of consciousness **395**
  - see also* somatosensory stimulation
- sensory testing **299–300**
- experimental spinal cord injury **535**
- serial casting **316**
- serotonergic (5-HT) neurons
- regenerative ability **382**
  - transplantation studies **182**
- serotonin (5-HT)
- autonomic function **417**
  - hippocampal neurogenesis and **290**
  - locomotor control in rats **171–3, 179, 182**
  - mediating classical conditioning **68**
  - mediating sensitization **65–7**
- serotonin (5-HT) agonists, locomotor effects **181–2, 184**
- serotonin (5-HT) receptor blockers, locomotion effects **181**
- serotonin (5-HT) receptors, injured spinal cord **177–8**
- serotonin-transporter-linked polymorphic region (5-HTTLPR) **28**
- serotonin<sub>2</sub> (5-HT<sub>2</sub>) receptors
- injured spinal cord **178**
  - locomotion and **182**
- serotonin<sub>7</sub> (5-HT<sub>7</sub>) receptors, locomotion and **182**
- serpentine splint **315**
- sertraline **559, 561**
- sexual dysfunction **429–30, 641**
- SF-36 (36-item short form health survey) **67**
- Shank protein **323**
- shavers, electric **155**
- Sherrington, Charles **529**
- shoehorns, long-handled **155**
- shopping, assistive devices **158**
- short message service (SMS)-based reminder systems **484**
- short-term depression **36, 43–4**
- quantal mechanisms **38**
  - synapse specificity **44–5**
- short-term (synaptic) enhancement (STE) **36**
- Ca<sup>2+</sup>-dependent mechanisms **38–43**
  - decay rates **42**
  - quantal mechanisms **38**
  - synapse specificity **44–5**
  - see also* augmentation, facilitation, potentiation
- short-term memory *see* working memory
- short-term plasticity **36–45**
- quantal mechanisms **36–8**
  - synaptic specificity **44–5**
- short-term sensitization, *Aplysia* **65–6**
- shoulder movements
- compensatory **601–2**
  - post-stroke, predicting recovery **334, 596**
  - stretch reflex thresholds **605**
- shoulder pain, hemiplegic (HSP) **263–4**
- functional electrical stimulation **124**
  - management **607**
- shoulder subluxation, post-stroke **124**
- showing, assistive technology **154**
- sialic acid residues **352**
- sign language, visual **132**
- sildenafil **430, 641**
- SIMA (maintaining and supporting independent living in old age) study **517**
- single blind clinical trials **234**
- single photon emission computed tomography (SPECT)
- parkinsonism **568**
  - stroke **12**
- siphon-gill withdrawal reflex, *Aplysia* **64**
- Sirt1 **275–6**
- sitting balance, post-stroke, predictive value **595**
- situational syncope **425**
- skills training, dementia **519**
- skin care
- disorders of consciousness **392**
  - spinal cord injury **621**
- Skinner, B.F. **27**
- SLC6A4 gene polymorphisms **28–9**
- sleep disorders, traumatic brain injury **544**
- sleep/wake cycles, disorders of consciousness **392**
- Slinky model **279**
- Slit proteins
- axon guidance **304–5, 308**
  - axon regeneration **310, 359, 383**
  - receptors **304–5**
- slow-wave sleep (SWS), non-invasive brain stimulation and **223**
- Smads **416**
- smart wheelchairs **167**
- smartphones
- assistive technology **157, 159**
  - memory aids **153, 483–4**
  - see also* mobile electronic devices
- SMART<sup>Wheel</sup> kinetic measurement system **161**
- SMS (short message service)-based reminder systems **484**
- soap dispensers **155**
- social concerns, implanted neural prostheses **550**
- social problems, epilepsy **550–1, 556–7**
- social reintegration, spinal cord injury **628–9**
- social worker **283**
- SOCS (suppressor of cytokine signaling) proteins, axon regeneration and **417**
- SOCS3, axon regeneration and **11, 417, 420**
- SOD1 *see* superoxide dismutase, copper/zinc
- sodium (Na<sup>+</sup>) channel blockers, demyelinating diseases **466**

## Index

- sodium (Na<sup>+</sup>) channels  
 demyelinated axons 460–1  
 impedance mismatch and matching 464–5  
 mechanisms of redistribution 462  
 prior to remyelination 462  
 transfer from glia 462–4  
 injured axons 462–3  
 maladaptive expression in demyelinating disease 462, 464  
 myelinated axons 458  
 olfactory ensheathing cell grafts and 506  
 putative blocking factors 460  
 remyelinated axons 464  
 subtypes 458
- somatosensory cortex  
 amputation-related plasticity 77, 245, 291–2  
 plasticity after sensory loss 13, 77–8, 245  
 developing systems 80  
 time course and mechanisms 78–9  
 plasticity after visual deprivation 142  
 post-stroke plasticity 196, 301–2  
 axon sprouting 197, 200  
 primary (S1) *see* primary somatosensory cortex  
 synapse-specificity of short-term plasticity 44–5  
 visual cortical input 143
- somatosensory evoked potentials (SSEPs)  
 disorders of consciousness 391  
 spinal cord injury 618–19  
 traumatic brain injury 398–9
- somatosensory function  
 assessment 299–300  
 defined 298  
 loss of *see* sensory loss
- somatosensory input  
 (peripheral) 244–6  
 disruption 76–80, 245–6  
 cortical reorganization 76–9, 245  
 developing systems 79–80  
 treatments to promote recovery 80  
*see also* peripheral nerve injury
- functional relevance in humans 136–7  
 increased *see* somatosensory stimulation  
 modulation in animals 135–6  
 somatosensory neglect 465  
 somatosensory pain memory 290–1  
 somatosensory stimulation
- animal studies 135–6  
 in congenital deafness 132  
 functional recovery and 244–5  
 visual cortical areas in blind animals 144  
*see also* peripheral nerve stimulation, tactile perception
- somatosensory system 75–80, 298  
 balance control 108, 356  
 complexity 75–6  
 plasticity after injury and sensory loss 76–80, 301–2  
 developing systems 79–80  
 immediate and short-term 76–7  
 long-term changes 77–8  
 time course and mechanisms 78–9  
 treatments to promote recovery 80
- somatotopic organization 75–6  
 songbirds 131  
 sonic hedgehog (Shh) 306, 370–1  
 Sony PlayStation *see* PlayStation, Sony
- sound localization *see* auditory spatial functions
- spaced repetition (or retrieval) technique 481, 518, 526
- spared axon conundrum 9
- spastic co-contraction 312  
 spastic dystonia 312  
 spastic paresis, deforming 312–21  
 clinical assessment 312–14  
 impact of medications on training 319–20  
 management 314–21  
 motor training 316–18  
 noninvasive brain stimulation 320–1  
 stretch therapy 314–16  
 treatment of muscle overactivity 318–19
- spasticity  
 defined 312, 542, 604  
 denervation supersensitivity 2–3  
 disorders of consciousness 392  
 energy costs of walking 377  
 functional electrical stimulation 123–4  
 gait disorder 345–8  
 generalized, fallacy of concept 318–19  
 grade 313  
 local treatments 318–19  
 multiple sclerosis 640  
 spinal cord injury 177–8, 620, 623  
 spinal cord plasticity and 84  
 strength training and 332–3  
 stretch reflex thresholds 605  
 stroke 604–5
- transcranial magnetic stimulation and 320  
 traumatic brain injury 542–3
- spastin 277
- spatial navigation, virtual reality applications 204–5
- spatial perception  
 auditory *see* auditory spatial functions  
 tactile, blind humans 140–1
- specificity of training  
 disorders of consciousness 394  
 somatosensory loss 306  
 stroke rehabilitation 10  
 upper extremity rehabilitation 336–7
- αII-spectrin breakdown  
 products, traumatic brain injury 536
- speech and language pathologist/therapist (SLP/SALT) 223, 225–6, 283
- speech and language therapy (SLT)  
 disorders of consciousness 395–7  
 multiple sclerosis 648  
 Parkinson's disease 573–4  
 stroke 271, 443–4, 609  
*see also* aphasia, rehabilitation
- speech brain-computer devices (BCIs), direct 579
- speech disorders 437
- speech generating devices (SGD) 220, 223
- speech perception 125, 129–31  
 aging effects 132–3  
 early phonetic environment and 131  
 via cochlear implants 133
- spermidine 357
- Sperry's chemoaffinity (or chemospecificity) hypothesis 115–18, 306, 334
- spina bifida, exercise capacity 370
- spinal commissural neurons, axon guidance 302–3
- spinal cord 83–92  
 isolated in vitro preparations, locomotor activity 171, 177  
 negotiated equilibrium concept 90, 92  
 neural precursor cells 286  
 oligodendrocyte development 370–2  
 traditional view 83
- spinal cord hemisection *see* *under* experimental spinal cord injury
- spinal cord independence measure (SCIM) 238–9
- spinal cord injury (SCI) 155, 242–50  
 adjustment to 628–9
- assessment 616–21  
 international core data sets 616–17  
 neuroimaging 619–20  
 neurological 617  
 neurophysiology 617–19  
 standardized protocols 616, 618  
*see also* sensorimotor function assessment
- autonomic dysreflexia 427, 621–2
- axon regeneration *see* *under* axon regeneration
- clinical syndromes 617, 619  
 clinical trials 249  
 outcome measures 237–8  
 principles of conducting valid 231–40
- depression 620, 628–9
- epidemiology 615
- exercise capacity 370
- experimental *see* experimental spinal cord injury
- locomotor function 61, 348–9, 627–8  
 assessment 350  
 prediction 624
- lower vertebrates 330–4
- medical complications 621–4  
 bladder function 427–8, 621  
 gastrointestinal 429, 621  
 reproductive 430  
 thermoregulatory 431, 624
- neurotrophins and repair 404–8, 418
- non-traumatic (NTSCI) 615
- pathophysiological responses 435–6, 530–1  
 astrocyte functional diversity 370–2  
 axon sprouting 5–14  
 denervation supersensitivity 2–3
- extracellular matrix 157–9  
 glial scar 157–9  
 inflammatory response 417–18  
 oligodendrocyte death and demyelination 6–8  
 retrograde degeneration of cortical motoneurons 5–6  
 Schwann cell accumulation 497–8
- plasticity after *see* spinal cord plasticity, post-injury
- prognostic factors 624–5
- recovery and functional outcomes 624–8
- rehabilitation 160–1, 615–31  
 body weight support system (BWSS) 628  
 body weight-supported treadmill training 65, 630

- chondroitinase ABC therapy  
with 161  
effects on plasticity 92,  
160–1, 536–7  
exercise training 373, 375  
extracellular matrix changes  
161  
functional electrical  
stimulation *see*  
*under* functional electrical  
stimulation  
gait training *see under* gait  
training  
neural prostheses *see*  
*under* neural prostheses  
new and emerging methods  
629–31  
by spinal level 625–8  
standard assessments 616  
strategies 155  
therapies 242–50, 629–31  
aiding locomotor recovery  
180–4  
cAMP elevation 159, 356  
cell-based *see* cell  
replacement therapies,  
cellular therapies, stem  
cell therapies  
chondroitinase *see*  
*under* chondroitinase  
clinical translation 247–9  
combinatorial 245–6  
enhancing axonal plasticity  
and regeneration 243–5  
gene therapy 518, 521, 247  
neurotrophins 406  
targeting extracellular  
matrix 159–60, 244  
traumatic 435–6, 615–16  
spinal cord injury locomotor trial  
(SCILT) 65  
spinal cord plasticity  
activity-dependent 83–92  
behavioral change and  
88–90  
development 84–6  
importance 84  
motor skill acquisition and  
maintenance 86–8  
multisite nature 88–90  
normal life 84–8  
principles underlying 90–1  
recognition 83–4  
theoretical and practical  
significance 91–2  
post-injury  
chondroitinase plus  
rehabilitation and 161  
chondroitinase therapy and  
159–60  
chronic phase 161  
effect of rehabilitation  
160–1, 536–7  
recovery of locomotion due  
to 166–84  
somatosensory system 77  
spontaneous 159  
stroke recovery and 15  
spinal cord stimulation  
clinical studies 126, 548  
experimental spinal cord  
injury 183–4  
spinal cord transection (complete  
section) 529–32  
locomotor recovery in cats  
166–9  
associated peripheral nerve  
lesions 178–9  
locomotor training effects  
180  
at other spinal levels 168–9  
at T13 166–8  
locomotor recovery in mice  
176–7, 180  
locomotor recovery in rats  
171–2, 180–1  
spinal fixation phenomenon,  
cerebellar lesions 84  
spinal muscular atrophy (SMA)  
658–9  
spinal pattern generator *see*  
*under* central pattern  
generator  
spinal shock 620  
spinal stretch reflexes *see* stretch  
reflex(es)  
spinalization *see* spinal cord  
transection  
spinobulbar muscular atrophy  
268  
splints  
dynamic 315  
static 315–16  
sprouting *see* axon sprouting  
squid giant axons 457  
stair lifts 157  
stair test 42  
stairs, handrails 151–2  
standing  
compensatory strategies after  
stroke 15, 602  
functional electrical  
stimulation for 126–7,  
547–8  
spinal cord injury 126–7, 627  
Stargazin-like TARPs 55  
STAT3 (signal transducer and  
activator of transcription  
3) 376, 417, 421  
statistical analysis, clinical trials  
5, 240  
statistical validity, prognostic  
studies 589–90  
status epilepticus  
cognitive impairment 552  
non-convulsive (NCSE) 265  
steady-state visual evoked  
potential (SSVEP)-based  
brain-computer  
interfaces 568  
Steele Richardson Olzewsky  
syndrome *see* progressive  
supranuclear palsy  
stem cell therapies 586–93  
memory dysfunction 479  
multiple sclerosis 586–8, 592  
spinal cord injury 439–48,  
588–90, 592  
cell delivery methods 449  
clinical trials 449–50  
isolation and properties of  
cells 437–9  
time of engraftment 449  
stroke 590–3  
*see also* cell replacement  
therapies, cellular  
therapies  
stem cells 591  
alternative sources, cell  
replacement therapies  
448  
multipotent *see* multipotent  
progenitor cells  
neural *see* neural stem cells  
pluripotent *see* pluripotent  
stem cells  
StemCells Inc. 441, 450  
stepping strategy, balance control  
109, 114  
steroid sulfatase gene 28  
stigma, epilepsy 556–7  
stimulus generalization training  
(SGT) 303–4  
stimulus–response (S–R)  
learning 24  
Stimulus Specific Training (SST)  
303–4  
STIMuSTEP™ 258  
STIWELL med4 257  
stochastic resonance effects,  
noninvasive brain  
stimulation 223  
strength  
defined 330  
inadequate, causing weakness  
330–1, 333  
motor function and 331–2  
strength training  
post-polio syndrome 659  
upper extremity rehabilitation  
332–3, 336  
stress  
family caregivers in dementia  
526  
hippocampal neurogenesis and  
283–90  
stress appraisal and coping  
(SAC) model 628–9  
stress-induced analgesia 291  
stretch  
animal research 314  
brief 314  
chronic 314–15  
deforming spastic paresis  
314–16  
modalities 315–16  
sustained 314  
stretch reflex(es)  
adaptive changes in normal life  
86–8  
development 85–6  
effects of stretch 314  
operant conditioning studies  
88–91  
spasticity 346–7  
therapeutic applications of  
conditioning 92  
thresholds 604–5  
striatum  
adult neurogenesis 293  
reward circuit 27  
STROBE (strengthening of  
reporting of  
observational studies in  
epidemiology) 587  
stroke light stimulation 117, 119  
stroke  
acute, complications and  
comorbidity 263–4  
anosognosia 470  
apraxia 448–9, 452–5, 457  
depression after 607–8  
exercise capacity 370  
functional neuroimaging *see*  
*under* functional  
neuroimaging  
gait disorder 63–4, 346–8, 604  
gene therapy 522  
interhemispheric competition  
concept 144–5  
motor map plasticity 13–14,  
85–9, 106, 108, 196  
neonatal 212  
neural repair  
parallelogram concept  
205–7  
principles 196–207  
noninvasive brain stimulation  
143–7  
outcome 7  
vs. recovery 7  
predicting activities after  
*see* stroke recovery,  
predicting  
reperfusion therapies 11  
sensory loss 299  
assessment 300  
recovery 300–1  
severe 611  
stem cell therapies 590–3  
upper extremity weakness  
330–3  
visual field deficits 500  
walking difficulties 61  
*see also* aphasia, dysphagia,  
hemiplegia/hemiparesis,  
neglect, unilateral  
stroke impact scale 67, 591  
stroke recovery 7–18  
Brunnstrom's stages 603–4

## Index

- stroke recovery (cont.)  
 cellular mechanisms 11–12, 196–207  
 axon growth inhibitors 201–4  
 axonal sprouting/new connections 12–13, 199–201  
 cellular regeneration 12–13, 204–5  
 peri-infarct excitatory signaling 197–9  
 early intensive training and 16–17  
 efficacy of rehabilitation 9–11  
 factors affecting 602  
 functional neuroimaging 13–14  
 functional or adaptive 602  
 genetic influences 27–9  
 mechanisms 8, 11–18, 602  
 compensation vs. restitution 8–9  
 compensatory strategies 15–16  
 experience-dependent plasticity 12–15  
 future research needs 18  
 modeling 17–18  
 reversal of diaschisis 12  
 salvage of penumbral tissue 11–12  
 motor compensations 8, 15–16, 595, 600–2  
 neurological 602  
 peripheral somatosensory input and 244–6  
 predicting 7, 585–97  
 ADL independence 593–4  
 assessing research quality 587–90  
 clinical relevance 597  
 definitions 585–7  
 functional neuroimaging 43–5, 90–1  
 rationale 587  
 upper limb function 333–4, 595–7  
 walking ability 595  
 spontaneous 9, 590  
 impact on activities 592  
 measuring impact 592–3  
 mechanisms 602  
 terminology 7–9  
 time course/patterns 9, 41, 590–2  
 measuring role of spontaneous recovery 592–3  
 plateau in chronic phase 593  
 vs. outcome 7  
*see also under* motor recovery  
 stroke rehabilitation 601–11  
 acute stage (early) 262–72, 603–4  
 aphasia *see under* aphasia  
 clinical pathways 73–4  
 constraint-induced movement therapy *see* constraint-induced movement therapy  
 dose–response relationships 9–10, 110  
 dysphagia 609–10  
 economics 285–6  
 efficacy 9–11  
 exercise training 9–10, 373, 375  
 early phase 268–71  
 functional electrical stimulation 124–5, 547–8, 605–6  
 gait training 190–5, 271, 348  
 growth factor therapy 248  
 intensity 9, 282–4, 604  
 long term 611  
 lower extremity 604–7  
 energy costs of walking and 378  
 neural prostheses 547–8  
 mixed reality system 338–9  
 models of delivery 601  
 motor learning strategies 98  
 noninvasive brain stimulation 143–7, 247–8  
 cognitive functions 146–7, 227–32  
 combined approaches 248  
 inhibition of intact side 247  
 stimulation of lesioned side 247–8  
 outcome measures 35–45  
 peripheral nerve stimulation 137–8  
 pharmacological interventions 242–4  
 pharmacological targets 241  
 principle of neural repair 206–7  
 role of prognostic information 587  
 sensory retraining 302–4, 306  
 severe stroke 611  
 somatosensory stimulation 245  
 spasticity management 604–5  
 specificity 10  
 task-oriented vs. repetitive therapy 605  
 timing 109–10, 16–17, 373, 603–4  
 training and practice 241  
 treadmill training 10, 190, 607  
 unilateral neglect *see under* neglect, unilateral  
 upper extremity 330–9, 604–7  
 clinical pathways 74  
 early onset of therapy 270–1, 335–6  
 functional electrical stimulation 124, 606  
 intensity of therapy 335–6  
 outcome measures 337–8  
 peripheral nerve stimulation 137–8  
 predicting prognosis 333–4  
 recovery vs. compensation 334–5  
 robotic therapy 178–82  
 somatosensory input influencing 244, 246  
 strength training 332–3  
*see also* constraint-induced movement therapy  
 virtual reality applications 43, 204, 206–10  
 stroke rehabilitation assessment of movement (STREAM) 38, 40  
 stroke units, specialized 601–2  
 stroke volume (SV), during exercise 368  
 stromal-derived factor (SDF1) 204  
 Stroop paradigm 490  
 stunned neural circuits, after stroke 197–9  
 subbasis bar 171  
 subcutaneous electrodes 255  
 subgranular zone (SGZ) 285, 288–9  
 fate of precursor cells 291  
 neurogenic response to stroke 204  
 type-1 cells 288  
 type-2 cells 288  
 type-3 cells 288  
 subplate neurons, perinatal injury 215–16  
 substitution (functional) 7  
 definition 8  
 sensory, balance rehabilitation 113–14  
 subthalamic nucleus (STN) stimulation 543–4, 568–9  
 subventricular zone (SVZ) 285  
 adult neurogenesis 286–7  
 fate of precursor cells 291  
 neurogenic response to stroke 204–5  
 suicide risk, spinal cord injury 629  
 sulfatide 203  
 sunlight exposure, Parkinson's disease 573  
 superior colliculus (SC) auditory spatial perception 125  
 blind animals 127–8  
 denervation, chondroitinase ABC therapy 160  
 superior temporal cortex, reorganization in congenital deafness 132  
 superior temporal gyrus (STG), speech processing 131  
 superiority trials 235  
 superoxide dismutase, copper/zinc (SOD1) mutations in amyotrophic lateral sclerosis 260, 395, 656  
 toxicity of mutant 264, 395–6  
 supervisory attention system (SAS) 491, 512–13  
 supine hypertension 427  
 supplementary motor area (SMA) 53, 99–100, 103  
 post-stroke changes 85–6, 89  
 reorganization after brain injury 55  
 voluntary motor control 53–5  
 supportive services, dementia caregivers 523  
 surface electrodes 121, 254–5  
 swallowing anatomy 405–6  
 difficulties *see* dysphagia  
 evaluation 407, 610  
 acute phase 264  
 disorders of consciousness 396  
 stroke 407  
 learned non-use 411–12  
 neurophysiology 405–7  
 phases 609–10  
 therapy *see* dysphagia, treatment  
 sweating disorders 431  
 sympathetic nervous system 415–16  
 sympathetic skin response (SSR) 618  
 sympathomimetics, orthostatic hypotension 423–4  
 synapse(s) activity-dependent elimination 323–4  
 ectopic, regenerating axons 10  
 formation of new *see* synaptogenesis  
 neuromuscular junction 317  
 reorganization after injury 1, 8–17, 200  
 silent 54  
 unmasking or disinhibition 76, 78  
 specificity long-term potentiation 51  
 short-term plasticity 44–5  
 during synapse formation 323  
 structure of CNS 317–18  
 synapse-associated protein 97kDa (SAP97) 55  
 synapsin 65  
 synaptic cell adhesion molecule (SynCAM) 320–1  
 synaptic plasticity long-term and long-term depression 50–8  
 myelin-associated axonal growth inhibitors and 345

- short-term 36–45  
*see also* activity-dependent plasticity
- synaptic stripping 6, 482
- synaptic transmission  
 chemical 36–7  
 newly forming synapses 319  
 quantal hypothesis 36–8  
 short-term depression  
*see* short-term depression
- short-term enhancement  
*see* short-term (synaptic) enhancement
- synaptic vesicles  
 depletion, causing depression 38, 43–4, 65  
 function 36  
 increased numbers, causing augmentation 43  
 phasic transmitter release 39  
 quantal hypothesis 36–8  
 during synapse formation 319
- synaptogenesis 317–24  
 activity dependence 323–4  
 adult brain 324  
 CNS 317–24  
 denervated neurons 14–15  
 initial axon–dendrite contact 318–19  
 molecular regulators 320–3  
 glial-derived factors 322  
 organizing postsynaptic terminal 322–3  
 secreted factors 322  
 trans-synaptic molecules 320–2  
 neuromuscular junction 317  
 specificity of synaptic connections 323  
 stroke recovery 12–13  
 synaptic differentiation 319–20
- synaptotagmins 41–2
- SynCAM (synaptic cell adhesion molecule) 320–1
- syncope  
 autonomic (neurally) mediated 425  
 vasovagal 420–1, 425
- syndrome of inappropriate antidiuretic hormone (SIADH) 541
- synergies, motor action 603
- $\alpha$ -synuclein 260, 567
- $\alpha$ -synucleinopathies 394
- syringomyelia  
 fetal spinal cord transplants 437  
 post-traumatic 623
- tablet computers  
 communication apps 221–3, 225
- memory apps 153  
*see also* mobile electronic devices
- tactile discrimination test (TDT) 300
- tactile hyperacuity task  
 blindness 141  
 effects of practice 141  
 visual cortical activation in blindness 145
- tactile motion perception 142, 146
- tactile perception  
 after blindfolding 141, 144  
 assessment measures 300  
 blindness 140–1  
 cross-modal visual cortical involvement 142–4  
 sighted subjects after practice 141  
 visual cortical function in blindness 145–7  
*see also* haptic discrimination
- Tadoma method 141
- Tai Chi training 114
- tail-siphon withdrawal reflex, *Aplysia* 64
- tailored activity program (TAP) 527–8
- TAJ *see* TROY
- Tardieu scale 542
- target cells  
 availability, and axon re-growth after axotomy 12  
 specificity of short-term plasticity 45
- Tarlov and Klinger locomotor rating scale 532–3
- TARPs (transmembrane AMPAR regulatory proteins) 55
- task-orientated training (TOT) stroke rehabilitation 10, 336–7, 605  
*see also* constraint-induced movement therapy
- task specificity of training  
*see* specificity of training
- taste aversion learning 25
- taste stimulation, disorders of consciousness 396
- tau 259, 394  
 Parkinson's disease 395  
 traumatic brain injury 536
- tauopathies, inflammatory response 394
- taxol 423
- tDCS *see* transcranial direct current stimulation
- TDP-43 (transactive response DNA-binding protein 43) 260–1, 268, 395
- team, rehabilitation  
*see* rehabilitation team
- telephones  
 assistive technology 157  
*see also* cell phones, smartphones
- telerehabilitation 66, 208, 212
- temperature  
 perception, testing 300  
 regulation, disordered 430–1, 624  
 short-term synaptic plasticity and 43
- temporal lobe, memory functions 31–2
- temporal lobe epilepsy (TLE)  
 hippocampal neurogenesis and 289, 294  
 surgery *see* temporal lobectomy
- temporal lobectomy 560  
 neurological complications 562–3  
 rehabilitation and 560–3  
 seizures after 560
- tenascin-C (TN-C) 158–9
- tenascin-R (TN-R) 157, 159, 383
- tendon transfers, spinal cord injury 627
- tenodesis splints 626–7
- tension headache, chronic 289
- territorial competition, hypothesis of 120–1, 246
- test–retest reliability 36
- tetrabenazine 577
- tetraplegia  
 autonomic dysfunction 421, 621  
 functional electrical stimulation  
 breathing assistance 126  
 hand grasp and release 127–9, 258–9  
 seated postural control 127  
 intracortical brain–computer interfaces 578–9  
 recovery and functional outcomes 625–7  
*see also* cervical spinal cord injury
- tetrodotoxin (TTX)  
 axonal neuroprotection 466  
 resistant (TTX-R) sodium channels 458  
 retinotectal pathways 117–19
- TGF *see* transforming growth factor
- thalamus  
 praxis 455  
 reorganization after sensory loss 77–8, 301
- thermal bathing technique 525
- thermoregulatory dysfunction 430–1, 624
- theta burst stimulation (TBS) 141, 219  
 continuous (cTBS) 219
- intermittent (iTBS) 219
- thoracic spinal cord  
 locomotion control in cats 166–8  
 locomotion control in rats 171–2, 175–6
- threshold control theory 604–5
- thrombolysis, acute ischemic stroke 9, 11
- thrombospondins (TSP) 159, 322
- thumb abduction supinator splint (TASS) 315
- thyroid hormone 333
- tic disorders 579
- time cells, hippocampal 29
- timed-up-and-go (TUG) test 42, 112  
 responsiveness 40–1
- timed walking tests 40, 42
- Timocco motion capture system 202
- tinnitus 133–5, 555
- tissue plasminogen activator (tPA) 9, 11, 233, 601–2
- tizanidine 605, 640
- toileting, assistive technology 151, 156
- Toilevator 156
- Toll-like receptors (TLRs) 393, 396  
 Alzheimer's disease 394  
 amyotrophic lateral sclerosis 395  
 cerebral palsy 214
- tolterodine 428, 641
- tone and positioning splint (TAPS) 315
- topiramate 552, 558
- torsinA 575
- torticollis, spasmodic *see* cervical dystonia
- total end range time (TERT) theory 315
- touch  
 clinical tests 300  
*see also* tactile perception
- Tourette syndrome 579
- toxic myopathies 80
- toxic polyneuropathy 664
- TP53 (p53) genotype 538
- trace conditioning 29–30
- tracheostomy 267–8
- Training BIG to move faster program 570
- training effects, in neurorehabilitation 240–1
- transactive responsive sequence DNA-binding protein-43 (TDP-43) 260–1, 268, 395
- transcranial direct current stimulation (tDCS) 141–2, 219–20  
 aphasia 443



## Index

- transcranial direct current stimulation (tDCS) (cont.)  
 cognitive rehabilitation 146–7  
 clinical evidence 227–32, 234  
 theoretical framework 221–3  
 vs. transcranial magnetic stimulation 221  
 deforming spastic paresis 320  
 dementia 528  
 neurorehabilitation role 247–8  
 safety 142  
 stroke 145–7  
 visual field defects 505
- transcranial magnetic stimulation (TMS) 141, 219–20  
 cognitive rehabilitation 147  
 clinical evidence 227–32, 234  
 diagnostic applications 223–4  
 theoretical framework 221–3  
 vs. transcranial direct current stimulation 221  
 deforming spastic paresis 320  
 dementia 528  
 with diffusion tensor imaging 224  
 dystonia 576, 578  
 with EEG (TMS-EEG) 224  
 with functional neuroimaging 224  
 genetic influences on  
 therapeutic response 29  
 neurorehabilitation role 246–7  
 paired pulse techniques 142–3  
 praxis 453–4  
 repetitive (rTMS) 141, 219  
 safety 142  
 stroke 87, 89  
 assessing GABA signaling 198  
 cognitive rehabilitation 147, 227–32  
 motor rehabilitation 145  
 predicting recovery 43–5, 90–1, 596  
 swallowing control 409–10  
 testing normal processes 142–3  
 visual cortical function in  
 blindness 144  
 visual cortical involvement in  
 tactile perception 142  
 vs. transcranial direct current stimulation 142
- transcranial magnetic stimulation (TMS)-evoked potentials (TEP) 224
- transcription factors, modulating axon regeneration 421–2
- transcriptome, post-stroke axon sprouting 200–1
- transcutaneous electrical nerve stimulation (TENS) 135, 578
- transcutaneous electrical stimulation of neck muscles, neglect 468
- transdifferentiation studies 448
- transdisciplinary team 281–2
- transforming growth factor- $\alpha$  (TGF- $\alpha$ ) 287
- transforming growth factor- $\beta$  (TGF- $\beta$ ) 67, 378
- transneuronal atrophy 3–4
- transneuronal degeneration 4
- transplantation therapies, cell  
*see* cell replacement therapies; cellular therapies; stem cell therapies
- transportation-related injuries 535
- traumatic brain injury (TBI) 535–44  
 acetylcholinesterase inhibitors 480, 541  
 acute phase treatment 391–400, 538–9  
 biomarkers 536  
 clinical syndromes 541–3  
 diagnostic assessment 536–7  
 disorders of consciousness 388  
 epidemiology 535  
 etiologies 385–6, 535  
 exercise capacity 370  
 exercise training 375  
 genetic influences on outcome 27, 537–8  
 military 535  
 motor recovery 544  
 neurobehavioral sequelae 543–4  
 neuroimaging 536–7  
 noninvasive brain stimulation 226  
 post-acute interventions 539–41  
 prognostic indicators 398  
 recent clinical trials 538–41  
 virtual reality applications 204–8  
*see also* consciousness, disorders of
- traumatic spinal cord injury (SCI) 435–6, 615–16
- traxoprodil 539
- treadmill locomotion  
 dorsolateral cord lesions 169  
 energy expenditure 377  
 experimental spinal cord injury 166, 534  
 unilateral hemisection 169–70  
 $VO_{2\max}$  measurement 368
- treadmill training  
 applying learning theories 100–3
- body weight-supported  
*see* body weight-supported treadmill training
- experimental spinal cord injury 180
- stroke rehabilitation 10, 190, 607  
*see also* exercise training, gait training
- tremor  
 essential (ET) 567, 569  
 multiple sclerosis 640
- trick maneuvers, Parkinson's disease 571–2
- trihexyphenidyl 577
- trk (tropomyosin-related kinase) receptors 400  
 descending spinal pathways 408  
 downstream signaling 401  
 injured spinal cord 405  
 neuronal uptake and transport 401  
 regulating neuronal survival 402
- trkA 400–1
- trkB 400  
 injured spinal cord 405  
 peripheral axonal regeneration and 403  
 peripheral neuron survival and 402–3
- trkC 400
- trophic factors *see* neurotrophic factors
- tropomyosin-related kinase receptors *see* trk receptors
- TROY 342, 352–3
- trunk  
 compensatory movements 600–1  
 motion in space, vestibular control 357–9  
 muscles, vestibular inputs 357  
 orientation, neglect 468
- TSC1 (tuberous sclerosis protein 1) 11, 379, 420
- tube feeding  
 disorders of consciousness 392  
 dysphagia 411
- tumor necrosis factor (TNF) 418
- tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) 215, 323, 557
- turtles, axon regeneration 334
- two-dimensionally (2D) varying patterns, perception in blindness 140–1
- ubiquitin fusion degradation protein 2 (Ufd2 or Ube4b) 275
- ubiquitin/proteasome system (UPS) 265
- neurodegenerative diseases 264, 266–7  
 relationship with autophagy 267
- ubiquitination, protein 66–7
- UCHL1 (ubiquitin carboxyl-terminal hydroxylase) gene 30
- Uthhoff's phenomenon 642, 647–8
- ulnar nerve stimulation  
 cortical effects 135–7  
 paretic hand in stroke 137–8
- UNAFET-4® device 256–7
- UNC-5 receptor  
 after stroke 203  
 axon regeneration 310  
 netrin binding 304, 358  
 netrin signaling 358  
 regenerating lamprey spinal cord 415
- UNC-6 323
- UNC-40 304
- unfolded protein response (UPR) 265–6
- unilateral neglect *see* neglect, unilateral
- unmasking *see* disinhibition
- unmyelinated axons 457
- unresponsive wakefulness *see* vegetative state
- upper extremity  
 botulinum toxin injections 319  
 repetitive strain injuries, wheelchair users 161–2  
*see also* forelimb, grasping, hand function, reaching
- upper extremity function  
 assessment 313, 337–8  
 stroke 604–5  
 predicting recovery 333–4, 595–7
- tetraplegia 625–7
- weakness and 330–3
- upper extremity rehabilitation 330–9  
 constraint-induced movement therapy *see* constraint-induced movement therapy
- deforming spastic paresis 318  
 dosage 335–6  
 functional electrical stimulation 124, 546–7, 606, 630  
 future prospects 338–9  
 interventions 334–7  
 measurement of outcome 337–8  
 mechatronic orthotics 177, 183–4  
 mechatronic prosthetics 177, 184–6  
 motor neuroprostheses 256–9

- predicting motor recovery 333–4  
 recovery vs. compensation 334–5  
 robotics 177–83, 338  
 specificity of training 336–7  
 strength training 332–3, 336  
 stroke *see under* stroke  
   rehabilitation  
 timing of onset 270–1, 335–6  
 virtual reality applications 208–10, 338  
 upper motor neuron (UMN)  
   lesions  
   electrodiagnostic testing 78  
   strength training 332–3  
   weakness 331–2  
 upper motor neurons  
   current views of function 51–2  
   *see also* cortical motoneurons;  
   corticospinal tract axons  
 urinals 156  
 urinary function *see* bladder  
   control  
 urinary tract, autonomic  
   dysfunction 427–9  
 urinary tract infections (UTI),  
   spinal cord injury 623  
 utterance-based technology 224  
  
 V1 *see* primary visual cortex  
 VA-ROBOTICS study 179–81  
 vagus nerve stimulation, tinnitus 135  
 validity  
   outcome measurement 36–7  
   prognostic research 588–90  
 valosin containing protein  
   (VCP/p97) 276  
 valproic acid 447, 552–3  
 vanishing cues technique 481–2,  
   516  
 variability of practice 98–100  
   context-conditioned 98–9  
   gait training 102–3  
   hypothesis 99  
 vascular dementia 511–12  
 vascular endothelial growth  
   factor (VEGF)  
   axon guidance 307  
   gene therapy 520–2  
   neural precursor cell responses 287, 290  
 vascular endothelial growth  
   factor receptor 2  
   (VEGFR2) 306–7  
 vascular parkinsonism 569  
 vasopressin *see* arginine  
   vasopressin  
 vasovagal syncope (VVS) 420–1,  
   425  
 vectors, gene therapy 515–17  
 VECTORS trial 336, 603–4, 607  
 vegetative state (VS) 262–3, 387  
  
 emergence 398  
   experience of pain 393  
   incidence and prevalence 388  
 venous thromboembolism, spinal  
   cord injury 620–2  
 ventilation, mechanical  
   *see* mechanical  
   ventilation  
 ventral funiculus, locomotor  
   control in rats 172–3  
 ventral premotor cortex (PMv  
   and pre-PMv) 53,  
   99–102  
   changes after primary motor  
   cortex injury 107–8  
   reorganization after stroke  
   85–6, 89  
   voluntary motor control 53–5  
 ventrolateral funiculus (VLF)  
   locomotor control in cats 167  
   locomotor control in rats  
   172–3  
 ventromedial prefrontal cortex  
   (VMPFC), modulation of  
   tinnitus 134–5  
 ventroposterior nucleus of  
   thalamus, reorganization  
   after sensory loss 77–8  
 VERITAS trial 269  
 versican 202, 381  
 vertebrates, non-mammalian  
   adult neurogenesis 284–5  
   nervous system regeneration  
   329–34  
   optic nerve regeneration  
   118–19, 332, 334  
 verticality, postural 107, 110  
 vestibular dysfunction  
   assessment 355–6  
   attentional demands 359  
   dynamic visual acuity testing  
   360  
   exercises *see* vestibular  
   rehabilitation  
   falls and falls risk 363–4  
   postural instability 357–9  
 vestibular feedback, virtual  
   reality systems 200–1  
 vestibular rehabilitation 360–4  
 vestibular stimulation  
   anosognosia 470  
   neglect 468  
 vestibular system  
   control of balance 108,  
   356–9  
   stabilization of gaze 360  
 vestibulo-ocular reflex (VOR),  
   balance control 359–60  
 vestibulospinal tract,  
   neurotrophins and axon  
   regeneration 408  
 Veterans Administration  
   (VA)/Department of  
   Defense (DoD), stroke  
   care guidelines 177  
  
 vibration exposure injuries,  
   wheelchair users 162  
 vibration perception tests 300  
 vibration stimulation of neck  
   muscles, neglect 468  
 vibrotactile perception  
   congenital deafness 132  
   congenital/early blindness 140  
   visual cortical activation in  
   blindness 145  
 video capture virtual reality  
   systems 199–200  
 video feedback, neglect  
   rehabilitation 468, 471  
 videofluoroscopic swallowing  
   evaluation (VFSE) 407, 610  
 viral vectors 515  
   safety concerns 522  
   selection 516–17  
 virtual action  
   planning–supermarket  
   (VAP-S) 206  
 virtual automated teller machine  
   (VR-ATM) 207  
 virtual classroom 203  
 virtual MET (VMET) 206  
 virtual office 204  
 virtual reality (VR) 198–212  
   based rehabilitation  
   applications 203–10  
   attributes for 202–3  
   balance 113, 209  
   model 211  
   Parkinson's disease 573  
   stroke 43, 204, 206–10  
   upper extremity 208–10,  
   338  
   vestibular dysfunction 362  
   head mounted displays  
   (HMD) 199–201  
   instrumentation 199–202  
   key concepts 198–9  
   postural control assessment  
   355  
   video capture systems 199–200  
   vs. computer games 182  
 virtual reality cognitive  
   performance assessment  
   test (VRCPAT) 205  
 vision restoration therapy (VRT)  
   502–4  
 visual cortex  
   auditory activation in  
   blindness 129–30, 132  
   auditory object recognition in  
   blindness 132  
   blood flow in blindness 127  
   cross-modal involvement in  
   tactile perception 142–4  
   modality-independent  
   perceptual-cognitive  
   functions 147  
   neurorehabilitative  
   applications of cross-  
   modality 148  
   nonvisual tasks involving, in  
   blindness 144–7  
   ocular dominance columns  
   116  
   *see also* occipital cortex,  
   primary visual cortex  
   visual cueing  
   Parkinson's disease 571–2  
   unilateral neglect 467–8  
 visual deprivation  
   auditory activation of occipital  
   cortex 129  
   monocular, chondroitinase  
   therapy 160  
   somatosensory cortical  
   plasticity 142  
   sound localization 126–7  
   neural basis of  
   improvements 127–9  
   visual cortex involvement in  
   nonvisual tasks 144  
   *see also* blindness  
 visual feedback  
   rehabilitation robotics 181–2  
   virtual reality systems 199–200  
 visual field impairment 500–5  
   ADL and quality of life  
   measures 504–5  
   after temporal lobectomy 562  
   mechanisms for recovery  
   503–4  
   rehabilitation 500–3  
 visual imagery  
   neglect rehabilitation 469  
   during tactile perception  
   143–4  
 visual loss *see* blindness  
 visual neuroprostheses 545–6,  
   554–5  
 visual scanning training, neglect  
   467  
 visual scene displays 220, 222,  
   225–6  
 visual system  
   anatomy in blindness 147–8  
   balance control 107–8, 356  
   critical period for development  
   140  
   cross-modal plasticity 140–8  
   plasticity of connections  
   114–20  
   regeneration in amphibians  
   333–4  
 visual word form area (VWFA)  
   147  
 visuo-haptic shape representation,  
   common 143  
 visuo-perceptual assessment,  
   dementia 512  
 visuo-spatial neglect 463, 465  
 vitamin D deficiency,  
   Parkinson's disease 573  
 VMall 206, 209  
 VO<sub>2 max</sub> (maximal oxygen  
   consumption) 367

## Index

- VO<sub>2 max</sub> (maximal oxygen consumption) (cont.)  
 effects of bedrest 270, 369  
 during exercise 367–8  
 factors affecting 368–9  
 measurement 368–9  
 neurological disorders 369–72  
 training-induced increases 268, 372
- VO<sub>2 peak</sub> 368  
 neurological disorders 369–72  
 training-induced increases 372
- Vocare bladder control system 129–30, 428–9, 543
- vocational rehabilitation  
 epilepsy 558  
 multiple sclerosis 649
- vocational rehabilitation therapist (VR) 283
- voice organizer 484
- vOICe technology 132
- voiding, voluntary control *see* bladder control
- voluntary motor control 51–7  
 descending tracts 55–7  
 non-primary cortical motor areas 53–5  
 parallel distributed model 53  
 primary motor cortex (M1) 51–3  
 role of spared territory in recovery 57
- VR-DiSTRO 204
- WalkAide® 256–7
- walkers 156
- walking 61–8  
 assessment 62–4, 313–14  
 assistive devices 64, 114, 156–7  
 difficulties 61  
 energy expenditure during 374–8  
 outcome measures 66–7  
 post-stroke  
 compensatory strategies 15–16, 602  
 functional electrical stimulation 125  
 predicting recovery 595  
*see also* foot drop
- retraining *see* gait training
- spinal cord injury 61, 348–9, 627–8  
 assessment 350  
 functional electrical stimulation 126–7  
 prediction 624  
*see also* gait, locomotion
- walking canes 114, 156
- walking competency  
 defined 40  
 electromechanical-assisted gait training and 193  
 stroke, selecting outcomes to measure 40–2  
 gait speed 40–1  
 more complex tests 41–2
- walking index for spinal cord injury (WISCI) 67
- walking speed (or velocity)  
 electromechanical-assisted gait training and 193  
 energy expenditure and 377  
 gait kinetics and 43  
 as measure of walking competency 40–1  
 recovery after stroke 593  
 reliability and validity 40
- walking tests 313–14  
 timed 40, 42
- Wallenda 416
- Waller, Augustus 274
- Wallerian degeneration 4, 7, 274–6  
 active nature 275–6  
 electrodiagnostic testing 78  
 granular degeneration of cytoskeleton 275  
 indirect 5, 7  
 latent phase 274  
 oligodendrocyte death and 6, 8  
 Wallerian-like degeneration 278–9
- washout period 235
- water temperature control devices 154
- weakness  
 defined 330  
 electrodiagnostic testing 77–80  
 as inadequate strength 330–1, 333  
 pathophysiology 331–2  
 upper extremity 330–3  
 motor function and 331–2  
 strength training 332–3
- Wechsler adult intelligence scale-revised (WAIS-R) 512
- Weiss, Paul 301
- wheelchair users  
 accidental injuries 162  
 functional electrical stimulation for postural control 127  
 mobility within home 157  
 pressure ulcers 163  
 upper extremity repetitive strain injuries 161–2  
 vibration exposure injuries 162
- wheelchairs 156–7, 161–73  
 active indoor/outdoor-use 165  
 amyotrophic lateral sclerosis 657  
 applying evidence-based practice 172–3  
 depot 163  
 electric powered (EPW) 165–8  
 with elevating seats 169  
 lightweight manual 163  
 manual 163–4  
 as motor vehicle seats 162  
 positioning hardware 170–2  
 preventing secondary conditions 161–3  
 pushrim activated power assisted (PAPAW) 164–5  
 robotic 166–7  
 seat cushions 170  
 with specialized features 168–70  
 spinal cord injury 625–7  
 stand-up 169–70  
 standards 172–3  
 tilt and recline functions 168–9  
 ultralight manual 163–4
- whisker maps, plasticity 13, 142
- whole-body vibration training, post-polio syndrome 659
- Wii, Nintendo 201–2, 209–10
- Wingless (Wg) proteins 306
- wisteria floribunda agglutinin (WFA) 156, 158
- withdrawal reflexes  
*Aplysia* 64, 68–9  
*see also* flexion-withdrawal reflexes
- Wlds fusion protein 275–6
- Wlds mouse 275
- Wnt proteins 306, 322
- Wolf motor function test (WMFT) 338
- work *see* employment
- working memory 478, 491–2, 495  
 dementia rehabilitation and 517  
 frontal lobe lesions 490
- World Health Organization (WHO)  
 model of rehabilitation 278–9  
*see also* International Classification of Functioning, Disability and Health
- wrist-driven flexor hinge splint 626
- wrist position sense test 300
- writer's cramp 576–8  
*see also* hand dystonia, focal
- writing aids 158
- Xbox Kinect gaming system 200, 202
- yohimbine 175, 181
- young animals  
 regenerative ability 8, 380, 414  
 retrograde degeneration and atrophy 5
- zebrafish, neural regeneration 284–5, 331–2
- zero-sum effect, noninvasive brain stimulation 223
- zolpidem 540
- zymosan 385